学术周报 · IF≥10 或专科旗舰刊

心血管科领域文献阅读汇编

2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
86
临床研究
60
基础研究
26
IF≥20
28
IF 10-20
48
子领域
27
期刊种类
31
数据日期
2026-11-13

★本周 Top 10 高影响力文献

#论文期刊IF
1Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fractio...Nature medicineIF 52.5
2Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fr...Nature medicineIF 52.5
3Incremental yield of genetic retesting in hypertrophic cardiomyopathy.European heart journalIF 45.3
4Inflammation and early atherosclerosis beyond traditional risk factors: an imaging study.European heart journalIF 45.3
5Micro-axial flow pump vs veno-arterial extracorporeal membrane oxygenation for high-risk percutaneou...European heart journalIF 45.3
6Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction pop...European heart journalIF 45.3
7A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the...European heart journalIF 45.3
8Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUND...European heart journalIF 45.3
9Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.European heart journalIF 45.3
10Takotsubo syndrome diagnosis: the biomarker-based BioTAK score.European heart journalIF 45.3

Ŧ期刊分布统计

期刊篇数IF
European heart journal12IF 45.3
Circulation11IF 41.3
Cardiovascular research11IF 12.5
European journal of preventive cardiology7IF 10.0
Stroke5IF 11.1
Hypertension research : official journal of the Japanese Society of Hypertension4IF 9.8
Circulation research3IF 18.0
Hypertension (Dallas, Tex. : 1979)3IF 9.8
Circulation. Heart failure3IF 8.3
Pharmacological research2IF 12.2

1高血压 (12篇)

临床研究 (7篇)

Ophthalmology IF 10.9 2026-11-12 PMID: 43020385
Open-angle glaucoma (OAG) is the leading cause of irreversible blindness and is highly heritable. Despite effective treatments, approximately 50% of cases remain undiagnosed. We aimed to develop and validate a clinically applicable, genetics-based risk prediction tool for OAG across diverse ancestries. Genetic association study and risk prediction analysis. More than 6 million individuals contributing genome-wide association study data from multiple ancestry groups. We constructed a comprehensive polygenic risk score (PRS) for OAG using a multitrait modeling framework that integrated glaucoma-related traits, including intraocular pressure, optic disc parameters, and ocular hypertension. PRS performance was evaluated for OAG risk across major ancestry groups and assessed for associations with age at diagnosis, treatment escalation, surgical outcomes, and familial risk. Odds ratios (ORs) for OAG by PRS percentile, age at disease onset, absolute risk estimates, treatment escalation, glaucoma surgery, and OAG risk in first-degree relatives. In Australian individuals of European ancestry, those in the top 10% of the PRS distribution had a 10-fold increased risk of OAG compared with the remainder (OR 10.04, 95% CI 7.43-13.59), substantially outperforming our previously published PRS (OR 4.2). Similar performance was observed in U.S. European ancestry data (OR 9.09, 95% CI 5.09-16.26). In UK Biobank Europeans the OR for the top 10% versus the remainder was 4.91 (95% CI 4.25-5.69). Although performance was attenuated in other ancestry groups (OR top 10% vs. remainder: 4.01 in South Asian, 3.39 in East Asian, and ranging from 2.26 to 3.81 in African ancestry populations depending on cohort), high PRS percentiles corresponded to elevated absolute risk across all groups. On average, individuals in the highest-risk decile developed glaucoma approximately 25 years earlier than those in the lowest decile and had ∼100-fold (OR 96.83, 95% CI 52.61-178.21) higher risk. The PRS also predicted treatment escalation in early disease, prevalent and incident glaucoma surgery, and OAG risk among first-degree relatives. This enhanced PRS, available for clinical use through an accredited genotyping workflow, enables effective risk stratification for OAG across diverse ancestries, facilitating earlier identification and treatment of high-risk individuals while supporting resource rationalisation for those at low risk. Performance is strongest in European ancestry populations, and further work is needed to improve equity of performance across ancestries.
中文摘要:开角型青光眼是造成不可逆失明的主要原因且遗传度极高。尽管治疗有效,约50%的病例仍未被诊断。本研究旨在开发并验证一种适用于临床、基于遗传学的开角型青光眼风险预测工具,涵盖不同祖先群体。研究采用遗传关联分析和风险预测方法,整合了来自多个祖先群体的超过600万人的全基因组关联研究数据。我们利用多性状建模框架构建了综合性的多基因风险评分,该框架整合了眼压、视盘参数和眼高血压等青光眼相关性状。我们在主要祖先群体中评估了该评分对开角型青光眼的预测性能,并分析了其与诊断年龄、治疗升级、手术结果及家族风险的关联。在澳大利亚欧洲裔个体中,多基因风险评分分布前10%的人群患青光眼风险是其余人群的10倍(OR 10.04, 95% CI 7.43-13.59),显著优于我们此前发布的评分(OR 4.2)。美国欧洲裔数据也观察到类似性能(OR 9.09, 95% CI 5.09-16.26)。在英国生物样本库欧洲裔中,前10%与其余人群的比值比为4.91(95% CI 4.25-5.69)。尽管在其他祖先群体中性能有所减弱(南亚为4.01,东亚为3.39,非洲裔因队列不同在2.26至3.81之间),但高评分百分位对应所有群体的绝对风险升高。平均而言,最高风险十分位人群比最低风险十分位人群早约25年发病,且风险高出约100倍(OR 96.83, 95% CI 52.61-178.21)。该评分还能预测早期疾病的治疗升级、现患及新发青光眼手术以及一级亲属的患病风险。这一增强型多基因风险评分通过认证的基因分型工作流程可用于临床,能够在不同祖先群体中实现有效的风险分层,促进高风险个体的早期识别和治疗,同时支持对低风险人群的资源合理化配置。该评分在欧洲裔群体中表现最强,需进一步工作以提高跨祖先群体的性能公平性。
European journal of preventive cardiology IF 10.0 2026-11-11 PMID: 42523037
To examine temporal trends and quantify changes in prevalence of major cardiovascular disease risk factors (hypertension, tobacco use, elevated cholesterol, diabetes mellitus, and insufficient physical activity) across World Health Organization (WHO) regions. Analysis of WHO Global Health Observatory, a global database compiling health indicators from over 190 countries. Prevalence (%) estimates were extracted for key modifiable Cardiovascular disease (CVD) risk factors from 1990 to 2022. Joinpoint regression analyses were conducted to calculate the annual percentage change (APC) for each segment identified to have a change in trend and the average annual percentage change (AAPC) with 95% confidence intervals (CIs) across the entire time trend. Global trends in CVD risk factors showed mixed patterns. Hypertension prevalence declined in most regions, with the greatest reduction in Europe (AAPC = -1.54, 95% CI: -1.55, -1.53), whilst the Western Pacific showed a slight increase (AAPC = 0.10, 95% CI: 0.08, 0.12). Tobacco use decreased across all regions, most markedly in South-East Asia (AAPC = -3.50, 95% CI: -3.56, -3.43), from 54.1% to 26.6%. Total cholesterol declined modestly in several regions, but increased slightly in the Western Pacific (AAPC = 0.25, 95% CI: 0.07, 0.43). Diabetes prevalence increased across all regions, highest in the Eastern Mediterranean (AAPC = 2.58, 95% CI: 2.57, 2.59) and lowest in Africa (AAPC = 1.58, 95% CI: 1.55, 1.61). Insufficient physical activity also increased in five regions, Africa being the only exception (AAPC = -1.10, 95% CI: -1.19, -1.01). Global trends in CVD risk factors show improvements in hypertension, tobacco use, and cholesterol, but worsening diabetes and insufficient physical activity, highlighting the need for region-specific strategies that drive sustainable, system-level change in modifiable risks.
中文摘要:本研究旨在分析世界卫生组织(WHO)各区域主要心血管疾病危险因素(高血压、烟草使用、胆固醇升高、糖尿病和体力活动不足)的患病率随时间变化的趋势并量化其变化。研究利用包含来自190多个国家健康指标的WHO全球卫生观察数据库,提取了1990年至2022年间关键可改变心血管病危险因素的比例估计值。采用Joinpoint回归分析计算每个识别出趋势发生变化的片段的年度百分比变化(APC),以及整个时间趋势的平均年度百分比变化(AAPC)及其95%置信区间(CI)。全球心血管疾病危险因素的趋势呈现混合模式。高血压患病率在大多数区域下降,其中欧洲降幅最大(AAPC = -1.54, 95% CI: -1.55, -1.53),而西太平洋地区略有上升(AAPC = 0.10, 95% CI: 0.08, 0.12)。烟草使用在所有区域均有所下降,东南亚地区降幅最为显著(AAPC = -3.50, 95% CI: -3.56, -3.43),从54.1%降至26.6%。总胆固醇在多个区域略有下降,但在西太平洋地区略有上升(AAPC = 0.25, 95% CI: 0.07, 0.43)。糖尿病患病率在所有区域均有所增加,东地中海地区最高(AAPC = 2.58, 95% CI: 2.57, 2.59),非洲最低(AAPC = 1.58, 95% CI: 1.55, 1.61)。体力活动不足在五个区域也呈增加趋势,非洲是唯一例外(AAPC = -1.10, 95% CI: -1.19, -1.01)。全球心血管疾病危险因素的趋势显示高血压、烟草使用和胆固醇有所改善,但糖尿病和体力活动不足状况恶化,凸显了需要采取区域特异性策略以推动可改变风险因素的可持续系统性变革。
Hypertension (Dallas, Tex. : 1979) IF 9.8 2026-11-10 PMID: 43007058
Catheter-based intravascular renal denervation produces modest, variable blood pressure reductions, partly because renal sympathetic nerves lie at variable depths within the periarterial adventitia and because accessory or early branching arteries are inaccessible to intraluminal catheters. We developed an extravascular renal denervation system (HyperQure) delivering circumferential radiofrequency energy from outside the artery and assessed its safety and efficacy. Here, we report the primary 3-month outcomes. This prospective, multicenter, single-arm, first-in-human pilot trial enrolled 10 patients with resistant hypertension (office blood pressure ≥140/90 mm Hg and daytime ambulatory systolic blood pressure [SBP] ≥135 mm Hg despite ≥3 antihypertensive agents) across 7 Korean centers. All underwent bilateral extravascular renal denervation on stable antihypertensive regimens. The primary end point was 3-month change in 24-hour ambulatory SBP; safety outcomes were assessed through 3 months. All 10 patients (median age, 52.5 years; 7 men) completed follow-up. Seven patients (70%) had accessory or early branching arteries <3 mm typically ineligible for intravascular renal denervation; all were successfully ablated. Median 24-hour ambulatory SBP decreased by 25.0 mm Hg (P=0.008) and median office SBP by 39.5 mm Hg (P=0.002). Seven of 10 (70%) achieved office SBP <140 mm Hg despite a reduction in median antihypertensive burden from 6.0 to 4.5 agents. No major or procedure-related adverse events occurred; follow-up computed tomography angiography showed no vascular complications and renal function was preserved. Extravascular renal denervation using the HyperQure renal denervation System warrants evaluation in a larger controlled trial, particularly in patients with complex renal arterial anatomy.
中文摘要:导管内血管性肾去神经支配产生的血压降低幅度有限且个体差异较大,部分原因是肾交感神经位于动脉周围外膜的不同深度,且副支或早期分支动脉无法通过管腔内导管触及。我们开发了一种经血管外肾去神经支配系统(HyperQure),该系统从动脉外部输送环形射频能量,并评估了其安全性和有效性。在此报告主要3个月结局。这项前瞻性、多中心、单臂、首次人体试点试验在7个韩国中心纳入了10名难治性高血压患者(尽管使用≥3种抗高血压药物,诊室血压仍≥140/90 mmHg且白天动态收缩压[SBP]≥135 mmHg)。所有患者在稳定的抗高血压治疗方案下接受了双侧经血管外肾去神经支配。主要终点为24小时动态SBP在3个月时的变化;安全性结局评估持续至3个月。全部10名患者(中位年龄52.5岁,男性7人)均完成随访。7名患者(70%)存在通常不符合血管内肾去神经支配适应症的<3 mm副支或早期分支动脉;所有动脉均成功消融。24小时动态SBP中位数降低25.0 mmHg(P=0.008),诊室SBP中位数降低39.5 mmHg(P=0.002)。尽管抗高血压药物负担中位数从6.0种减少至4.5种,仍有7/10名患者(70%)实现诊室SBP<140 mmHg。未发生主要或程序相关不良事件;随访计算机断层扫描血管造影显示无血管并发症,肾功能得以保留。使用HyperQure肾去神经支配系统的经血管外肾去神经支配值得在更大规模的对照试验中进一步评估,特别是在具有复杂肾动脉解剖结构的患者中。
Hypertension research : official journal of the Japanese Society of Hypertension IF 9.8 2026-11-09 PMID: 43003893
Angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs) lower blood pressure, but evidence directly comparing their clinical outcomes in patients with hypertension without heart failure is limited. We compared long-term outcomes associated with ARNI versus MRA initiation in this population. Adults with essential hypertension without heart failure were included if they had documented use of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker plus at least one additional antihypertensive drug class. Patients receiving sacubitril or spironolactone or eplerenone after a 1-year washout period were assigned to the ARNI and MRA cohorts, respectively. The primary outcome was all-cause mortality; secondary outcomes were a composite of acute myocardial infarction and stroke, acute kidney injury (AKI), acute myocardial infarction, and stroke. Outcomes were assessed for up to 1095 days. After 1:1 propensity score matching, 11,832 patients were included in each group. During follow-up, the rates of all-cause mortality in the ARNI and the MRA groups were 7.6% (894 patients) and 10.2% (1 201 patients), respectively. The ARNI group compared to MRA group was associated with a lower risk of all-cause mortality, stroke, and AKI, whereas no significant differences were observed in the composite cardiovascular outcome or acute myocardial infarction. Mean systolic blood pressure was modestly lower in the ARNI group, while diastolic blood pressure and the most recently recorded estimated glomerular filtration rate were similar between groups. These findings are hypothesis-generating and require confirmation in prospective studies.
中文摘要:血管紧张素受体-脑啡肽酶抑制剂(ARNI)和盐皮质激素受体拮抗剂(MRA)可降低血压,但在无心力衰竭的高血压患者中直接比较其临床结局的证据有限。本研究比较了该人群中启动ARNI与MRA治疗的长期结局。纳入的成年原发性高血压患者无心衰,且记录使用过血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂加上至少一种其他降压药物类别。患者在1年洗脱期后接受沙库巴曲缬沙坦或螺内酯/依普利酮分别被分配至ARNI组和MRA组。主要结局为全因死亡率;次要结局包括急性心肌梗死和卒中的复合终点、急性肾损伤(AKI)、急性心肌梗死及卒中。随访评估时间长达1095天。经1:1倾向评分匹配后,每组纳入11832名患者。随访期间,ARNI组和MRA组的全因死亡率分别为7.6%(894例)和10.2%(1201例)。与MRA组相比,ARNI组全因死亡率、卒中和AKI风险较低,而在心血管复合结局或急性心肌梗死方面未见显著差异。ARNI组的平均收缩压略低,而舒张压和最近记录的估算肾小球滤过率在两组间相似。这些发现具有生成假设的性质,需在前瞻性研究中进一步证实。
Hypertension research : official journal of the Japanese Society of Hypertension IF 9.8 2026-11-09 PMID: 43003891
Out-of-office blood pressure (BP) measurement is central to contemporary hypertension management. However, conventional oscillometric BP monitors often require substantial cuff inflation, potentially causing discomfort, sleep disturbance, and reduced adherence to repeated BP measurement. We developed a novel low-pressure and rapid oscillometric method designed to reduce the cuff pressure and measurement duration while maintaining accuracy. Here, we evaluated the novel automated upper-arm BP monitor incorporating this method (i.e., the Omron HEM-7290T) according to the ISO 81060-2:2018/Amd1:2020/Amd2:2024 standard. The device was assessed in 85 adults using the ISO same-arm sequential measurement protocol. Reference BP values were obtained by simultaneous auscultation. The device's performance was evaluated according to Criteria 1 and 2 of the ISO standard. For Criterion 1, the mean device-observer differences were 0.5  ±  7.09 mmHg for systolic BP (SBP) and 0.6  ±  5.50 mmHg for diastolic BP (DBP). For Criterion 2, the standard deviations of the subject-level mean differences were 5.79 mmHg for SBP and 5.05 mmHg for DBP. All results fulfilled the ISO 81060-2:2018/Amd1:2020/Amd2:2024 validation requirements across the required BP and arm circumference distributions. The Omron HEM-7290T successfully fulfilled ISO validation requirements in adults with 20- to 45-cm arm circumferences. These findings demonstrate that a low-pressure and rapid oscillometric method can achieve international-standard accuracy while potentially reducing the measurement burden. This study provides the clinical validation of a patient-centered BP monitoring technology designed to improve comfort without compromising performance, with potential applications in home BP monitoring, nocturnal BP assessment, and digital hypertension management.
中文摘要:院外血压测量是当代高血压管理的核心。然而,传统的示波法血压计通常需要较高的袖带充气压力,可能导致不适、睡眠干扰以及降低重复测量的依从性。我们开发了一种新型低压快速示波法,旨在降低袖带压力和测量时间,同时保持准确性。本研究根据ISO 81060-2:2018/Amd1:2020/Amd2:2024标准评估了采用该方法的新型自动上臂血压计(即Omron HEM-7290T)。在85名成年人中,使用ISO同臂连续测量方案对设备进行了评估。参考血压值通过同时进行的听诊法获得。根据ISO标准的标准1和标准2评估设备的性能。对于标准1,收缩压的设备和观察者平均差异为0.5±7.09mmHg,舒张压为0.6±5.50mmHg。对于标准2,受试者水平平均差异的标准差分别为:收缩压5.79mmHg,舒张压5.05mmHg。所有结果均符合ISO 81060-2:2018/Amd1:2020/Amd2:2024验证要求,覆盖了所需的血压和臂围分布。Omron HEM-7290T在臂围为20至45厘米的成年人中成功满足了ISO验证要求。这些发现表明,低压快速示波法可以在不牺牲性能的情况下实现国际标准精度,并可能减少测量负担。本研究提供了以患者为中心的血压监测技术的临床验证,旨在提高舒适度而不影响性能,具有家庭血压监测、夜间血压评估和数字高血压管理的潜在应用价值。
Hypertension research : official journal of the Japanese Society of Hypertension IF 9.8 2026-11-06 PMID: 42995223
Hypertension is a prevalent non-communicable disease and a significant cardiovascular risk factor in India, affecting 25% of adults. Among those treated, only 52.5% achieved controlled clinic blood pressure (CBP). We investigated blood pressure (BP) control in India using CBP and home BP (HBP). This multicenter, cross-sectional study across 18 centers in 12 states within 7 regions enrolled hypertensive participants aged 20-70 years receiving antihypertensive medications for ≥3 months who regularly visited their clinic. A background survey and four CBP readings were collected at baseline ("Clinic Visit 1") and Clinic Visit 2. Participants underwent HBP monitoring for seven days. Based on average CBP across the two clinic visits and average HBP, participants were classified as having well-controlled hypertension (CBP < 140/90 mmHg and HBP < 135/85 mmHg), white-coat uncontrolled hypertension (WUCH; CBP ≥ 140/90 mmHg and HBP < 135/85 mmHg), masked uncontrolled hypertension (MUCH; CBP < 140/90 mmHg and HBP ≥ 135/85 mmHg), or sustained uncontrolled hypertension (SUCH; CBP ≥ 140/90 mmHg and HBP ≥ 135/85 mmHg). Among 1920 participants, 1578 with appropriate CBP and HBP readings were analyzed. Of these, 55.9% had well-controlled hypertension, 5.1% had WUCH, 21.8% had MUCH, and 17.2% had SUCH. The proportion classified as controlled was 77.7% using clinic BP alone versus 55.9% using both clinic and home BP, a difference of 21.8 percentage points. These findings highlight the importance of incorporating HBP alongside CBP for comprehensive assessment of BP control and identification of BP control phenotypes. Clinical trial registration: Registered at Clinical Trials Registry-India (CTRI) under CTRI/2023/02/049486 on 06 February 2023.
中文摘要:高血压是印度流行的非传染性疾病和重要的心血管危险因素,影响25%的成年人。在接受治疗的患者中,仅有52.5%实现了诊室血压(CBP)控制。本研究利用CBP和家庭血压(HBP)调查印度的血压控制情况。这项在多中心、横断面研究中,在7个地区的12个邦的18个中心招募了接受抗高血压药物≥3个月并定期就诊的20-70岁高血压参与者。基线(首次诊室访视)和第二次诊室访视时收集背景调查及四次CBP读数。参与者进行为期七天的HBP监测。根据两次诊室访视的平均CBP和平均HBP,将参与者分类为血压控制良好(CBP<140/90 mmHg且HBP<135/85 mmHg)、白大衣未控制高血压(WUCH;CBP≥140/90 mmHg且HBP<135/85 mmHg)、隐匿性未控制高血压(MUCH;CBP<140/90 mmHg且HBP≥135/85 mmHg)或持续性未控制高血压(SUCH;CBP≥140/90 mmHg且HBP≥135/85 mmHg)。在1920名参与者中,分析了1578名具有适当CBP和HBP读数的人员。其中55.9%为血压控制良好,5.1%为WUCH,21.8%为MUCH,17.2%为SUCH。仅使用诊室血压分类的控制比例为77.7%,而同时使用诊室和家庭血压的分类控制比例为55.9%,差异达21.8个百分点。这些发现强调了将HBP与CBP结合用于全面评估血压控制和识别血压控制表型的重要性。临床试验注册号:于2023年2月6日在印度临床试验注册中心(CTRI)注册,编号为CTRI/2023/02/049486。
Circulation research IF 18.0 2026-11-06 PMID: 42803000
Potassium-enriched table salt lowers blood pressure (BP) and reduces cardiovascular mortality. Whether these beneficial effects stem from reduced Na+ intake, increased K+ intake, or both is unknown. We tested the hypothesis that oral potassium chloride (KCl) supplementation lowers body Na+ content and BP in patients with essential hypertension (EH) or hyperaldosteronism, independent of salt intake. Between February 2024 and February 2025, we conducted a single-arm, prospective, longitudinal study with nonrandomized oral KCl intervention in 40 participants with hypertension. All received personalized (blood K+-adjusted) KCl supplementation (SPAN-K tablets, potassium chloride 600 mg; Aspen Pharmacare Australia Pty, Ltd) for 6 to 9 weeks. After the intervention, participants completed a routine diagnostic workup and were classified with EH or hyperaldosteronism. Primary end point: baseline muscle Na+ surplus in hyperaldosteronism. Secondary end point: interventional muscle Na+ mobilization and BP reduction. Seventeen participants were diagnosed with EH, and 23 with hyperaldosteronism. At baseline, patients with hyperaldosteronism showed higher muscle Na+ content (24.67±2.93 versus 22.48±3.37 mmol/L tissue volume, P=0.023; primary end point). Oral KCl increased 24-hour urine K+ excretion without altering 24-hour urine Na+. KCl supplementation successfully eliminated the muscle Na+ surplus in the hyperaldosteronism group (-1.90 mmol/L tissue volume [95% CI, -3.20 to -0.60]; P=0.005; secondary end point), lowered blood Na+/K+ ratios in both groups (EH, -5.34 [95% CI, -7.69 to -2.99]; P=4.6×10-5; hyperaldosteronism, -7.02 [95% CI, -9.04 to -5.01]; P=2.1×10-8), and reduced systolic BP (EH, -8.33 mm Hg [95% CI, -14.55 to -2.12]; P=0.010; hyperaldosteronism, -7.35 mm Hg [95% CI, -12.69 to -2.01]; P=0.008). To account for early study termination, a conservative significance threshold of α=0.025 was implemented, which all end points crossed. Oral KCl supplementation mobilizes intracellular Na+ stores, corrects pathological Na+/K+ distribution, and lowers BP across hypertension phenotypes. This safe, targeted approach warrants consideration as a scalable public health strategy for cardiovascular disease prevention. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06569589.
中文摘要:富钾食盐可降低血压并减少心血管死亡率。这些益处究竟是源于钠摄入减少、钾摄入增加,还是两者兼有,目前尚不清楚。本研究旨在验证口服氯化钾补充剂能否在不改变盐摄入量的情况下,降低原发性高血压或原发性醛固酮增多症患者体内的钠含量及血压。2024年2月至2025年2月,我们对40名高血压患者进行了单臂、前瞻性纵向研究,实施非随机口服氯化钾干预。所有参与者均接受了基于血钾水平调整的个性化氯化钾补充治疗(SPAN-K片剂,含氯化钾600 mg;Aspen Pharmacare Australia Pty, Ltd),持续6至9周。干预结束后,参与者完成了常规诊断检查,并被确诊为原发性高血压或原发性醛固酮增多症。主要终点为原发性醛固酮增多症患者的基线肌肉钠含量过剩。次要终点为干预后的肌肉钠动员情况及血压降低幅度。17名参与者被确诊为原发性高血压,23名被确诊为原发性醛固酮增多症。基线时,原发性醛固酮增多症患者的肌肉钠含量较高(24.67±2.93 vs 22.48±3.37 mmol/L组织体积,P=0.023;主要终点)。口服氯化钾增加了24小时尿钾排泄量,而未改变24小时尿钠排泄量。氯化钾补充成功消除了原发性醛固酮增多症组的肌肉钠过剩(-1.90 mmol/L组织体积 [95% CI, -3.20 to -0.60];P=0.005;次要终点),降低了两组的血液钠钾比值(原发性高血压组,-5.34 [95% CI, -7.69 to -2.99];P=4.6×10-5;原发性醛固酮增多症组,-7.02 [95% CI, -9.04 to -5.01];P=2.1×10-8),并降低了收缩压(原发性高血压组,-8.33 mm Hg [95% CI, -14.55 to -2.12];P=0.010;原发性醛固酮增多症组,-7.35 mm Hg [95% CI, -12.69 to -2.01];P=0.008)。考虑到研究提前终止的情况,设定了保守的显著性阈值α=0.025,所有终点均达到此阈值。口服氯化钾补充剂可动员细胞内钠储存,纠正病理性钠钾分布,并降低不同类型高血压患者的血压。这种安全且针对性的方法值得作为心血管疾病预防的可扩展公共卫生策略加以考虑。

基础研究 (5篇)

Nucleic acids research IF 15.0 2026-11-13 PMID: 43021690
The Evo2 Variant Effect Database (Evo2VED; https://dnallmved.org/) is a publicly accessible resource cataloging precomputed Evo2-derived variant effect scores, defined as allelic score differences, for 6.48 million human variants common in the gnomAD non-Finnish European population. Evo2VED includes scores from the 7B and 40B models under three scoring schemes, alongside annotations of variant function, evolutionary constraint, allele age, and disease associations. It integrates genome-wide association study (GWAS) data from UK Biobank, FinnGen, and the Million Veteran Program. Three complementary modules support variant-level interpretation, regional and region-set exploration, and trait-level analysis through flexible queries, interactive visualizations, and downloadable results. Evo2VED also catalogs associations between Evo2 annotations and per-SNP heritability across thousands of traits from these biobanks. A guided workflow connects GWAS with associated regions and individual variant evidence. Case studies of hypertension and depression illustrate how regional comparisons of Evo2 scores and GWAS signals can guide candidate variant prioritization. Evaluations using massively parallel reporter assays, molecular QTLs, fine-mapping probabilities, and clinical annotations assess associations with Evo2 scores alone and their added value beyond conservation and regulatory annotations. By providing accessible scores, contextual annotations, and comparative analyses, Evo2VED facilitates exploration and application of genomic language model predictions in human genetics research.
中文摘要:Evo2变异效应数据库(Evo2VED;https://dnallmved.org/)是一个公开资源,收录了648万个在gnomAD非芬兰欧洲人群中常见的DNA变异的预计算Evo2衍生变异效应评分,定义为等位基因评分差异。Evo2VED包含来自7B和40B模型在三种评分方案下的评分,以及变异功能、进化约束、等位基因年龄和疾病关联的注释。它整合了来自UK Biobank、FinnGen和百万退伍军人计划的基因组关联研究(GWAS)数据。三个互补模块支持通过灵活查询、交互式可视化和可下载结果进行变异水平解读、区域及区域集探索以及性状水平分析。Evo2VED还收录了这些生物库中数千个性状的Evo2注释与每单核苷酸多态性(SNP)遗传力之间的关联。一个引导式工作流将GWAS与相关区域和个体变异证据联系起来。高血压和抑郁症的案例研究说明了Evo2评分的区域比较和GWAS信号如何指导候选变异的优先排序。利用大规模平行报告基因测定、分子数量性状位点(QTL)、精细映射概率和临床注释进行的评估,检验了与Evo2评分本身的关联及其在保守性和调控性注释之外的附加价值。通过提供可访问的评分、上下文注释和比较分析,Evo2VED促进了基因组语言模型预测在人类遗传学研究中的探索和应用。
Hypertension (Dallas, Tex. : 1979) IF 9.8 2026-11-10 PMID: 43007060
Upregulation of the RNA-binding protein HuR (human antigen R) has been reported in patients with chronic kidney disease (CKD), but its pathogenic role remains incompletely understood. We hypothesized that HuR promotes renal and vascular injury in hypertensive CKD and that pharmacological inhibition of HuR attenuates disease progression. We therefore investigated the role of HuR in deoxycorticosterone acetate (DOCA) plus Ang II (angiotensin II)-induced CKD and evaluated the therapeutic efficacy of the HuR inhibitor, KH3 . Male mice underwent uninephrectomy followed by DOCA+Ang II infusion with 1% NaCl in drinking water and were treated with KH3 or vehicle for 3 weeks. Control mice received saline without DOCA or Ang II. DOCA+Ang II markedly increased HuR expression in circulating exosomes and kidney tissues, which was attenuated by KH3 treatment. KH3 reduced albuminuria, improved renal function, and attenuated kidney hypertrophy, glomerular, and tubulointerstitial fibrosis. These renoprotective effects were associated with reduced podocyte and tubular injury, decreased macrophage infiltration, and suppression of NF-κB (nuclear factor-kappa B) p65, Nox2 (NADPH oxidase 2), AKT (protein kinase B) phosphorylation, TGFβ1 (transforming growth factor β1), and Wisp1 (WNT1-inducible signaling pathway protein 1) signaling. KH3 also partially lowered arterial blood pressure in DOCA+Ang II-treated mice. Further studies in vascular smooth muscle cells and mesenteric resistance arteries suggested that HuR inhibition may suppress vascular profibrotic signaling associated with SGLT2 (sodium-glucose cotransporter 2). HuR is upregulated in renal and vascular tissues in DOCA+Ang II-induced CKD and contributes to renal inflammation, oxidative stress, fibrosis, and vascular dysfunction. Pharmacological inhibition of HuR attenuates renal and vascular injury, supporting HuR as a promising therapeutic target for CKD.
中文摘要:慢性肾脏病患者的RNA结合蛋白HuR(人类抗原R)上调已被报道,但其致病作用尚不完全清楚。我们假设HuR促进高血压性慢性肾脏病的肾和血管损伤,并且药理学抑制HuR可减轻疾病进展。因此,我们研究了HuR在醋酸脱氧皮质酮加Ang II诱导的慢性肾脏病中的作用,并评估了HuR抑制剂KH3的治疗效果。雄性小鼠接受单侧肾切除后,给予DOCA加Ang II输注及含1% NaCl的饮水,并用KH3或载体治疗3周。对照组小鼠仅接受不含DOCA或Ang II的生理盐水。DOCA加Ang II显著增加了循环外泌子和肾脏组织中HuR的表达,而KH3处理可减轻这种增加。KH3减少了蛋白尿,改善了肾功能,并减轻了肾脏肥大、肾小球和肾小管间质纤维化。这些肾脏保护作用与足细胞和小管损伤减少、巨噬细胞浸润减少以及NF-κB p65、Nox2、AKT磷酸化、TGFβ1和Wisp1信号抑制有关。KH3还部分降低了DOCA加Ang II处理小鼠的动脉血压。在血管平滑肌细胞和肠系膜阻力动脉中的进一步研究表明,HuR抑制可能通过SGLT2相关机制抑制血管促纤维化信号。HuR在DOCA加Ang II诱导的慢性肾脏病的肾和血管组织中上调,并导致肾脏炎症、氧化应激、纤维化和血管功能障碍。药理学抑制HuR可减轻肾和血管损伤,支持HuR作为慢性肾脏病的有前景的治疗靶点。
Hypertension research : official journal of the Japanese Society of Hypertension IF 9.8 2026-11-09 PMID: 43003892
Cardiovascular events cluster in the early morning and peak in winter, when the morning blood pressure surge is accentuated by cold. The Japanese Society of Hypertension has identified the winter morning as a critical window in which cold stress, awakening-related sympathetic activation, physical activity, and arising from bed converge, and has recommended gentle activity such as light stretching and deep breathing on waking, without specifying its content. For a national public broadcaster, under the Society's supervision, we designed a 2-minute routine to be performed in bed after awakening: five slow, deep breaths combined with a whole-body stretch, slow rolling from side to side, ankle circles and ankle pumps, followed by sitting up in stages on the bed and five shoulder-blade lifts combined with slow, deep breathing and gentle neck extension before standing. We describe the physiological rationale for each element, drawing on evidence that the morning rise in blood pressure is related mainly to arising rather than awakening, that slow breathing enhances baroreflex sensitivity, that neck posture modulates carotid sinus input, that the blood pressure response to physical activity predicts the morning surge and is heightened in winter and older age, and that orthostatic hypertension is linked to the surge. The routine is intended to make the rise from the sleep trough to the standing morning blood pressure slower and smoother, and thereby to lower the morning peak. Future studies using ambulatory blood pressure monitoring on winter mornings are needed to test whether the routine attenuates the morning surge.
中文摘要:心血管事件在冬季清晨聚集并达到高峰,此时寒冷会加剧晨起血压升高。日本高血压学会将冬季清晨确定为关键窗口期,认为此时冷应激、觉醒相关的交感神经激活、体力活动及起床动作相互汇聚,并推荐醒来后进行轻柔活动如轻度伸展和深呼吸,但未明确具体内容。在日本高血压学会的监督下,我们为国家公共广播机构设计了一套2分钟的床上晨起后常规动作:包括五次缓慢深呼吸结合全身伸展、左右缓慢翻滚、踝关节环绕及踝泵运动,随后分阶段在床上坐起,接着进行五次肩胛骨上提结合缓慢深呼吸和轻柔颈部伸展,最后站立。我们基于现有证据阐述了每个元素的生理学原理,即晨起血压升高主要与起床动作而非觉醒本身有关,缓慢呼吸可增强压力感受器敏感性,颈部姿势可调节颈动脉窦输入,体力活动引起的血压反应可预测晨起血压升高且在冬季和老年人群中更为显著,且体位性高血压与该升高有关。该常规动作旨在使从睡眠低谷到站立状态下的晨起血压上升过程更缓慢平稳,从而降低晨峰血压。未来需要利用动态血压监测在冬季清晨进行的研究来验证该常规动作是否能减弱晨起血压升高。
Annual review of physiology IF 20.3 2026-11-06 PMID: 42994451
Aldosterone has long been viewed as a master regulator of fluid and electrolyte homeostasis, acting through the mineralocorticoid receptor (MR) to stimulate electrogenic Na+ transport via the epithelial sodium channel (ENaC) in the distal nephron. This primary effect is thought to drive both K+ secretion and Cl- reabsorption; however, the underlying mechanism has remained obscure and the dual regulation has generated an enigma often referred to as the aldosterone paradox. Here we propose a model for regulated K+ secretion centered on local regulation of ENaC in the late distal convoluted tubule and early connecting tubule. In this segment, the MR is constitutively activated by glucocorticoids rather than by aldosterone, and yet ENaC activity and K+ secretion through the renal outer medullary K+ channel (ROMK) are not constitutive but, rather, are highly regulated. The model holds that the key regulatory step for K+ secretion involves a cell-autonomous mechanism through which local interstitial [K+] stimulates mechanistic target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of the ENaC regulatory serum- and glucocorticoid-induced kinase 1 (SGK1); the K+-sensing kinase augments this phosphorylation by serving as a scaffold to enhance the physical interaction of mTORC2 with SGK1. Aldosterone acts further downstream to stimulate ENaC primarily in the late CNT and cortical collecting duct, in which ROMK apical expression is relatively low and Na+-Cl- reabsorption is favored. This revised paradigm resolves the aldosterone paradox and has important implications for hypertension, potassium disorders, and potentially medical therapies.
中文摘要:醛固酮长期以来被视为调节体液和电解质稳态的主要调控因子,它通过盐皮质激素受体(MR)刺激远端肾小管中上皮钠通道(ENaC)的电致性钠离子转运。这一主要效应被认为驱动了钾离子的分泌和氯离子的重吸收;然而,其潜在机制一直不明,这种双重调节产生了一个常被称为醛固酮悖论的谜团。本文提出了一种以远端小管晚期和连接小管早期局部调节ENaC为中心的受控钾离子分泌模型。在该节段中,MR由糖皮质激素而非醛固酮组成性激活,但通过肾外髓质钾通道(ROMK)进行的ENaC活性和钾离子分泌并非组成性的,而是受到高度调控。该模型认为,钾离子分泌的关键调控步骤涉及一个细胞自主机制,即局部间质钾离子浓度刺激雷帕霉素靶蛋白复合物2(mTORC2)依赖性磷酸化ENaC调节因子血清和糖皮质激素诱导激酶1(SGK1);这种钾感应激酶通过作为支架增强mTORC2与SGK1的物理相互作用来促进该磷酸化。醛固酮在更下游发挥作用,主要在连接小管晚期和皮质集合管中刺激ENaC,在这些部位ROMK的顶膜表达相对较低且有利于钠氯重吸收。这一修正范式解决了醛固酮悖论,并对高血压、钾代谢紊乱及潜在的医疗治疗具有重要启示。
Circulation research IF 18.0 2026-11-06 PMID: 42845244
Hypertension is a major driver of neurovascular dysfunction and cognitive decline, yet the molecular mechanisms linking elevated arterial pressure to impaired cerebral blood flow remain poorly defined. Piezo1, a mechanosensitive cation channel enriched in the brain endothelium, is a candidate mediator of cerebral blood flow deficits during hypertension. Using 2 distinct mouse models of hypertension-BPH/2J mice (genetically hypertensive strain) and angiotensin II-infused C57BL/6J mice-we assessed brain endothelial Piezo1 activity using patch-clamp electrophysiology. Endothelial-specific Piezo1 deletion models were used to evaluate the role of the channel in hypertension-associated cerebrovascular impairment. Cerebral blood flow responses were measured in vivo by laser speckle contrast imaging, and super-resolution nanoscopy was used to quantify Piezo1 nanoscale organization. Behavioral testing was used to assess cognition. Genetic manipulation of endothelial Piezo1 had minimal impact on baseline blood pressure. However, cerebral endothelial Piezo1 activity was markedly elevated in different hypertension models. Deletion of endothelial Piezo1 protected against hypertension-induced cerebrovascular deficits, including impaired vasomotion, reduced functional hyperemia, and blunted CO2-evoked hyperemia. Super-resolution imaging revealed that hypertension increased Piezo1 clustering, consistent with electrophysiological findings of enhanced channel coupling and open probability. Mechanistically, Piezo1 hyperactivity was PKC (protein kinase C)-dependent, and the PKC-Piezo1 spatial association was enhanced during hypertension. Importantly, PKC inhibition normalized brain endothelial Piezo1 activity, restored cerebral blood flow responses, and rescued cognitive performance. Hypertension increased the gain of Piezo1 function in brain endothelial cells, promoting dysfunctional neurovascular signaling and cognitive impairment. Targeting Piezo1 or PKC signaling selectively restored cerebrovascular regulation. This work identifies a mechanosensitive pathway that could be leveraged to protect the hypertensive brain.
中文摘要:高血压是神经血管功能障碍和认知能力下降的主要驱动因素,但连接动脉压升高与脑血流受损的分子机制尚不明确。Piezo1是一种富集于脑内皮细胞的机械敏感性阳离子通道,可能是高血压期间脑血流缺陷的候选介导因子。本研究利用两种不同的血压升高小鼠模型-BPH/2J小鼠(遗传性高血压品系)和注射血管紧张素II的C57BL/6J小鼠-通过膜片钳电生理技术评估了脑内皮Piezo1活性。使用内皮特异性Piezo1敲除模型评估该通道在高血压相关脑血管损伤中的作用。通过激光散斑对比成像体内测量脑血流反应,并利用超分辨率纳米显微镜量化Piezo1的纳米级组织。行为学测试用于评估认知功能。对内皮Piezo1进行基因操控对基础血压影响甚微。然而,在不同的高血压模型中,脑内皮Piezo1活性显著升高。敲除内皮Piezo1可保护免受高血压诱导的脑血管缺陷,包括血管运动受损、功能性充血减少以及CO2诱发的充血减弱。超分辨率成像显示高血压增加了Piezo1的聚集,这与电生理发现的通道耦合增强和开放概率增加一致。机制上,Piezo1过度活性依赖于PKC(蛋白激酶C),且高血压期间PKC-Piezo1的空间关联增强。重要的是,抑制PKC可恢复正常脑内皮Piezo1活性,恢复脑血流反应并挽救认知表现。高血压增加了脑内皮细胞中Piezo1功能的增益,促进了神经血管信号功能障碍和认知损害。选择性靶向Piezo1或PKC信号通路可恢复脑血管调节。本研究鉴定了一条机械敏感性通路,可用于保护高血压患者的脑部。

2心力衰竭 (11篇)

临床研究 (8篇)

Progress in cardiovascular diseases IF 10.6 2026-11-10 PMID: 43008840
Advanced heart failure management is increasingly defined by the interactions between evolving donor utilization and preservation strategies, mechanical circulatory support (MCS) technologies, and organ allocation frameworks. Heart donation after circulatory death has significantly expanded transplant availability in recent years, while advances in allograft preservation and ex vivo perfusion continue to challenge traditional constraints on ischemic time and donor selection. At the same time, modern temporary MCS platforms have demonstrated the feasibility of more prolonged support, enabling greater utilization of direct bridge-to-transplant pathways within allocation systems that prioritize temporary over durable support. Meanwhile, improvements in durable left ventricular assist device (LVAD) technology have progressively shifted their utilization toward destination therapy. Amid this dynamic therapeutic landscape, we sought to review current trends in donor utilization, preservation, mechanical support, and organ allocation. In doing so, we also evaluate how their intersection is reshaping contemporary treatment algorithms, resource stewardship, and pathways toward definitive heart replacement therapy.
中文摘要:晚期心力衰竭的管理日益由供体利用与保存策略的演变、机械循环支持(MCS)技术以及器官分配框架之间的相互作用所定义。近年来,循环死亡后心脏捐献显著扩大了移植的可及性,而移植物保存和体外灌注技术的进步不断挑战着传统的缺血时间限制和供体选择标准。同时,现代临时性MCS平台已证明更长期支持的可行性,使得在优先于持久性支持的分配系统中,能够更充分地利用直接桥接至移植的路径。与此同时,持久性左心室辅助装置(LVAD)技术的改进逐渐将其应用重心转向终点治疗。在这一动态的治疗格局中,我们旨在回顾供体利用、保存、机械支持和器官分配的当前趋势,并评估其交叉融合如何重塑当代治疗算法、资源管理以及通向最终心脏替代治疗的途径。
European heart journal IF 45.3 2026-11-10 PMID: 41978340
Conduction system pacing has emerged as an alternative to biventricular pacing (BiVP) for cardiac resynchronization therapy (CRT). The left-bundle CRT trial evaluated whether left-bundle branch area pacing (LBBAP) is non-inferior to BiVP in patients eligible for CRT. The left-bundle CRT trial was a multi-centre, randomized, investigator-initiated, and non-inferiority study. Patients with guideline-based CRT indications and left-bundle branch block per Strauss criteria were randomized to BiVP-CRT or LBBAP-CRT. The primary endpoint was the proportion of patients with a positive CRT response at 6-months, defined as either an improved clinical composite score (CCS) or a ≥15% reduction in left ventricular end-systolic volume. The non-inferiority margin was the lower bound of the 95% confidence interval (CI) and was set at 10%. Patients were followed for 12-months; secondary endpoints included echocardiographic, clinical, and quality-of-life outcomes. The baseline characteristics of the 176 patients randomized to BiVP-CRT (n=84) or LBBAP-CRT (n=92) were similar, except for a wider intrinsic QRS in the LBBAP group: median 172 ms [IQR 158-184] vs. 165 ms [152-180]; P=0.04. Crossovers occurred in 26 patients (14.9%). In the intention-to-treat analysis, the primary endpoint was achieved in 94.6% of BiVP-CRT and 89.7% of LBBAP-CRT patients (RR 0.95; 95% CI 0.88-1.02), not meeting non-inferiority. CCS improved in 77% and 68% of patients randomized to BiVP-CRT and LBBAP-CRT, respectively and 85% and 79% had a ≥15% reduction in left ventricular end-systolic volume. Rates of adverse events and heart failure hospitalization were similar between groups. In CRT candidates with typical LBBB, LBBAP-CRT was not shown to be non-inferior to BiVP-CRT. Both strategies yielded high response rates and similar clinical outcomes.
中文摘要:传导系统起搏已成为心脏再同步治疗(CRT)中双心室起搏(BiVP)的替代方案。LEFT-BUNDLE-CRT试验评估了在符合CRT适应证的患者中,左束支区域起搏(LBBAP)是否非劣于BiVP。该试验是一项多中心、随机、研究者发起的非劣效性研究。根据指南具有CRT适应证且符合Strauss标准的左束支传导阻滞患者被随机分配至BiVP-CRT组或LBBAP-CRT组。主要终点为6个月时出现阳性CRT反应的患者比例,定义为临床复合评分(CCS)改善或左室收缩末期容积减少≥15%。非劣效性界值设定为95%置信区间(CI)下限的10%。患者随访12个月;次要终点包括超声心动图、临床和生活质量结局。随机至BiVP-CRT组(n=84)和LBBAP-CRT组(n=92)的176名患者的基线特征相似,除LBBAP组的内在QRS波更宽:中位数172 ms [IQR 158-184] vs. 165 ms [152-180];P=0.04。共有26名患者(14.9%)发生交叉。在意向性治疗分析中,BiVP-CRT组94.6%和LBBAP-CRT组89.7%的患者达到主要终点(RR 0.95;95% CI 0.88-1.02),未达到非劣效性标准。随机至BiVP-CRT组和LBBAP-CRT组的患者中,分别有77%和68%的CCS改善,85%和79%的患者左室收缩末期容积减少≥15%。两组不良事件和心力衰竭住院率相似。在典型左束支传导阻滞(LBBB)的CRT候选者中,未显示LBBAP-CRT非劣于BiVP-CRT。两种策略均产生了高反应率和相似的临床结局。
European heart journal IF 45.3 2026-11-10 PMID: 41884984
While the prevalence, drivers, and impact of cardiometabolic risk factors are known to differ between women and men, less is known about sex differences in the cardiovascular-kidney-metabolic (CKM) syndrome. In this prespecified analysis, individual participant-level data were pooled from two trials of chronic kidney disease and type 2 diabetes (FIDELIO-DKD and FIGARO-DKD) and a trial of heart failure (HF) with mildly reduced or preserved ejection fraction (FINEARTS-HF). The risk of first HF hospitalization, cardiovascular death, major adverse cardiovascular events, kidney composite outcome, and all-cause death, was compared between men and women using adjusted Cox regression models. Treatment effect heterogeneity in response to finerenone was evaluated using interaction analyses. Of the 18 991 participants in FINE-HEART, 6664 (35%) were women. Compared with men, women were slightly older (69 vs 67 years) and had a lower median urine albumin-to-creatinine ratio (183 vs 337 mg/g). Women were more likely to have Stage 4 CKM syndrome but less likely to receive medical therapies commonly indicated for the management of CKM conditions at baseline, such as aspirin, statins, renin-angiotensin system inhibitors, sodium-glucose co-transporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists. During a median follow-up of 2.9 years, both women and men had similarly high rates of HF hospitalization or cardiovascular death (4.8 vs 3.9 per 100 patient-years, adjusted hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.89-1.06, P = .52) but lower risk of all-cause mortality (adjusted HR 0.83, 95% CI 0.76-0.91, P < .001) compared with men. There was no evidence of treatment heterogeneity by sex with finerenone in reducing cardiovascular, kidney, and mortality outcomes (all Pinteraction >.05). In this pooled analysis of individuals with advanced CKM syndrome, women had a higher burden of multimorbidity and were less likely to receive commonly indicated CKM therapies than men. Finerenone conferred consistent benefits in women and men, reinforcing its use while underscoring persistent sex-based treatment disparities in CKM care. PROSPERO identifier: CRD42024570467.
中文摘要:尽管已知心血管代谢危险因素在女性和男性中的患病率、驱动因素及影响存在差异,但关于心血管-肾脏-代谢(CKM)综合征的性别差异了解甚少。在这项预设分析中,我们将两项慢性肾病和2型糖尿病试验(FIDELIO-DKD和FIGARO-DKD)以及一项射血分数轻度降低或保留的心力衰竭(HF)试验(FINEARTS-HF)的个体参与者水平数据进行了汇总。使用调整后的Cox回归模型比较了男性和女性首次因HF住院、心血管死亡、主要不良心血管事件、肾脏复合结局和全因死亡的风险。通过交互分析评估了非奈利酮治疗反应的异质性。在FINE-HEART的18991名参与者中,6664名(35%)为女性。与男性相比,女性年龄稍大(69岁对67岁),尿白蛋白肌酐比值中位数较低(183对337 mg/g)。女性更可能患有4期CKM综合征,但在基线时接受常用于管理CKM疾病的药物治疗(如阿司匹林、他汀类药物、肾素-血管紧张素系统抑制剂、钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂)的可能性较低。在中位随访2.9年期间,女性和男性因HF住院或心血管死亡的比例均较高(4.8对3.9每100患者年,调整后的风险比[HR] 0.97,95%置信区间[CI] 0.89-1.06,P = .52),但与男性相比,全因死亡率风险较低(调整后的HR 0.83,95% CI 0.76-0.91,P < .001)。没有证据表明非奈利酮在降低心血管、肾脏和死亡结局方面存在性别治疗异质性(所有交互作用P值 > .05)。在这项针对晚期CKM综合征患者的汇总分析中,女性面临更高的多病负担,且接受常用CKM治疗的可能性低于男性。非奈利酮为女性和男性带来了一致的益处,强化了其使用价值,同时突显了CKM护理中持续存在的基于性别的治疗差异。PROSPERO注册号:CRD42024570467。
Nature medicine IF 52.5 2026-11-08 PMID: 43000472
The glucagon-like peptide-1 receptor agonist semaglutide improves symptoms in heart failure with preserved ejection fraction (HFpEF) through unclear mechanisms. Here, in this double-blind, placebo-controlled trial, we randomly assigned 81 patients (47 women) with HFpEF and obesity to semaglutide (2.4 mg weekly) or placebo for 52 weeks. The primary outcome was the change in invasively measured pulmonary artery wedge pressure (PAWP), a direct measure of cardiac congestion, during low-intensity exercise. Additional mechanistic outcomes included other hemodynamic measures and hemodynamic HFpEF remission (defined as normal PAWP under conditions of both rest and exercise at 52 weeks). At baseline, PAWP was 17.5 ± 4.3 mmHg at rest and 31.7 ± 5.2 mmHg during exercise. After 52 weeks, the mean change in PAWP during exercise was -9.8 (95% confidence interval (CI): -11.3 to -8.2) mmHg with semaglutide and +0.9 (95% CI: -1.3 to 3.0) mmHg with placebo (estimated difference, -10.6 mmHg; 95% CI: -13.3 to -8.0; P < 0.0001). As compared to placebo, semaglutide also decreased resting PAWP (estimated difference, -7.1 mmHg; 95% CI: -9.8 to -4.4; P < 0.0001), and semaglutide-treated patients were more likely to experience hemodynamic remission (53.7% versus 7.4%, odds ratio = 14.1, 95% CI: 3.0-134.6, P < 0.001). The results from this trial indicate that, in patients with HFpEF and obesity, treatment with semaglutide reduced left heart filling pressures during exercise and at rest and was associated with hemodynamic HFpEF remission in over half of treated patients. ClinicalTrials.gov identifier: NCT05371496 .
中文摘要:胰高血糖素样肽-1受体激动剂司美格鲁肽可改善射血分数保留的心力衰竭(HFpEF)患者的症状,但其机制尚不明确。本研究为一项双盲安慰剂对照试验,将81名(47名为女性)患有HFpEF和肥胖的患者随机分配至司美格鲁肽组(每周2.4 mg)或安慰剂组,持续52周。主要终点为低强度运动期间经导管测量的肺动脉楔压(PAWP,反映心脏充血程度的直接指标)的变化。其他机制性终点包括其他血流动力学指标及HFpEF血流动力学缓解情况(定义为在52周时静息和运动状态下PAWP均正常)。基线时,静息状态下PAWP为17.5±4.3 mmHg,运动时为31.7±5.2 mmHg。经过52周治疗后,司美格鲁肽组运动期间PAWP的平均变化为-9.8(95%置信区间CI:-11.3至-8.2)mmHg,而安慰剂组为+0.9(95% CI:-1.3至3.0)mmHg(估计差异为-10.6 mmHg;95% CI:-13.3至-8.0;P < 0.0001)。与安慰剂相比,司美格鲁肽还降低了静息状态下的PAWP(估计差异为-7.1 mmHg;95% CI:-9.8至-4.4;P < 0.0001),且接受司美格鲁肽治疗的患者更有可能实现血流动力学缓解(53.7%对7.4%,比值比OR=14.1,95% CI:3.0-134.6,P < 0.001)。本试验结果表明,在患有HFpEF和肥胖的患者中,司美格鲁肽治疗降低了运动及静息状态下的左心充盈压,并与超过半数接受治疗患者实现HFpEF血流动力学缓解相关。ClinicalTrials.gov标识符:NCT05371496。
Nature medicine IF 52.5 2026-11-08 PMID: 43000112
Glucagon-like peptide-1 receptor agonists improve symptoms in patients with obesity and heart failure with preserved ejection fraction (HFpEF). We recently demonstrated that semaglutide reduces exertional pulmonary artery wedge pressure (PAWP) in obesity-related HFpEF, but potential effects of semaglutide on cardiac structure and function that may underlie these hemodynamic improvements remain unclear. In this prespecified cardiovascular magnetic resonance (CMR) substudy of the randomized CAMEO-SEMA trial, 49 participants (33 semaglutide, 16 placebo, 28 female) underwent CMR at baseline and 52 weeks, within 1 day of invasive exercise hemodynamic assessment. The prespecified primary CMR endpoint was change in left atrial (LA) reservoir strain; other prespecified CMR endpoints included LV filling dynamics, which were assessed by early filling rate indexed to end-diastolic volume (eFR/EDV). Compared with placebo, semaglutide improved LA reservoir strain (+5.7% [95% CI, +0.3 to +9.7]; P=0.037) and eFR/EDV (+0.64 s-1 [95% CI, +0.42 to +1.00]; P<0.0001). Improvements in LA reservoir strain and LV filling dynamics were associated with reductions in exercise PAWP (r=-0.46, P<0.001 and r=-0.65, P<0.0001, respectively). With respect to other prespecified CMR endpoints, semaglutide reduced LV mass, restored more physiologic LV geometry, and improved right ventricular function and biventricular myocardial mechanics. The results of this CMR substudy indicate that in patients with obesity-related HFpEF, semaglutide improves LA function and LV diastolic filling dynamics, identifying improvements in myocardial function that may contribute to semaglutide's improvement of hemodynamics. ClinicalTrials.gov number: NCT05371496.
中文摘要:胰高血糖素样肽-1受体激动剂可改善肥胖和射血分数保留的心力衰竭(HFpEF)患者的症状。我们近期证实,司美格鲁肽可降低肥胖相关HFpEF患者的运动性肺动脉楔压(PAWP),但其对心脏结构和功能的潜在影响尚不明确,这些影响可能是血流动力学改善的基础。在本项随机CAMEO-SEMA试验的预先指定的心脏磁共振(CMR)亚组研究中,49名参与者(33人接受司美格鲁肽治疗,16人接受安慰剂治疗,28名为女性)在基线和52周时接受了CMR检查,并在有创运动血流动力学评估后1天内完成。预先指定的主要CMR终点是左心房(LA)储应变的变化;其他预先指定的CMR终点包括左心室充盈动力学,通过早期充盈率与舒张末期容积之比(eFR/EDV)进行评估。与安慰剂组相比,司美格鲁肽改善了左心房储应变(+5.7% [95% CI, +0.3 to +9.7]; P=0.037)和eFR/EDV(+0.64 s-1 [95% CI, +0.42 to +1.00]; P<0.0001)。左心房储应变和左心室充盈动力学的改善与运动性PAWP的降低相关(r=-0.46, P<0.001 和 r=-0.65, P<0.0001,分别)。关于其他预先指定的CMR终点,司美格鲁肽降低了左心室质量,恢复了更生理性的左心室几何形态,并改善了右心室功能和双心室心肌力学。本CMR亚组研究结果表明,在肥胖相关HFpEF患者中,司美格鲁肽改善了左心房功能和左心室舒张充盈动力学,识别出可能有助于司美格鲁肽改善血流动力学的心肌功能改善。ClinicalTrials.gov编号:NCT05371496。
Circulation. Heart failure IF 8.3 2026-11-08 PMID: 42999997
Background: Despite clear evidence that guideline-directed medical therapy (GDMT) significantly reduces mortality and hospitalizations in patients with heart failure (HF) with reduced and mildly reduced ejection fraction, real-world implementation remains suboptimal. Digital health interventions may promote GDMT titration after hospital discharge. Methods: The ENGAGE-HF trial was a multicenter, two-arm, open-label, randomized controlled trial across three academic centers, funded by the AHA Strategically Focused Research Network (SFRN) for Health Technology and Innovation. Patients recently hospitalized with HF, with or without a primary hospital diagnosis of HF, and LVEF <50% receiving suboptimal GDMT were randomized 1:1 to either the ENGAGE-HF app or usual care for 90 days. The ENGAGE-HF intervention consisted of a patient-facing mobile app and a clinician dashboard overseen by study coordinators. The primary outcome was the Medication Optimization Score (MOS, scale 0-100%) at 90 days. Secondary outcomes were individual GDMT therapies and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 90 days. Results: A total of 134 participants were randomized. At 90 days, the adjusted MOS was significantly higher in the ENGAGE-HF group compared to the control group (83.7% vs. 74.0%, p = 0.010). Results remained consistent across multiple sensitivity analyses. Overall prescribing prevalence increased more in the ENGAGE-HF group for MRAs (+15.9 vs. +2.5 percentage points) and SGLT2 inhibitors (+10.9 vs. +2.5 percentage points). Furthermore, the ENGAGE-HF group demonstrated greater increases in achieving target doses for ARNI (+18.8% vs. +6.3%) and beta-blockers (+8.5% vs. +0.6%). KCCQ-23 CSS at 90 days was 75.2 (SE 2.6) in the intervention group versus 72.2 (SE 2.6) in the control group (between-group p = 0.40). Conclusions: ENGAGE-HF, a digital health intervention that integrates remote monitoring, patient engagement, and clinical decision support, significantly improved GDMT optimization at 90 days compared with usual care among patients with HF. Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT06750549.
中文摘要:背景:尽管有明确证据表明指南指导的药物治疗(GDMT)能显著降低射血分数降低和轻度降低的心力衰竭(HF)患者的死亡率和住院率,但现实世界中的实施效果仍不理想。数字健康干预可能促进患者出院后的GDMT滴定调整。方法:ENGAGE-HF试验是一项多中心、两臂、开放标签的随机对照试验,在三个学术中心开展,由美国心脏协会战略重点研究网络(SFRN)资助。近期因HF住院且LVEF<50%接受亚优化GDMT治疗的患者被1:1随机分配至ENGAGE-HF应用程序组或常规护理组,干预持续90天。ENGAGE-HF干预措施包括患者端移动应用程序和由研究协调员监督的临床医生仪表板。主要结局为90天时的药物优化评分(MOS,范围0-100%)。次要结局包括个体GDMT治疗药物的使用情况及90天时的堪萨斯城心肌病问卷临床摘要评分(KCCQ-23 CSS)。结果:共随机分配134名参与者。在90天时,ENGAGE-HF组的调整MOS显著高于对照组(83.7% vs 74.0%,p=0.010)。多种敏感性分析结果保持一致。ENGAGE-HF组中MRAs(+15.9 vs +2.5个百分点)和SGLT2抑制剂(+10.9 vs +2.5个百分点)的总体处方比例增加更多。此外,ENGAGE-HF组在达到ARNI目标剂量(+18.8% vs +6.3%)和β受体阻滞剂目标剂量(+8.5% vs +0.6%)方面表现出更大的增长。90天时干预组的KCCQ-23 CSS为75.2(SE 2.6),对照组为72.2(SE 2.6)(组间p=0.40)。结论:与常规护理相比,ENGAGE-HF这一整合远程监测、患者参与和临床决策支持的数字健康干预措施,显著改善了HF患者在90天时的GDMT优化水平。注册:URL: https://clinicaltrials.gov 唯一标识符:NCT06750549
Circulation. Heart failure IF 8.3 2026-11-06 PMID: 42993694
Barriers to optimizing guideline-directed medical therapy (GDMT) for heart failure include infrequent clinical visits, clinician inertia, and poor patient knowledge. Digital health interventions (DHIs) may mitigate these barriers, but evidence from low- and middle-income countries is limited. We evaluated whether a DHI would improve GDMT use and other outcomes in Brazil. We enrolled adults admitted for heart failure with ejection fraction <50% and GDMT gaps (≥1 GDMT class not started or ≥2 classes ≤50% target dose) across 5 Brazilian public hospitals from November 2023 to August 2025. Participants were randomized to usual care or the DHI comprising a patient-facing app linked to a provider dashboard, supporting nurse-led remote monitoring, cardiologist teleconsultations, and self-care education. The primary outcome was the between-group difference in mean heart failure GDMT score (0-12) at 90 days. Secondary outcomes included differences in health status, self-care, hospitalization rates, and all-cause mortality. Intention-to-treat analyses used baseline-adjusted linear regression and estimated risk ratios. Among 154 randomized patients (DHI: 87; usual care: 67), mean age was 65±14 years; 62% were male, 66% were Black, 44% had ≤4 years of education, and 68% were New York Heart Association class III/IV. Primary outcome data were available for 141 participants (91.6%; DHI: 81; usual care: 60). Mean GDMT scores increased from 7.2 in both groups to 10.5 with DHI versus 7.5 with usual care at 90 days (changes: +3.3 versus +0.3 points; adjusted difference, 3.01 [95% CI, 2.30-3.73]; P<0.001). A borderline difference was observed in health status (7.89; P=0.052). Improvements were observed in self-care (β=14.79 [95% CI, 9.78-19.81]; P<0.001). Fewer participants were hospitalized with DHI than usual care (9/87 [10.3%] versus 15/67 [22.4%]; risk ratio, 0.46 [95% CI, 0.21-0.99]; P=0.048), with no statistically significant difference for deaths. In patients hospitalized for heart failure in Brazil, a context-adapted DHI improved GDMT use, self-care, and reduced hospitalizations. These findings provide early randomized evidence supporting DHI for GDMT optimization in low-resource settings. URL: https://ensaiosclinicos.gov.br/rg/RBR-10vpf9bm; Unique identifier: U1111-1295-1864.
中文摘要:优化心力衰竭指南指导的药物治疗(GDMT)面临的障碍包括临床就诊频率低、医生惰性以及患者知识匮乏。数字健康干预(DHI)可能缓解这些障碍,但来自中低收入国家的证据有限。本研究评估了巴西的一项DHI是否能改善GDMT使用及其他结局。我们于2023年11月至2025年8月在巴西5家公立医院招募了因射血分数<50%且存在GDMT缺口(≥1类GDMT未启动或≥2类药物剂量≤目标剂量的50%)而入院的心力衰竭成年患者。参与者被随机分配至常规护理组或DHI组,后者包括面向患者的应用程序、连接医生仪表板、支持护士主导的远程监测、心脏病学远程会诊及自我护理教育。主要结局为90天时两组间平均心力衰竭GDMT评分(0-12分)的差异。次要结局包括健康状况、自我护理、住院率和全因死亡率的差异。意向性治疗分析采用基线调整的线性回归和估计风险比。在154名随机分配的参与者中(DHI组87人,常规护理组67人),平均年龄为65±14岁;男性占62%,黑人占66%,受教育年限≤4年者占44%,纽约心脏协会心功能III/IV级者占68%。主要结局数据在141名参与者中可用(91.6%;DHI组81人,常规护理组60人)。两组基线GDMT评分均值均为7.2分,90天时DHI组增至10.5分,常规护理组增至7.5分(变化幅度:+3.3分 vs +0.3分;调整后差异为3.01 [95% CI, 2.30-3.73];P<0.001)。健康状况方面观察到边缘性差异(7.89; P=0.052)。自我护理方面有显著改善(β=14.79 [95% CI, 9.78-19.81]; P<0.001)。DHI组住院人数少于常规护理组(9/87 [10.3%] vs 15/67 [22.4%]; 风险比0.46 [95% CI, 0.21-0.99]; P=0.048),死亡差异无统计学意义。在巴西因心力衰竭住院的患者中,情境适应的DHI改善了GDMT使用和自我护理,并降低了住院率。这些发现提供了支持在资源有限环境中使用DHI优化GDMT的早期随机证据。
European heart journal IF 45.3 2026-11-06 PMID: 41879158
Cardiovascular disease remains the leading global cause of morbidity and mortality. Although advances in prevention, diagnostics, and disease-modifying therapies have prolonged survival, many individuals now live longer with high symptom burden, functional decline, and complex decisional needs. Palliative care (PC) for adults with advanced cardiovascular disease can improve quality of life, support caregivers, and align treatments with patient values and goals. Core elements include symptom management, effective communication, shared decision-making, advance care planning, and integration of psychosocial and spiritual support across the disease trajectory and different care settings. Current evidence demonstrates that early PC intervention can improve symptom control, enhance quality of life, reduce psychological distress, and decrease high-intensity yet low-value care near the end of life. Nevertheless, outside of heart failure populations, gaps in widespread PC implementation across populations supported with cardiac devices as well as across diverse cultural and health systems remain. This state-of-the-art review (i) synthesizes conceptual foundations, referral triggers, and delivery models for PC in cardiovascular medicine; (ii) reviews disease-specific considerations across heart failure, valvular disease, pulmonary hypertension, arrhythmias, and congenital heart disease; (iii) outlines ethical and legal issues including advance directives and device deactivation; (iv) provides practical guidance for symptom management and communication frameworks; and (v) proposes a pragmatic algorithm to support clinical integration of PC into cardiovascular medicine.
中文摘要:心血管疾病仍是全球发病率和死亡率的主要原因。尽管预防、诊断和疾病修饰疗法的进步延长了生存期,但许多人长期承受高症状负担、功能衰退和复杂的决策需求。针对晚期心血管疾病成年患者的姑息治疗可改善生活质量,支持照护者,并使治疗与患者价值观和目标保持一致。核心要素包括症状管理、有效沟通、共同决策、预先护理计划以及贯穿疾病轨迹和不同照护环境的心理社会和精神支持整合。现有证据表明,早期姑息治疗干预可改善症状控制,提高生活质量,减轻心理困扰,并减少生命末期高强度但低价值的医疗照护。然而,除心力衰竭人群外,在广泛实施姑息治疗方面仍存在缺口,特别是在接受心脏设备支持的群体以及不同文化和卫生系统中。本综述(一)综合了心血管医学中姑息治疗的概念基础、转诊触发因素和交付模式;(二)回顾了心力衰竭、瓣膜病、肺动脉高压、心律失常和先天性心脏病等不同疾病的具体考量;(三)概述了包括预先指示和设备停用在内的伦理和法律问题;(四)提供了症状管理和沟通框架的实践指导;(五)提出了支持姑息治疗整合到心血管医学中的实用算法。

基础研究 (3篇)

Pharmacological research IF 12.2 2026-11-12 PMID: 43020397
Heart failure is characterized by sympathetic remodeling, altered myocardial adrenergic responsiveness, and cardiomyocyte injury, with ferroptosis emerging as a potential contributor to adverse cardiac remodeling. This review proposes a dynamic "sympathetic-ferroptosis continuum" within a "nerve terminal-cardiomyocyte" dual-compartment framework linking cardiac sympathetic dysfunction, β1-adrenergic receptor (β1-AR)/cyclic adenosine monophosphate (cAMP) signaling, and cardiomyocyte ferroptosis susceptibility. Sustained sympathetic drive can coexist with altered norepinephrine (NE) homeostasis at cardiac nerve terminals and myocardial β1-AR desensitization, creating a functional mismatch between sympathetic activity and myocardial signaling responsiveness. At sympathetic nerve terminals, altered β1-AR/cAMP signaling may influence tyrosine hydroxylase-dependent NE synthesis and synapsin 1/RIM1α-associated vesicle mobilization and release, alongside changes in NE transporter-mediated reuptake. In cardiomyocytes, dysregulated compartment-specific cAMP signaling may affect YAP-associated iron homeostasis, LPCAT3-mediated phospholipid remodeling, SLC7A11/GSH/GPX4-dependent antioxidant defenses, and NOX4-related oxidative stress, thereby modifying ferroptosis susceptibility. Together, these pathways provide an integrated mechanistic framework linking neurocardiac signaling imbalance with cardiomyocyte ferroptosis susceptibility. This framework identifies potential targets for preserving adaptive cAMP signaling, improving sympathetic neurotransmitter homeostasis, and limiting ferroptosis-related injury, providing new directions for compartment-specific cardioprotective strategies in heart failure.
中文摘要:心力衰竭的特征包括交感神经重塑、心肌肾上腺素能反应性改变及心肌细胞损伤,其中铁死亡被认为是导致不良心脏重塑的潜在因素。本综述在“神经末梢-心肌细胞”双室框架下提出动态的“交感-铁死亡连续体”,将心脏交感功能障碍、β1-肾上腺素能受体(β1-AR)/环磷酸腺苷(cAMP)信号通路与心肌细胞铁死亡易感性联系起来。持续的交感驱动可与心脏神经末梢去甲肾上腺素(NE)稳态改变及心肌β1-AR脱敏共存,导致交感活性与心肌信号反应性之间的功能不匹配。在交感神经末梢,改变的β1-AR/cAMP信号可能影响酪氨酸羟化酶依赖的NE合成、突触蛋白1/RIM1α相关的囊泡动员与释放,以及NE转运体介导的重摄取变化。在心肌细胞中,失调的室特异性cAMP信号可能影响YAP相关的铁稳态、LPCAT3介导的磷脂重塑、SLC7A11/GSH/GPX4依赖的抗氧化防御及NOX4相关的氧化应激,从而改变铁死亡易感性。这些通路共同提供了将神经心脏信号失衡与心肌细胞铁死亡易感性联系起来的整合机制框架。该框架确定了保护适应性cAMP信号、改善交感神经递质稳态及限制铁死亡相关损伤的潜在靶点,为心力衰竭的室特异性心脏保护策略提供了新方向。
Circulation. Heart failure IF 8.3 2026-11-06 PMID: 42990086
Skeletal muscle dysfunction is a major peripheral determinant of exercise intolerance and physical disability in heart failure with preserved ejection fraction (HFpEF). Metabolic and mitochondrial dysfunction are considered to be key components of skeletal muscle dysfunction, but comprehensive profiling of metabolic pathways has not been conducted. Elucidation of dysregulated metabolic pathways is essential to determine viable targets for the treatment of exercise intolerance in HFpEF. Male ZSF1 Obese rats (HFpEF, n=8) and Wistar Kyoto lean normotensive controls (Control, n=8) were studied at 26 weeks of age. The gastrocnemius was analyzed using bulk RNA sequencing, proteomics, metabolomics, and lipidomics. Differential expression across all omics layers was determined using standard statistical modeling with thresholds of absolute fold‑change >1.5 and FDR <0.05, unless otherwise specified. Additional targeted plasma and skeletal muscle metabolomics and lipidomics were performed in HFpEF and control rats, including analyses of the soleus and the extensor digitorum longus, to validate features associated with predominantly oxidative and glycolytic muscle, respectively. Pathway-level analysis for RNA sequencing and proteomics revealed significant downregulation of oxidative phosphorylation (natural enrichment score (NES), -2.1; P<0.005), electron transport chain (NES, -2.0; P<0.005), and tricarboxylic acid cycle cycle (-1.8; P<0.05). The most upregulated pathways were PPAR signaling (NES, 2.2; P<0.0001), tryptophan metabolism (NES, 1.8; P<0.005), and amino acid oxidation (NES, 1.8; P<0.005) pathways. Metabolomics revealed an accumulation of tricarboxylic acid cycle cycle intermediate, isocitrate, and phosphate reduction. Branched-chain amino acids were significantly increased, whereas amino acids related to tryptophan metabolism were reduced and shifted towards increased serotonin accumulation. Phospholipid species were differentially regulated with increased palmitoylated phosphatidylcholines but reduced arachidonoyl-phosphatidylcholine species. Phosphatidylethanolamines species (16:0/16:1-18:0/18:2) were increased. HFpEF skeletal muscle shows signatures of profound mitochondrial and peroxisomal dysfunction with lipid overload, impaired branched chain amino acid and tryptophan metabolism, and a shift in membrane phospholipid composition, supporting an acquired metabolic myopathy in cardiometabolic HFpEF.
中文摘要:骨骼肌功能障碍是射血分数保留的心力衰竭(HFpEF)患者运动不耐受和身体残疾的主要外周决定因素。代谢和线粒体功能障碍被认为是骨骼肌功能障碍的关键组成部分,但尚未对代谢通路进行综合分析。阐明失调的代谢通路对于确定治疗HFpEF运动不耐受的可行靶点至关重要。本研究在26周龄时分析了男性ZSF1肥胖大鼠(HFpEF,n=8)和Wistar Kyoto瘦削正常血压对照大鼠(Control,n=8)。采用批量RNA测序、蛋白质组学、代谢组学和脂质组学分析腓肠肌。使用标准统计模型确定所有多组学层面的差异表达,阈值设定为绝对倍数变化大于1.5且FDR小于0.05,除非另有说明。在HFpEF和对照大鼠中进行了额外的靶向血浆和骨骼肌代谢组学与脂质组学分析,包括对主要具有氧化特性的比目鱼肌和主要具有糖酵解特性的趾长伸肌的分析,以验证与这些特性相关的特征。RNA测序和蛋白质组学的通路水平分析显示氧化磷酸化(自然富集分数NES为-2.1;P<0.005)、电子传递链(NES为-2.0;P<0.005)和三羧酸循环(NES为-1.8;P<0.05)显著下调。上调最显著的通路包括PPAR信号通路(NES为2.2;P<0.0001)、色氨酸代谢(NES为1.8;P<0.005)和氨基酸氧化(NES为1.8;P<0.005)通路。代谢组学显示三羧酸循环中间产物异柠檬酸积累以及磷酸盐还原。支链氨基酸显著增加,而与色氨酸代谢相关的氨基酸减少并转向血清素积累增加。磷脂种类差异调节,棕榈酰化磷脂酰胆碱增加而花生四烯酰基磷脂酰胆碱种类减少。磷脂酰乙醇胺种类(16:0/16:1-18:0/18:2)增加。HFpEF骨骼肌表现出严重的线粒体和过氧化物酶体功能障碍、脂质超载、支链氨基酸和色氨酸代谢受损以及膜磷脂组成改变的迹象,支持在心脏代谢性HFpEF中存在获得性代谢性肌病。
Cardiovascular research IF 12.5 2026-11-06 PMID: 42626971
Heart failure is marked by suppression of fatty acid oxidation (FAO) and mitochondrial ATP production gene expression. While transcriptional downregulation via PGC-1 and PPARα/ERRα has been well documented, the involvement of the general transcriptional machinery remains insufficiently understood. Distinct from its salutary role in many cardiac conditions, endogenous Sirt1 negatively affects cardiac function during pressure overload (PO). This study investigates how Sirt1 modulates preinitiation complex (PIC) assembly and RNA polymerase II (Pol II) recruitment during pathological PO. Cardiac-specific Sirt1 knock-out (Sirt1 cKO) mice were subjected to PO. Interaction between Sirt1 and Sub1, a protein recruiting GTFs to the gene promoter, was assessed with co-immunoprecipitation, protein pull-down, and molecular docking. Pol II recruitment was evaluated with chromatin immunoprecipitation-sequencing (ChIP-seq) and ChIP-qPCR analyses. The binding affinity of Sirt1 and GTF to the Sub1 GTF binding domain was assessed by immunoprecipitation and protein pull-down assays. Unbiased ChIP-seq and ChIP-qPCR analyses showed that Pol II binding to metabolic gene promoters was downregulated during PO, which was reversed in Sirt1 cKO mice. PO upregulated Sirt1 in the heart and increased its binding to Sub1, which interacts with PPARα and ERRα but not NF-kB. Sirt1 binding to Sub1 competitively displaced the interaction between Sub1 and GTFs, thereby inhibiting PIC formation at the Sub1-PPARα/ERRα complex. Sirt1 impairs metabolic gene transcription during PO by competitively inhibiting Sub1-mediated recruitment of GTFs and PIC formation. This repression of general transcriptional machinery contributes to the metabolic disturbance and may represent a maladaptive component of the heart failure phenotype.
中文摘要:心力衰竭的特征是脂肪酸氧化和线粒体ATP产生基因表达的抑制。虽然通过PGC-1和PPARα/ERRα的转录下调已有充分记载,但一般转录机制的作用仍不清楚。与在许多心脏疾病中的有益作用不同,内源性Sirt1在压力超负荷期间对心脏功能产生负面影响。本研究探讨Sirt1如何在病理性压力超负荷期间调节前起始复合物的组装和RNA聚合酶II的招募。将心脏特异性Sirt1敲除小鼠置于压力超负荷模型中。通过共免疫沉淀、蛋白下拉和分子对接评估Sirt1与Sub1(一种将通用转录因子招募至基因启动子的蛋白)之间的相互作用。通过染色质免疫沉淀测序和ChIP-qPCR分析评估RNA聚合酶II的招募情况。通过免疫沉淀和蛋白下拉实验评估Sirt1和通用转录因子与Sub1结合域的亲和力。无偏倚的ChIP-seq和ChIP-qPCR分析显示,压力超负荷期间代谢基因启动子上的RNA聚合酶II结合下调,这在Sirt1敲除小鼠中逆转。压力超负荷上调心脏中的Sirt1并增加其与Sub1的结合,Sub1与PPARα和ERRα相互作用但不与NF-kB相互作用。Sirt1与Sub1的结合竞争性取代了Sub1与通用转录因子之间的相互作用,从而抑制Sub1-PPARα/ERRα复合物处前起始复合物的形成。Sirt1通过竞争性抑制Sub1介导的通用转录因子招募和前起始复合物形成来损害压力超负荷期间的代谢基因转录。这种一般转录机制的抑制导致代谢紊乱,并可能代表心力衰竭表型的一种适应不良成分。

3心肌梗死/ACS (10篇)

临床研究 (5篇)

European journal of preventive cardiology IF 10.0 2026-11-11 PMID: 43017810
Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor generally considered stable over an individual's lifetime. Acute coronary syndrome (ACS) may transiently alter Lp(a) concentrations, complicating interpretation. We systematically evaluated temporal changes in Lp(a) following ACS. This PRISMA 2020-guided systematic review searched MEDLINE and Embase from database inception to February 2026. Eligible studies reported serial Lp(a) measurements at two or more time points after index ACS event. Exploratory random-effects meta-analysis of percent change in mean Lp(a) was performed. Of 3,811 records, 16 studies comprising 1,396 patients met inclusion criteria. Lp(a) demonstrated a dynamic post-ACS trajectory. Using initial post-ACS measurements as the reference, pooled percent change in mean Lp(a) was non-significant at 24 hours post-ACS (+2.5%, 95% CI -6.8 to 11.7; p=0.602). Lp(a) was significantly higher at 7-14 days (+44.0%, 95% CI 4.0-84.1; p=0.031), 1 month (+28.3%, 95% CI 2.7-54.0; p=0.030), and 3-6 months (+22.2%, 95% CI 2.4-42.0; p=0.028). Across two studies, absolute Lp(a) increases >25 nmol/L occurred in 17% and 22% of patients by 3 and 6 months, respectively. Lp(a) is not static post-ACS. Early post-ACS measurements may underestimate long-term concentrations and risk. Repeat measurement weeks to months later is most informative when initial post-ACS Lp(a) values are near clinical decision thresholds or would influence eligibility for emerging Lp(a)-lowering therapies.
中文摘要:脂蛋白[a](Lp[a])是一种遗传决定的心血管危险因素,通常被认为在个体一生中保持稳定。急性冠脉综合征(ACS)可能会暂时改变Lp[a]浓度,从而增加解读难度。我们系统评估了ACS后Lp[a]的时间变化。本PRISMA 2020指南指导的系统评价检索了从数据库建库至2026年2月的MEDLINE和Embase数据库。纳入标准的研究报告了索引ACS事件后两个或多个时间点的连续Lp[a]测量值。我们对平均Lp[a]的百分比变化进行了探索性随机效应Meta分析。在3,811条记录中,16项包含1,396名患者的研究符合纳入标准。Lp[a]在ACS后表现出动态轨迹。以初始ACS后测量值为参考,ACS后24小时平均Lp[a]的合并百分比变化无统计学意义(+2.5%,95% CI -6.8至11.7;p=0.602)。在ACS后7-14天(+44.0%,95% CI 4.0-84.1;p=0.031)、1个月(+28.3%,95% CI 2.7-54.0;p=0.030)和3-6个月(+22.2%,95% CI 2.4-42.0;p=0.028),Lp[a]显著升高。在两项研究中,分别在ACS后3个月和6个月时,17%和22%的患者出现绝对Lp[a]增加超过25 nmol/L。ACS后Lp[a]并非静止不变。早期ACS后测量值可能低估长期浓度和风险。当初始ACS后Lp[a]值接近临床决策阈值或会影响新兴Lp[a]降低疗法的资格时,数周至数月后的重复测量最具信息价值。
European heart journal IF 45.3 2026-11-10 PMID: 42183826
In patients with myocardial infarction (MI), no heart failure, and left ventricular ejection fraction (LVEF) ≥ 40%, the combined BETAMI-DANBLOCK trial showed that beta-blockers reduced the risk of all-cause mortality or major adverse cardiovascular events. This study evaluated the representativeness of the trial. Participants in BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with a cohort of revascularized MI patients with LVEF ≥40%, and no heart failure from the Norwegian Myocardial Infarction Registry (the NORMI cohort)(n = 20 804). Baseline characteristics were evaluated, and absolute risks of all-cause mortality and/or MI were estimated. A transportability analysis was conducted by weighting the BETAMI-DANBLOCK population according to the NORMI cohort. Median age was 66 years (interquartile range [IQR]: 57-74) in the NORMI cohort and 63 years (IQR: 55-70) in BETAMI and DANBLOCK. Patients in the NORMI cohort had a higher prevalence of diabetes, previous coronary artery disease, and LVEF 40-49%, compared with trial participants. At 3-year follow-up, the absolute risk of all-cause mortality or MI was 12.0% in the NORMI cohort, 7.7% in BETAMI, and 7.8% in DANBLOCK. Corresponding risks of MI were 6.3%, 5.6%, and 4.3%, respectively. The treatment effects of beta-blockers were similar when the trial population was weighted according to the characteristics of the NORMI cohort. Compared with the NORMI cohort, participants in BETAMI and DANBLOCK were younger, had a lower proportion of certain comorbidities, and experienced a lower risk of all-cause mortality and MI. Despite these differences, the effect of beta-blockers remained consistent when the trial population was weighted according to the NORMI cohort.
中文摘要:在心肌梗死患者中,若无心力衰竭且左室射血分数≥40%,联合BETAMI-DANBLOCK试验显示β受体阻滞剂可降低全因死亡或主要不良心血管事件的风险。本研究评估了该试验的代表性。将BETAMI(n=2867)和DANBLOCK(n=2707)的参与者与来自挪威心肌梗死登记数据库(NORMI队列,n=20804)中接受血运重建、左室射血分数≥40%且无心衰的心肌梗死患者队列进行比较。评估了基线特征,并估算了全因死亡和/或心肌梗死的绝对风险。通过对BETAMI-DANBLOCK人群根据NORMI队列特征进行加权,进行了可迁移性分析。NORMI队列的中位年龄为66岁(四分位距57-74),而BETAMI和DANBLOCK为63岁(四分位距55-70)。与试验参与者相比,NORMI队列患者糖尿病、既往冠心病及左室射血分数40-49%的比例更高。在3年随访中,NORMI队列的全因死亡或心肌梗死绝对风险为12.0%,BETAMI为7.7%,DANBLOCK为7.8%。心肌梗死的相应风险分别为6.3%、5.6%和4.3%。当根据NORMI队列的特征对试验人群进行加权时,β受体阻滞剂的治疗效果相似。与NORMI队列相比,BETAMI和DANBLOCK的参与者更年轻,某些合并症的比例较低,全因死亡和心肌梗死的风险也较低。尽管存在这些差异,但当根据NORMI队列特征对试验人群进行加权时,β受体阻滞剂的效果保持一致。
European heart journal IF 45.3 2026-11-10 PMID: 42085325
There is a lack of long-term outcome data supporting the role of nurses in cardiovascular (CV) risk management. The ALLEPRE [ALLiance for sEcondary PREvention after an acute coronary syndrome (ACS)] trial was a pragmatic, randomized, multicentre, interventional trial comparing the efficacy of a nurse-coordinated prevention program (NCPP) with standard of care (SOC). The NCPP patients attended nine individual educational sessions over four years at which a centrally trained nurse provided counselling aimed at identifying CV risk factors and encouraging healthier lifestyles and medication adherence; the SOC patients followed the standard practices of their hospitals. The trial's primary endpoint was the composite of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke (MACE). A total of 2057 ACS patients were randomized 1:1 to the NCCP (n=1031) or SOC group (n=1026). In comparison with SOC, the NCPP significantly reduced MACE [16.2% vs 22.6%; hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.57-0.85; P-value <0.001], a benefit mainly driven by a reduction in non-fatal MI (9.3% vs 15.2%; HR 0.60; 95% CI 0.46-0.77; P-value=0.0001). The occurrence of the pre-specified secondary outcome of MACE plus ischaemia-driven revascularization was significantly reduced (HR 0.77, 95% CI 0.64-0.92; P-value= 0.005). Exercise frequency (P<0.0001), body weight control (P=0.003), and medication adherence (P<0.001) improved more in the NCPP group. The NCPP significantly reduced long-term MACE, improved physical activity, body weight control, and pharmacotherapy adherence in post-hospitalization ACS patients. Including an NCPP in healthcare provision may contribute to the successful implementation of secondary prevention strategies.
中文摘要:目前缺乏支持护士在心血管风险管理中作用长期结局数据。AL LEPRE试验是一项务实的多中心随机干预试验,比较了护士协调预防项目与标准护理的疗效。接受护士协调预防项目的患者四年内参加九次个体化教育课程,由中央培训的护士提供咨询,旨在识别心血管危险因素并鼓励健康生活方式和药物依从性;接受标准护理的患者遵循其所在医院的常规做法。主要终点为心血管死亡、非致死性心肌梗死和非致死性卒中的复合终点。共2057名急性冠脉综合征患者按1:1随机分配至护士协调预防组或标准护理组。与标准护理相比,护士协调预防项目显著降低主要不良心血管事件发生率,这一获益主要由非致死性心肌梗死的减少驱动。预先指定的次要结局包括合并缺血驱动血运重建的主要不良心血管事件的发生率也显著降低。护士协调预防组在运动频率、体重控制和药物依从性方面改善更明显。护士协调预防项目显著降低了急性冠脉综合征患者出院后的长期主要不良心血管事件,改善了体力活动、体重控制和药物治疗依从性。将护士协调预防项目纳入医疗保健可能有助于成功实施二级预防策略。
European journal of preventive cardiology IF 10.0 2026-11-08 PMID: 42999996
Lipoprotein(a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease. Using Lp(a) concentrations measured during stable follow-up as the reference, we aimed to assess the temporal variability of Lp(a) after acute myocardial infarction (AMI) and to explore a pragmatic strategy for Lp(a) measurement. The FRENCHIE-Lp(a) cohort enrolled consecutive adults hospitalized for AMI in 21 centres. Lp(a) mass concentration, measured at admission, hospital discharge, and 3-12 months follow-up, was analysed both as a continuous and predefined categorical variable (≤20, >20-≤50, >50-≤70, >70 mg/dL). Assuming follow-up Lp(a) as the reference, we aimed to identify the threshold values that would allow us to accurately identify patients with Lp(a) > 70mg/dL, the threshold mostly used for patient selection in phase III trials of targeted Lp(a) therapies. A cumulative threshold analysis was performed to identify the Lp(a) value below which the misclassification rate (i.e. % of patients with follow-up Lp(a) > 70 mg/dL) remained <1%. Among 1561 patients (aged 61 ± 12 years; 21.3% women), median Lp(a) was 13 mg/dL at admission and remained stable over time (median difference overtime = 0 mg/dL). However, only 68.5% of patients remained in the same Lp(a) category overtime. In patients with discharge-Lp(a) ≤37 mg/dL (72.5% of the population), only 0.97% had Lp(a) >70 mg/dL at follow-up compared to 39.9% of those with discharge-Lp(a) >37 mg/dL. Although the median Lp(a) level remained stable between admission and follow-up, one-third of AMI patients shifted within Lp(a) categories over time. Pending external validation, an exploratory two-step strategy based on Lp(a) measurement at discharge, followed by repeat testing in patients with Lp(a) >37 mg/dL, showed a misclassification rate below 1% for identifying patients potentially needing intervention. Clinical trial Number: NCT04050956.
中文摘要:脂蛋白[a](Lp[a])是动脉粥样硬化性心血管疾病的公认危险因素。本研究以稳定随访期测得的Lp[a]浓度为参考,旨在评估急性心肌梗死(AMI)后Lp[a]的时间变异性,并探索一种实用的Lp[a]检测策略。FRENCHIE-Lp(a)队列纳入了21个中心连续入院的AMI成年患者。分析入院时、出院时及3-12个月随访时的Lp[a]质量浓度,既作为连续变量也作为预设分类变量(≤20、>20-≤50、>50-≤70、>70 mg/dL)进行分析。假设随访Lp[a]为参考值,旨在确定能够准确识别Lp[a]>70mg/dL患者的阈值,该阈值是III期靶向Lp[a]治疗药物患者选择中最常用的标准。进行累积阈值分析以确定Lp[a]值,使得误分类率(即随访Lp[a]>70 mg/dL的患者百分比)保持在1%以下。在1561名患者(年龄61±12岁;女性占21.3%)中,入院时中位Lp[a]为13 mg/dL,且随时间保持稳定(时间中位数差异=0 mg/dL)。然而,只有68.5%的患者在随访期间保持在相同的Lp[a]类别中。在出院Lp[a]≤37 mg/dL的患者(占人群的72.5%)中,只有0.97%在随访时Lp[a]>70 mg/dL,而在出院Lp[a]>37 mg/dL的患者中这一比例为39.9%。尽管入院至随访期间Lp[a]的中位水平保持稳定,但三分之一的AMI患者随时间在Lp[a]类别间发生转变。在等待外部验证的同时,一种基于出院时Lp[a]检测、随后对Lp[a]>37 mg/dL患者进行重复测试的两步探索性策略,显示识别可能需要干预的患者时的误分类率低于1%。临床试验编号:NCT04050956。
Circulation IF 41.3 2026-11-07 PMID: 42998293
In acute myocardial infarction complicated by cardiogenic shock (AMI-CS), the myocardium sustains a dual injury: ischemia of the culprit territory and global hypoperfusion from low cardiac output. Whether platelet inhibition at reperfusion affects the microcirculation, the infarct, the noninfarcted myocardium, and ventricular function, and over what time course, has not been examined with serial imaging. The prespecified multimodality imaging substudy of the randomized DAPT-SHOCK-AMI trial (intravenous cangrelor versus crushed oral ticagrelor) addressed this question. Patients at prespecified imaging sites underwent serial echocardiography (208 enrolled; evaluable examinations in 175, 120, and 99 patients in the acute phase, at 1 month, and at 1 year) and cardiac magnetic resonance (CMR; 93 enrolled; 73, 68, and 63); 81 patients (40 and 41) underwent both modalities. Blinded core laboratories analyzed all studies. The primary imaging endpoint was microvascular obstruction (MVO) on acute CMR, evaluable in 60 patients; secondary endpoints were infarct size, native T1 of the global, infarcted, and remote myocardium, left ventricular (LV) ejection fraction (LVEF), global longitudinal strain (GLS), E/e', and left atrial volume, and their changes. Comparisons between the cangrelor and crushed ticagrelor arms used covariate-adjusted logistic or linear regression; the substudy was not separately powered. The odds of acute MVO were lower with cangrelor (adjusted odds ratio 0.27 [95% CI 0.08 to 0.98]; P=0.023). Infarct size did not differ between the arms. At 1 year, native T1 of the remote myocardium was lower with cangrelor (adjusted mean 1114 [95% CI 1057 to 1171] versus 1171 [1115 to 1228] ms; P=0.005). Over 1 year, LVEF increased more with cangrelor on echocardiography (37.9% versus 21.7% of the acute value; adjusted P=0.046) and CMR (15.8% versus 2.1%; P=0.027), with greater improvement in GLS, lower E/e', and less left atrial enlargement; no parameter differed between the arms at 1 month. In AMI-CS, serial multimodality imaging characterized microvascular, tissue-level, and functional injury over 1 year. Cangrelor was associated with less acute MVO, lower remote native T1, and more complete recovery of LV function than crushed ticagrelor, without a difference in infarct size; these hypothesis-generating findings suggest differences in the microcirculation and non-infarcted myocardial injury but do not establish a treatment mechanism.
中文摘要:在急性心肌梗死合并心源性休克中,心肌遭受双重损伤:罪犯血管供血区的缺血和低心排血量导致的全身低灌注。目前尚未通过系列影像学检查评估再灌注时的血小板抑制是否影响微循环、梗死区、非梗死心肌及心室功能及其时间进程。本研究为随机DAPT-SHOCK-AMI试验(静脉注射坎格瑞洛与嚼服替格瑞洛)预设的多模态影像亚组研究,旨在回答上述问题。在预设的影像中心入组的患者接受了系列超声心动图检查(208例入组;急性期、1个月和1年可评估病例分别为175、120和99例)及心脏磁共振成像(CMR;93例入组;73、68和63例);其中81例患者同时接受了两种模态检查。盲法核心实验室对所有影像进行了分析。主要影像终点为急性期CMR上的微血管阻塞,可评估病例为60例;次要终点包括梗死面积、全局及梗死区和远端心肌的原生T1值、左室射血分数、整体纵向应变、E/e'比值及左房容积及其变化。坎格瑞洛组与嚼服替格瑞洛组的比较采用协变量调整的logistic或线性回归分析;该亚组研究并非独立设计样本量。坎格瑞洛组急性微血管阻塞的发生率较低(调整后的比值比为0.27 [95% CI 0.08至0.98];P=0.023)。两组间梗死面积无差异。1年时,坎格瑞洛组远端心肌的原生T1值较低(调整后均值1114 [95% CI 1057至1171] ms vs 1171 [1115至1228] ms;P=0.005)。在1年随访期间,超声心动图显示坎格瑞洛组左室射血分数增加更多(占急性期基线的37.9% vs 21.7%;调整后P=0.046),CMR也显示类似结果(15.8% vs 2.1%;P=0.027),且整体纵向应变改善更显著、E/e'比值更低、左房扩大更少;1个月时各组间无参数差异。在急性心肌梗死合并心源性休克中,系列多模态影像在1年内刻画了微循环、组织层面及功能损伤的变化。与嚼服替格瑞洛相比,坎格瑞洛与较少的急性微血管阻塞、较低的远端原生T1值及更完全的左室功能恢复相关,且梗死面积无差异;这些产生假设的发现提示微循环和非梗死心肌损伤存在差异,但并未确立治疗机制。

基础研究 (5篇)

ACS sensors IF 10.9 2026-11-12 PMID: 43019401
Rapid clinical decision-making for acute myocardial infarction (AMI) relies on the timely and precise assessment of cardiac biomarkers. However, detecting cardiac troponin I (cTnI), as the gold-standard biomarker for AMI, with both laboratory-grade sensitivity and rapid clinical turnaround remains a formidable challenge in point-of-care (POC) settings. To address this, we develop a one-pot surface-enhanced Raman scattering (SERS) aptasensor that integrates aptamer-mediated cTnI recognition, catalytic hairpin assembly (CHA) amplification, and plasmonic hotspot assembly. The assay supports two kinetic operating modes within the same assay: a 60-min high-sensitivity mode with a serum limit of detection (LOD) of 53.58 fg/mL and a 20-min rapid-triage mode with an LOD of 14.25 pg/mL, below the clinical decision threshold of 40 pg/mL. In a cohort of 100 clinical serum samples, the bootstrap optimism-corrected diagnostic accuracy was 91.3% for the SERS aptasensor, significantly outperforming conventional ELISA (77.8%). In a subset of 94 subjects with available routine cTnT results, the SERS-cTnI assay achieved an area under the receiver operating characteristic curve (AUC) of 0.988, comparable to that of the hospital's routine chemiluminescence cTnT assay (0.976), supporting its potential as a complementary diagnostic tool for cTnI-based AMI assessment. Furthermore, compatibility with a handheld Raman spectrometer was evaluated in an independent validation cohort (n = 36), achieving 97.2% accuracy using only 4 μL of serum within 20 min following serum preparation. This reliable one-pot SERS platform bridges ultra-sensitive detection and rapid portable readout, holding promise as a potential tool for future decentralized cardiovascular POC diagnostics.
中文摘要:急性心肌梗死(AMI)的快速临床决策依赖于对心脏生物标志物的及时且精确的评估。然而,在床旁检测(POC)环境中,同时具备实验室级灵敏度和快速临床周转时间的肌钙蛋白I(cTnI)检测仍是一项艰巨挑战,尽管cTnI是AMI的金标准生物标志物。为解决这一问题,我们开发了一种一表面增强拉曼散射(SERS)适配体传感器,该传感器整合了适配体介导的cTnI识别、催化发夹组装(CHA)扩增以及等离子体热点组装。该检测在同一实验中支持两种动力学操作模式:一种为耗时60分钟的高灵敏度模式,其血清检测限(LOD)为53.58 fg/mL;另一种为耗时20分钟的快速分诊模式,其LOD为14.25 pg/mL,低于40 pg/mL的临床决策阈值。在100例临床血清样本队列中,SERS适配体传感器的Bootstrap乐观校正诊断准确率为91.3%,显著优于传统ELISA(77.8%)。在94名拥有常规cTnT结果的受试者子集中,SERS-cTnI检测的受试者工作特征曲线下面积(AUC)为0.988,与医院常规化学发光cTnT检测(0.976)相当,支持其作为基于cTnI的AMI评估的补充诊断工具的潜力。此外,在独立验证队列(n=36)中评估了其与手持式拉曼光谱仪的兼容性,仅使用4 μL血清并在血清制备后20分钟内即实现了97.2%的准确率。这一可靠的一SERS平台桥接了超灵敏检测和快速便携式读数,有望成为未来去中心化心血管POC诊断的工具。
Circulation IF 41.3 2026-11-10 PMID: 42741827
The innate immune system plays a pivotal role in orchestrating the response to myocardial infarction (MI), with monocytes and macrophages acting as central mediators of tissue injury and repair. Following MI, a dynamic sequence of inflammatory, anti-inflammatory, and reparative phases unfolds over the course of several days. While timely resolution of inflammation and initiation of reparative programs are critical for favorable cardiac remodeling and improved long-term outcomes, the mechanisms by which recruited monocyte-derived macrophages are instructed within the postinfarct niche to adopt a reparative phenotype remain incompletely understood. Human peripheral blood mononuclear cells were isolated from individuals with and without MI for single-cell RNA sequencing analysis. The murine cardiac monocyte-derived macrophage behaviors after MI were characterized by genetic lineage tracing, lineage tracing plus bone marrow transplantation, metabolite profiling, and cell phenotyping approaches. The role of macrophage CCND1 (cyclin D1) in MI-induced adverse remodeling was investigated using macrophage-specific Ccnd1 knockout mice. Epigenetic experiments were conducted to study the mechanisms underlying metabolic reprogramming and macrophage phenotypic transition. The therapeutic efficacy of lentivirus-targeting macrophage CCND1 and its downstream regulator PDK4 (pyruvate dehydrogenase kinase 4) were assessed in vivo using an MI mouse model. We found that CCND1 levels in peripheral blood mononuclear cells, monocytes, and cardiac macrophages from patients with MI were significantly decreased. Both macrophage-specific and monocyte-derived macrophage-specific deletion of CCND1 worsened MI-induced cardiac dysfunction and adverse remodeling, driven by amplified inflammatory responses. Mechanistically, CCND1 directly interacted with PDK4 and facilitated its ubiquitination by recruiting RPL11 (ribosomal protein L11) and mouse double minute 2. Through this axis, CCND1 suppressed PDK4-driven PDH (pyruvate dehydrogenase) phosphorylation, enhanced glucose oxidation, and shifted macrophages toward an anti-inflammatory phenotype. Targeted overexpression of the CCND1-PDK4 binding motif or knockdown of PDK4 in macrophages improved cardiac function and mitigated adverse remodeling after MI, independent of the canonical cell cycle-regulatory role of CCND1. Our findings identify the CCND1-PDK4 axis as a key regulator of macrophage functional reprogramming toward a reparative phenotype after MI, highlighting it as a potential therapeutic target in postinfarction remodeling.
中文摘要:先天免疫系统在协调心肌梗死(MI)反应中发挥关键作用,单核细胞和巨噬细胞是组织损伤与修复的核心介质。MI后数天内会经历炎症、抗炎及修复的动态阶段。尽管及时消除炎症并启动修复程序对心脏重塑及长期预后至关重要,但招募的单核细胞衍生巨噬细胞在梗死后微环境中如何被指导以采取修复表型的机制尚不完全清楚。本研究从有无MI的个体中分离外周血单个核细胞进行单细胞RNA测序分析;利用遗传谱系示踪、谱系示踪联合骨髓移植、代谢物分析及细胞表型鉴定等方法表征小鼠心脏单核细胞衍生巨噬细胞在MI后的行为;使用巨噬细胞特异性Ccnd1敲除小鼠探究巨噬细胞CCND1(细胞周期蛋白D1)在MI诱导的不良重塑中的作用;通过表观遗传实验研究代谢重编程及巨噬细胞表型转换的机制;利用MI小鼠模型评估靶向巨噬细胞CCND1及其下游调节因子PDK4(丙酮酸脱氢酶激酶4)的慢病毒的治疗效果。我们发现MI患者外周血单个核细胞、单核细胞及心脏巨噬细胞中的CCND1水平显著降低。巨噬细胞特异性或单核细胞衍生巨噬细胞特异性删除CCND1会因炎症反应放大而加重MI诱导的心脏功能障碍和不良重塑。机制上,CCND1直接与PDK4相互作用,通过招募RPL11(核糖体蛋白L11)和小鼠双微基因2促进其泛素化。通过该轴,CCND1抑制PDK4驱动的PDH磷酸化,增强葡萄糖氧化,并使巨噬细胞向抗炎表型转变。在巨噬细胞中靶向过表达CCND1-PDK4结合基序或敲低PDK4可在独立于CCND1经典细胞周期调节作用的情况下改善心脏功能并减轻MI后的不良重塑。我们的研究确定CCND1-PDK4轴是MI后巨噬细胞向修复表型功能重编程的关键调节因子,凸显其作为梗死后重塑潜在治疗靶点的价值。
Nature cardiovascular research IF 12.6 2026-11-09 PMID: 43003910
Myc is an evolutionarily conserved transcription factor that is necessary for the restoration of tissues in multiple regenerative species. The adult mammalian heart lacks regenerative capacity and cardiomyocytes fail to divide following damage-induced signaling. Transgenic expression of Myc and cyclin T1 can drive substantial adult cardiomyocyte proliferation to replace lost cardiomyocytes. Here, using transgenic models and a prototypical mRNA therapeutic, we show that Myc and cyclin T1 require transient induction for cardiomyocyte proliferation that leads to myocardial repair and functional recovery after myocardial infarction in mice. This research provides a strategy to translate Myc-cyclin T1 coexpression for cardiac regeneration to address serious unmet needs in the treatment of cardiovascular disease.
中文摘要:Myc是一种进化上保守的转录因子,在多种再生物种的组织修复中不可或缺。成年哺乳动物心脏缺乏再生能力,心肌细胞在损伤诱导的信号发生后无法分裂。转基因表达Myc和cyclin T1可驱动成年心肌细胞大量增殖以替代丢失的心肌细胞。本研究利用转基因模型和一种原型mRNA治疗药物,表明Myc和cyclin T1需要瞬时诱导才能促进心肌细胞增殖,从而在小鼠心肌梗死后实现心肌修复和功能恢复。该研究提供了一种将Myc-cyclin T1共表达用于心脏再生的策略,以解决心血管疾病治疗中严重的未满足需求。
Pharmacological research IF 12.2 2026-11-06 PMID: 42994540
Plasma ceramide levels are elevated in cardiovascular disease and predict recurrent adverse events and mortality after myocardial infarction (MI). However, mechanisms driving post-MI ceramide accumulation and pharmacologically actionable targets to counteract ceramide-driven myocardial damage are still lacking. Here, we identify FK506-binding protein 5 (FKBP5) as a druggable immunometabolic regulator of ceramide metabolism in cardiac macrophages, linking FKBP5 suppression to interrupted pathological crosstalk among sphingolipid remodeling, mitochondrial impairment and post-MI inflammatory injury. Using murine MI models and FKBP5-deficient cells, we examined FKBP5 inhibition or deficiency reduced infarct size and fibrosis, improved cardiac function, and protected against adverse remodeling. Mechanistically, FKBP5 was associated with the sphingomyelin phosphodiesterase 3 (Smpd3) promoter region and contributed to the regulation of its transcriptional activity after MI, thereby promoting ceramide accumulation. Specifically, FKBP5-mediated ceramide 24:1 (Cer24:1) upregulation impaired mitochondrial redox homeostasis by disrupting electron transport chain integrity, thereby reinforcing M1 polarization and exacerbating myocardial injury. Elevated Cer24:1 directly bound the mitochondrial TU translation elongation factor (TUFM), disrupting electron transport chain integrity and mitochondrial respiration, providing a defined link between ceramide species and mitochondrial dysfunction. Notably, in vivo treatment with Cer24:1 attenuated the cardioprotective effects of FKBP5 inhibition after MI. Collectively, we describe a previously unrecognized FKBP5-Smpd3-Cer24:1-TUFM signaling axis in cardiac macrophages. FKBP5-governed ceramide metabolism drives macrophage immunometabolic reprogramming, marking FKBP5 as a promising pharmacological target for ischemic heart disease. Our findings support the role of the FKBP5-ceramide axis in mediating post-infarct myocardial dysfunction and highlight pharmacological FKBP5 inhibition as a therapeutic strategy against post-MI cardiac injury.
中文摘要:心血管疾病患者血浆神经酰胺水平升高,并预测心肌梗死后的不良事件复发和死亡率。然而,驱动心肌梗死后神经酰胺积累的机制以及对抗神经酰胺驱动心肌损伤的药理学靶点仍然缺乏。本研究鉴定出FK506结合蛋白5(FKBP5)为心脏巨噬细胞中神经酰胺代谢的可药理学免疫代谢调节因子,将FKBP5抑制与鞘脂重塑、线粒体损伤和心肌梗后炎症损伤之间的病理串扰中断联系起来。利用小鼠心肌梗模型和FKBP5缺陷细胞,我们考察了FKBP5抑制或缺失可减小梗死面积和纤维化,改善心脏功能,并防止不良重构。在机制上,FKBP5与鞘磷脂磷酸二酯酶3(Smpd3)启动子区域相关,并在心肌梗后促进其转录活性的调节,从而促进神经酰胺积累。具体而言,FKBP5介导的神经酰胺24:1(Cer24:1)上调通过破坏电子传递链完整性损害线粒体氧化还原稳态,从而强化M1极化并加剧心肌损伤。升高的Cer24:1直接结合线粒体TU翻译延伸因子(TUFM),破坏电子传递链完整性和线粒体呼吸,提供了神经酰胺物种与线粒体功能障碍之间的明确联系。值得注意的是,体内使用Cer24:1治疗减弱了心肌梗后FKBP5抑制的心脏保护作用。综上所述,我们描述了心脏巨噬细胞中先前未被认识的FKBP5-Smpd3-Cer24:1-TUFM信号轴。FKBP5控制的神经酰胺代谢驱动巨噬细胞免疫代谢重编程,将FKBP5标记为缺血性心脏病的有前景的药理学靶点。我们的研究结果支持FKBP5-神经酰胺轴在介导心肌梗后心肌功能障碍中的作用,并强调药理学FKBP5抑制作为对抗心肌梗后心脏损伤的治疗策略。
Cardiovascular research IF 12.5 2026-11-06 PMID: 42831433
Vascular endothelial growth factors (VEGFs) and their endothelial tyrosine kinase receptors are crucial mediators of vasculogenesis and angiogenesis, with FLT1 (VEGFR1) acting as a decoy receptor for VEGFs. Alternative polyadenylation (APA) of Flt1 transcripts produces a truncated mRNA transcript encoding soluble (s) FLT1, which contains only the extracellular ligand-binding domain. The relative roles of full-length (fl) FLT1 and sFLT1 in angiogenesis are incompletely understood. Alternative polyadenylation is an important post-transcriptional mechanism of gene regulation that is increasingly recognized to affect the expression of many genes related to cardiovascular diseases. However, there are no in vivo models available to target APA and to examine the physiological roles of gene isoforms. We here generated mice by introducing silent mutations into the Flt1 exon 13/intron 13 5' splice site through homology-directed repair with CRISPR/Cas9 gene editing. Embryonic development, postnatal retinal vascular development, and reparative angiogenesis were evaluated in models of hindlimb ischaemia and myocardial infarction, complemented by assessments of cardiac functional recovery and cell phenotypes through snRNAseq, as well as in vitro assays examining endothelial cell phenotype and function. The introduction of specific splice site mutations within Flt1 to activate APA led to a complete loss of flFLT1 and an increase in sFLT1 expression. Using this mouse model, we demonstrate that sFLT1 alone is sufficient for developmental vasculogenesis, whereas the specific loss of flFLT1 enhances reparative revascularization and angiogenesis and improves cardiac recovery after myocardial infarction. Our findings show that APA can be effectively targeted to modulate FLT1 isoform expression in vivo. Our mouse model may help to understand diseases driven by an imbalance in FLT1 isoform expression. Given the widespread presence of APA signals, our approach could furthermore serve as a model for studying the function of other truncated gene isoforms.
中文摘要:血管内皮生长因子及其内皮酪氨酸激酶受体是血管生成和血管发生的关键介质,其中FLT1作为VEGF的诱饵受体。Flt1转录本的替代多聚腺苷酸化产生编码可溶性sFLT1的截短mRNA转录本,该蛋白仅包含细胞外配体结合域。全长flFLT1与sFLT1在血管生成中的相对作用尚不完全清楚。替代多聚腺苷酸化是一种重要的基因调控后转录机制,日益被认为影响许多与心血管疾病相关基因的表达。然而,目前缺乏针对替代多聚腺苷酸化并检验基因亚型生理作用的体内模型。本研究通过CRISPR/Cas9基因编辑技术,利用同源定向修复将沉默突变引入Flt1外显子13/内含子13的5剪接位点,构建了小鼠模型。在后肢缺血和心肌梗死模型中评估了胚胎发育、出生后视网膜血管发育及修复性血管生成,并结合单核RNA测序评估心脏功能恢复和细胞表型,以及体外实验检测内皮细胞表型和功能。在Flt1中引入特定剪接位点突变以激活替代多聚腺苷酸化,导致flFLT1完全缺失且sFLT1表达增加。利用该小鼠模型,我们证明仅sFLT1足以支持发育性血管发生,而flFLT1的特异性缺失增强修复性血管重建和血管生成并改善心肌梗死后的心脏恢复。我们的研究结果表明,替代多聚腺苷酸化可有效靶向以调节体内FLT1亚型表达。该小鼠模型有助于理解由FLT1亚型表达失衡驱动的疾病。鉴于替代多聚腺苷酸化信号的广泛存在,该方法还可作为研究其他截短基因亚型功能的模型。

4脑卒中/脑血管病 (8篇)

临床研究 (8篇)

Stroke IF 11.1 2026-11-12 PMID: 43017794
CT perfusion (CTP) hemodynamic thresholds may overestimate the ischemic core (ghost core) in early presenters. We hypothesized that a metabolic model, defining the core by decreased cerebral metabolic rate of oxygen and penumbra by increased oxygen extraction fraction, estimated from standard CTP, would better predict tissue fate and early neurological outcome. This retrospective single-center study (October 2015 to October 2025) included consecutive thrombectomy-treated patients with anterior-circulation large-vessel occlusion, admission CTP, and 48±12-hour diffusion-weighted imaging. Predefined relative cerebral metabolic rate of oxygen and oxygen extraction fraction thresholds (metabolic model) were compared with relative cerebral blood flow ≤30% and time-to-maximum (Tmax) ≥6 seconds (hemodynamic model) against diffusion-weighted imaging. Each imaging model (core and penumbra volumes) was added to clinical covariates predicting 48-hour lesion volume (linear regression) and 24-hour and discharge National Institutes of Health Stroke Scale (ANCOVA), tested by nested F-tests; imaging models were compared by paired bootstrap of cross-validated R2. Of 3011 thrombectomy patients, 227 were included (median age, 70 years; 46% male; median onset-to-CTP, 108 minutes; 162 recanalized). Relative cerebral metabolic rate of oxygen ≤30% reduced core overestimation versus relative cerebral blood flow ≤30% (bias, +2.6 versus +20.0 mL; dice, 0.20 versus 0.18; both P<0.001; reproduced in temporal validation), but >10-mL underestimation was more frequent (17% versus 6%). Relative cerebral blood flow error decreased with onset-to-recanalization delay (ρ=-0.30), unlike relative cerebral metabolic rate of oxygen (ρ=0.01). In 65 nonrecanalized patients, relative oxygen extraction fraction ≥125% outperformed time-to-maximum on bias (+14.3 versus +19.3 mL; P<0.001) and dice (P=0.002), but not absolute error (P=0.24). The metabolic model better explained 48-hour lesion volume (cross-validated R2, 0.32 versus 0.22; P=0.002). Only the metabolic model improved 24-hour (P=0.004) and discharge (P=0.009) National Institutes of Health Stroke Scale score prediction over clinical covariates, outperforming the hemodynamic model at discharge (P=0.04) but not at 24 hours (P=0.21). A CTP-derived metabolic model reduced ghost-core misclassification, particularly in early presenters, and better explained 48-hour lesion volume than hemodynamic thresholds, with modest added value for early neurological outcome. Positron emission tomography and external validation are warranted.
中文摘要:CT灌注血流动力学阈值可能在早期就诊者中高估缺血核心(幽灵核心)。我们假设基于标准CT灌注估算的代谢模型,通过降低脑氧代谢率定义核心、增加氧摄取分数定义半暗带,能更好地预测组织结局和早期神经功能结果。这项回顾性单中心研究(2015年10月至2025年10月)纳入连续接受取栓治疗的前循环大血管闭塞患者,具备入院CT灌注及48±12小时扩散加权成像数据。将预定义的相对脑氧代谢率和氧摄取分数阈值(代谢模型)与相对脑血流量≤30%及时间至最大延迟≥6秒(血流动力学模型)进行对比,以扩散加权成像为参照。将各影像模型(核心和半暗带体积)加入预测48小时病灶体积(线性回归)及24小时和出院时美国国立卫生研究院卒中量表评分(协方差分析)的临床协变量中,采用嵌套F检验;通过交叉验证R2的配对Bootstrap比较影像模型。在3011名取栓患者中,纳入227例(中位年龄70岁,男性46%,发病至CT灌注中位时间108分钟,162例再通)。与相对脑血流量≤30%相比,相对脑氧代谢率≤30%减少了核心高估(偏倚分别为+2.6和+20.0 mL;Dice系数分别为0.20和0.18;均P<0.001;在时间验证中复现),但大于10mL的低估更常见(17%对6%)。相对脑血流量误差随发病至再通延迟增加而降低(ρ=-0.30),而相对脑氧代谢率无此变化(ρ=0.01)。在65例未再通患者中,相对氧摄取分数≥125%在偏倚(+14.3对+19.3 mL;P<0.001)和Dice系数(P=0.002)上优于时间至最大延迟,但在绝对误差上无优势(P=0.24)。代谢模型更好地解释了48小时病灶体积(交叉验证R2为0.32对0.22;P=0.002)。仅代谢模型在预测24小时(P=0.004)和出院时(P=0.009)美国国立卫生研究院卒中量表评分方面优于临床协变量,在出院时优于血流动力学模型(P=0.04),但在24小时时无优势(P=0.21)。CT灌注衍生的代谢模型减少了幽灵核心的误分类,尤其在早期就诊者中,且比血流动力学阈值更好地解释了48小时病灶体积,对早期神经功能结果具有适度的附加价值。需进行正电子发射断层扫描和外部验证。
Stroke IF 11.1 2026-11-12 PMID: 43017772
Poststroke spasticity significantly impairs recovery, yet preventive strategies remain limited. This study evaluated the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in reducing the development and severity of spasticity in patients with early subacute stroke, offering a possible early intervention. In this double-blind, randomized, sham-controlled trial, 70 patients with early subacute stroke (7-30 days) were randomized to receive 3 sessions of low-frequency (1 Hz, 1000 pulses at 90% resting motor threshold) rTMS over contralesional primary motor cortex (n=35) or sham stimulation (n=35), alongside standard care. The primary outcome was upper-limb spasticity assessed using the modified Modified Ashworth Scale. Secondary outcomes included handgrip strength, muscle power assessed by the Medical Research Council scale, pain assessed by the Visual Analogue Scale, modified Rankin Scale, and Stroke Impact Scale 3.0. rTMS therapy significantly lowered spasticity scores at 1 and 3 months across all assessed upper-limb joints (P=0.001), improved handgrip strength (P=0.01), and prevented pain (P=0.001). Stroke Impact Scale scores at 1 month showed greater gains in activities of daily living, mobility, hand function, social participation, and recovery in the rTMS group (P=0.001). Functional independence (modified Rankin Scale) was significantly better in the rTMS group (P=0.006) at 3 months. On binary logistic regression, sham stimulation was associated with greater odds of developing spasticity at 1 month (shoulder odds ratio [OR], 8.29 [95% CI, 1.95-35.27], P=0.04; elbow OR, 7.62 [95% CI, 1.69-34.35], P=0.08; wrist OR, 5.18 [95% CI, 1.60-16.78], P=0.06). At 3 months, sham stimulation remained predictive, with higher odds of spasticity at the shoulder (OR, 15.3 [95% CI, 8.26-28.43]), elbow (OR, 13.43 [95% CI, 3.94-45.78]), wrist (OR, 19.9 [95% CI, 4.9-80.96]), and fingers (OR, 26.25 [95% CI, 5.19-132.87], all P=0.001). Minor adverse events like headache and light-headedness were observed in 5 patients. Low-frequency rTMS over contralesional primary motor cortex significantly prevented spasticity, improved motor recovery, reduced pain, improved functional outcomes and quality of life in early subacute stroke, supporting its role as a promising adjunctive therapy in early stroke rehabilitation. URL: https://ctri.nic.in/; Unique identifier: CTRI/2024/01/061225.
中文摘要:卒中后痉挛严重影响康复,但预防策略仍然有限。本研究评估了重复经颅磁刺激(rTMS)在降低早期亚急性期卒中患者痉挛发生率和严重程度方面的有效性,旨在提供一种可能的早期干预措施。在这项双盲、随机、假刺激对照试验中,70名早期亚急性期卒中(发病7-30天)患者被随机分配接受低频(1 Hz,1000脉冲,90%静息运动阈值)rTMS刺激对侧初级运动皮层(n=35)或假刺激(n=35),同时接受标准护理。主要结局指标是使用改良版Modified Ashworth量表评估的上肢痉挛情况。次要结局指标包括握力、通过医学研究委员会量表评估的肌力、通过视觉模拟量表评估的疼痛、改良Rankin量表评分以及卒中影响量表3.0评分。rTMS治疗在1个月和3个月时显著降低了所有评估的上肢关节的痉挛评分(P=0.001),改善了握力(P=0.01),并预防了疼痛(P=0.001)。卒中影响量表评分在1个月时显示,rTMS组在日常活动、移动能力、手部功能、社会参与和康复方面获得更大改善(P=0.001)。在3个月时,rTMS组的独立性(改良Rankin量表)显著更好(P=0.006)。二元逻辑回归分析显示,假刺激与1个月时发生痉挛的更高几率相关(肩部比值比[OR]为8.29 [95% CI, 1.95-35.27], P=0.04;肘部OR为7.62 [95% CI, 1.69-34.35], P=0.08;腕部OR为5.18 [95% CI, 1.60-16.78], P=0.06)。在3个月时,假刺激仍具有预测性,肩部(OR为15.3 [95% CI, 8.26-28.43])、肘部(OR为13.43 [95% CI, 3.94-45.78])、腕部(OR为19.9 [95% CI, 4.9-80.96])和手指(OR为26.25 [95% CI, 5.19-132.87], 均P=0.001)发生痉挛的几率更高。5名患者出现了头痛和头晕等轻微不良事件。对侧初级运动皮层的低频rTMS显著预防了痉挛,改善了运动恢复,减轻了疼痛,改善了功能结局和生活质量,支持其作为早期卒中康复中有前景的辅助疗法的地位。URL: https://ctri.nic.in/; 唯一标识符: CTRI/2024/01/061225.
Stroke IF 11.1 2026-11-12 PMID: 43017770
Ischemic stroke preventive therapies have been slow to emerge due to a limited understanding of the underlying molecular mechanisms. We aimed to discover new protein risk factors that are potential etiologic factors and may be candidates for therapeutic intervention. We included ARIC study (Atherosclerosis Risk in Communities) and CHS (Cardiovascular Health Study) participants without prevalent stroke at the time of proteomic profiling (1990-1992 in ARIC and 1992-1993 in CHS). Relative concentrations of proteins in blood were assessed with aptamers (n=4954). Ischemic stroke events were adjudicated through 2019 in ARIC and 2015 in CHS. Study-specific Cox regression adjusting for ischemic stroke risk factors was used to estimate associations between proteins and incident ischemic stroke. Study-specific estimates were combined using fixed-effects meta-analysis. Replication was conducted in 2 independent cohorts (AGES-Reykjavik, UK Biobank). Proteins with a false discovery rate q value <0.05 were considered replicated. Mendelian randomization analyses assessed for potential causal associations between proteins and ischemic stroke. Median follow-up was 25 and 12 years in ARIC and CHS. 1397 out of 14 139 (10%) participants experienced an ischemic stroke. 44 proteins were significantly associated with ischemic stroke risk (P<1.0×10-5), of which 26 are novel. In 2 independent cohorts, 37 (84%) associations were directionally concordant, and 26 (59%) met criteria for replication. Mendelian randomization analyses suggested MMP12 (matrix metallopeptidase-12) and CNTN1 (contactin-1) may be causally related to ischemic stroke risk. In multivariable Mendelian randomization analyses, higher MMP12 levels had a direct protective effect on ischemic stroke risk, while CNTN1 had a direct harmful effect. This proteomic and genomic investigation of ischemic stroke identified novel risk biomarkers and 2 potential etiologic CNTN1 factors that are regulated in response to atherosclerosis and obesity. If future studies confirm our findings, these results may have implications for the development of new preventive therapies.
中文摘要:由于对潜在分子机制的理解有限,缺血性卒中的预防疗法进展缓慢。我们旨在发现新的蛋白质风险因素,这些潜在病因因子可能成为治疗干预的候选者。我们纳入了在蛋白组学分析时(ARIC研究为1990-1992年,CHS研究为1992-1993年)无卒中病史的ARIC研究和CHS研究参与者。使用适配体评估血液中的蛋白质相对浓度(n=4954)。通过2019年(ARIC)和2015年(CHS)对缺血性卒中事件进行判定。采用调整了缺血性卒中风险因素的特定研究Cox回归模型来估计蛋白质与首次发生缺血性卒中之间的关联。利用固定效应荟萃分析合并特定研究的估计值。在两个独立队列(AGES-Reykjavik、UK Biobank)中进行验证。假发现率q值小于0.05的蛋白质被视为已验证。孟德尔随机化分析评估了蛋白质与缺血性卒中之间潜在的因果关联。ARIC和CHS的中位随访时间分别为25年和12年。在14139名参与者中有1397人(10%)发生了缺血性卒中。44种蛋白质与缺血性卒中风险显著相关(P<1.0×10-5),其中26种为新型标志物。在两个独立队列中,37个(84%)关联的方向一致,26个(59%)符合验证标准。孟德尔随机化分析表明MMP12(基质金属肽酶12)和CNTN1(接触蛋白1)可能与缺血性卒中风险存在因果关联。在多变量孟德尔随机化分析中,较高的MMP12水平对缺血性卒中风险具有直接保护作用,而CNTN1具有直接有害作用。这项针对缺血性卒中的蛋白组学和基因组学研究发现了新的风险生物标志物以及两种受动脉粥样硬化和肥胖调节的潜在病因因子CNTN1。如果未来研究证实我们的发现,这些结果可能对开发新的预防疗法产生影响。
Medical image analysis IF 14.0 2026-11-09 PMID: 43014078
Effective stroke prevention relies on identifying at-risk individuals before neurological symptoms arise, yet this is severely limited by the absence of scalable screening tools. To address this, we developed RetCEVD, a diagnostic framework that uses rapid, non-invasive retinal Optical Coherence Tomography Angiography (OCTA) for auxiliary assessment of ICVD. At its core, RetCEVD introduces a memory-guided mutual information optimization strategy that maximizes shared disease-relevant information within the same diagnostic category while suppressing redundant or confounding dependencies across different categories. This dual information constraint encourages compact, discriminative representations of subtle retinal microvascular abnormalities. Trained and validated on a multi-center cohort of 24,438 retinal images, RetCEVD addresses three primary tasks: auxiliary detection of existing ICVD, etiological subtyping (large artery atherosclerosis vs. small vessel disease), and current symptomatic-status classification (asymptomatic vs. symptomatic LAA). The model achieved AUCs of 0.95 internal and 0.94 external for ICVD detection, 0.83 internal and 0.81 external for etiological subtyping, and 0.75 internal and 0.76 external for current symptomatic-status classification. The two-year ALAA follow-up provided supplementary longitudinal validation for subsequent stroke events (AUC, 0.71). By comprehensively evaluating the model's clinical interpretability, including its learned pathological features and alignment with established clinical patterns, we provide novel insights into retina-based stroke evaluation. Ultimately, RetCEVD may serve as an efficient, low-cost screening and triage tool to identify individuals who may benefit from confirmatory neurovascular imaging and specialist assessment.
中文摘要:有效的卒中预防依赖于在神经系统症状出现前识别高危人群,但这一目标因缺乏可扩展的筛查工具而受到严重限制。为解决这一问题,我们开发了RetCEVD诊断框架,利用快速、非侵入性的视网膜光学相干断层扫描血管成像(OCTA)对缺血性脑血管病(ICVD)进行辅助评估。RetCEVD的核心是一种记忆引导的互信息优化策略,该策略在最大化同一诊断类别内共享的疾病相关信息的同时,抑制不同类别间冗余或混淆的依赖关系。这种双重信息约束鼓励形成紧凑且具有判别力的视网膜微血管细微异常表征。基于包含24,438张视网膜图像的多中心队列进行训练和验证,RetCEVD解决了三个主要任务:现有ICVD的辅助检测、病因分型(大动脉粥样硬化与小血管病)以及当前症状状态分类(无症状与有症状LAA)。该模型在ICVD检测方面取得了0.95的内部AUC和0.94的外部AUC,在病因分型方面取得了0.83的内部AUC和0.81的外部AUC,在当前症状状态分类方面取得了0.75的内部AUC和0.76的外部AUC。为期两年的ALAA随访为后续卒中事件提供了补充性的纵向验证(AUC为0.71)。通过全面评估模型的临床可解释性,包括其学习的病理特征与既定临床模式的一致性,我们为基于视网膜的卒中评估提供了新见解。最终,RetCEVD可能作为一种高效、低成本的筛查和分诊工具,用于识别可能从确认性神经血管影像检查和专科评估中受益的人群。
Stroke IF 11.1 2026-11-09 PMID: 43001457
Infections have been linked as short-term triggers for stroke, but the extent of their contribution is unclear. We examined population-level temporal and spatiotemporal associations between common respiratory viruses and stroke in an ecological study in Victoria, Australia. The statewide Victorian Admitted Episodes data set, covering all hospital admissions for stroke between June 2010 and December 2022, was analyzed against statewide representative data from SnotWatch respiratory polymerase chain reaction tests. Population size, climate, and air pollution data sets for the same period were treated as population-level confounders. Time-series analysis was used to model weekly stroke events and respiratory virus levels (% of polymerase chain reaction tests positive for each pathogen), and attributable fractions were computed using distributed lag nonlinear modeling. To examine spatiotemporal variation, the weekly association by Statistical Area Level 2 was modeled using a Bayesian Integrated Nested Laplace Approximation. We analyzed 153 730 stroke events (61% ischemic, 25% hemorrhagic, and 14% unspecified) and 6 180 896 respiratory specimens. In the time-series analysis, higher weekly levels of specific respiratory viruses were associated with increased rates of stroke after controlling for confounders. Our model estimated that the fractions of strokes attributed to enterovirus and human metapneumovirus 4.6% (95% CI, 2.5-6.6) and 1.3% (95% CI, 0.3-2.3), respectively, which rose during peak viral weeks. The attributable fractions differed between ischemic stroke (human metapneumovirus 3.7%) and hemorrhagic stroke (enterovirus, 5.8%; parainfluenza, 3.2%). Spatiotemporal analysis revealed greater effect sizes in areas potentially associated with agricultural/industrial activity, as well as in outer-urban areas, based on the regionality of the Statistical Area Level 2 of usual patient residence. At the population level, there were clear, observable time- and space-time-related associations between respiratory virus activity and stroke. People living in higher-risk areas during peak respiratory virus periods may be more susceptible to acute stroke. This warrants further investigation.
中文摘要:感染已被证实是卒中的短期诱因,但其贡献程度尚不明确。本研究在澳大利亚维多利亚州开展了一项生态学研究,旨在探讨常见呼吸道病毒与卒中之间的人口水平时间及时空关联。研究分析了2010年6月至2022年12月期间覆盖全州所有卒中住院记录的维多利亚州 admitted episodes 数据集,并与代表全州的 SnotWatch 呼吸道聚合酶链反应检测数据进行对比。人口规模、气候和空气污染数据作为人口水平的混杂因素纳入分析。采用时间序列分析对每周卒中事件和呼吸道病毒水平(每种病原体聚合酶链反应检测阳性率)进行建模,并使用分布滞后非线性模型计算归因分数。为考察时空变异,基于统计区域第二级按周建模了关联关系。研究共分析了153730例卒中事件(其中缺血性61%,出血性25%,未指定14%)和6180896份呼吸道标本。时间序列分析显示,在控制混杂因素后,特定呼吸道病毒每周水平的升高与卒中发生率增加相关。模型估计肠道病毒和人偏肺病毒导致的卒中归因分数分别为4.6%(95% CI, 2.5-6.6)和1.3%(95% CI, 0.3-2.3),且在病毒高峰期上升。缺血性卒中与人偏肺病毒(3.7%)相关,而出血性卒中与肠道病毒(5.8%)和副流感病毒(3.2%)相关。时空分析显示,在可能与农业或工业活动相关的区域以及基于常住地统计区域第二级划分的远郊区域,效应量更大。在人口水平上,呼吸道病毒活动与卒中之间存在清晰可辨的时间及时空关联。在呼吸道病毒高峰期居住于高风险区域的人群可能对急性卒中更敏感。这一发现值得进一步调查。
Nature communications IF 18.1 2026-11-06 PMID: 42995186
Intra-arterial tenecteplase during endovascular treatment (EVT) may increase first-pass recanalization and dissolve microcirculatory thrombi, but its efficacy and safety are uncertain. We hypothesised that this strategy would improve functional outcomes versus EVT alone. This phase 3, randomised, adaptive-enrichment, open-label, blinded-endpoint multicentre study aims to evaluate whether intra‑arterial tenecteplase improves clinical outcomes for patients with acute ischemic stroke. Patients with large‑vessel occlusion eligible for EVT within 24 hours of symptom onset were randomly assigned (1:1) to the tenecteplase group receiving intra‑arterial tenecteplase during EVT or the control group receiving EVT alone. The primary endpoint was favorable functional outcome. Of 380 randomised patients (192 in the tenecteplase group and 188 in the control group), primary outcome data were available for 190 and 186 patients, respectively. Favorable 90-day functional outcomes (modified Rankin Scale 0-2) occurred in 40.0% of the tenecteplase group versus 46.8% of the control group (unadjusted odds ratio 0.76, [95% CI 0.50-1.14], P = 0.19). This work suggests intra-arterial tenecteplase during thrombectomy did not improve 90-day functional outcomes in this population. (Funded by National Science and Technology Major Project and hospital-initiated grants; ClinicalTrials.gov registration: NCT05657444).
中文摘要:在血管内治疗期间进行动脉内替奈普酶输注可能提高首次再通率并溶解微循环血栓,但其疗效和安全性尚不确定。我们假设该策略能改善患者功能预后优于单纯血管内治疗。这项三期随机适应性富集开放标签盲法终点多中心研究旨在评估动脉内替奈普酶是否能改善急性缺血性卒中患者的临床结局。发病24小时内符合血管内治疗适应证的大血管闭塞患者被随机分配(1:1)至接受血管内治疗期间动脉内注射替奈普酶的替奈普酶组,或仅接受血管内治疗的对照组。主要终点为良好的功能预后。在380名随机分组的患者中(替奈普酶组192人,对照组188人),分别有190人和186人拥有主要结局数据。替奈普酶组40.0%的患者在90天时获得良好功能预后(改良Rankin量表0-2分),而对照组为46.8%(未调整比值比0.76,95%置信区间0.50-1.14,P=0.19)。本研究结果表明,在该人群中,取栓期间动脉内注射替奈普酶并未改善90天功能预后。
Nature communications IF 18.1 2026-11-06 PMID: 42995180
In patients with acute ischemic stroke caused by medium vessel occlusion (MeVO), intra-arterial tenecteplase may offer a targeted strategy to improve recanalization; we hypothesized that intra-arterial tenecteplase would increase successful reperfusion compared with standard care with a comparable safety profile. This phase 2, prospective, randomised, open-label, blinded-endpoint, multicentre study aims to assess the efficacy and safety of intra-arterial tenecteplase for patients with acute ischemic stroke caused by MeVO. Patients with MeVO were randomly (1:1) assigned to receive intra-arterial tenecteplase or standard care. The primary outcome was successful reperfusion of medium vessel occlusion. A total of 80 patients were randomized to either the tenecteplase group (n = 41) or control group (n = 39). Successful reperfusion reached 61.0% (25/41) in the tenecteplase group versus 28.2% (11/39) in the control group (unadjusted odds ratio 3.98, 95% CI 1.56-10.16; P = 0.004). Symptomatic intracranial hemorrhage within 24 h was similar between the tenecteplase and control groups. This work suggests that intra-arterial tenecteplase significantly increased the probability of successful reperfusion compared with standard care, with a comparable safety profile in this stroke population. (Funded by Shenyang Science Tech Project and hospital-initiated grants; ClinicalTrials.gov registration: NCT05657470).
中文摘要:在由中等血管闭塞(MeVO)引起的急性缺血性卒中患者中,动脉内替奈普酶可能提供一种靶向策略以改善再通;我们假设与标准治疗相比,动脉内替奈普酶能增加成功再灌注率且安全性相当。这项二期、前瞻性、随机、开放标签、盲法终点评估的多中心研究旨在评估动脉内替奈普酶对MeVO引起的急性缺血性卒中患者的疗效和安全性。MeVO患者被随机(1:1)分配接受动脉内替奈普酶或标准治疗。主要结局是中等血管闭塞的成功再灌注。共80名患者被随机分配至替奈普酶组(n=41)或对照组(n=39)。替奈普酶组的成功再灌注率为61.0%(25/41),而对照组为28.2%(11/39)(未调整比值比3.98,95% CI 1.56-10.16;P=0.004)。替奈普酶组和对照组在24小时内的症状性颅内出血发生率相似。本研究结果表明,与标准治疗相比,动脉内替奈普酶显著提高了成功再灌注的概率,且在该卒中人群中具有相当的安全性。(由沈阳市科技项目和医院发起的资助提供资金;ClinicalTrials.gov注册号:NCT05657470)。
Stroke IF 11.1 2026-11-06 PMID: 42990092
The past decade has seen a transformation in our understanding of the genetics of stroke. However, a commonly asked question is how do these advances impact the practicing clinician now, and what are their implications for clinical care in the future? This review outlines the major recent advances in stroke genetics and addresses 4 questions most relevant to the clinician: What do we now know about the genetic architecture of stroke? When and how should genetic testing be used to identify monogenic stroke? How can genetic information be applied to risk stratification and prevention? And what therapeutic implications are emerging from genetic discoveries? It highlights the success of genome-wide association studies in stroke and how these have transformed how we understand the genetic architecture of stroke. An increasing number of monogenic forms of cerebral small vessel disease are being identified, and guidance on when and how to test for them is covered. Polygenic risk scores are gaining increasing attention. How these can be applied, and the challenges in their use are discussed. Lastly, the impact of genomics on stroke therapeutics, whether by identifying new targets, assessing causality using techniques such as Mendelian randomization, or pharmacogenomics, is discussed.
中文摘要:过去十年间我们对脑卒中的遗传学理解发生了转变。然而一个常被问到的问题是这些进展如何影响当前的临床医生以及它们对未来临床护理意味着什么。本综述概述了脑卒中遗传学的主要最新进展并回答了与临床医生最相关的四个问题:我们现在对脑卒中的遗传结构了解多少?何时以及如何利用基因检测来识别单基因型脑卒中?如何利用遗传信息进行风险分层和预防?基因发现带来了哪些治疗方面的启示?文章强调了全基因组关联研究在脑卒中领域的成功以及它们如何改变了我们对脑卒中遗传结构的理解。越来越多的脑小血管病单基因形式被鉴定出来并涵盖了关于何时以及如何对其进行检测的指导。多基因风险评分正受到越来越多的关注。文章讨论了这些评分的应用及其使用中的挑战。最后探讨了基因组学对脑卒中治疗的影响无论是通过识别新靶点、利用孟德尔随机化等技术评估因果关系还是药物基因组学。

5冠心病/心绞痛 (7篇)

临床研究 (6篇)

European journal of preventive cardiology IF 10.0 2026-11-11 PMID: 40038072
To investigate the relationship between socio-economic status, plaque burden on coronary computed tomography angiography (CCTA), management, and outcomes. In a post-hoc analysis of a multi-centre randomized control trial, we assessed associations between socio-economic status and qualitative (stenosis and adverse plaque characteristics) and quantitative (total plaque, calcified plaque, non-calcified, and low attenuation) CCTA plaque features and examined the interaction of socio-economic status on cardiovascular outcomes. Socio-economic status was available in 3948 participants of whom 1989 were randomized to CCTA and 1629 scans were suitable and available for quantitative plaque analysis. Within these 1629 participants, 15% were from the lowest socio-economic quintile and 25% from the highest socio-economic quintile. Participants in the most deprived socio-economic group were younger, had lower cardiovascular risk, and were less likely to have severe stenosis or multi-vessel disease. After adjustment for cardiovascular risk factors, there was no difference in quantitative plaque burden between socio-economic groups. After a median of 4.75 years of follow-up, CCTA-guided management was associated with similar changes in medical therapy, similar reductions in the risk of coronary heart disease death, or non-fatal myocardial infarction in low and high socio-economic groups, with no difference between the base and interaction models (P = 0.35). Socio-economic status is not an independent predictor of coronary artery disease severity; rather, the association is mostly determined by modifiable risk factors. Preventive therapies, guided by CCTA, achieve similar benefits in both low and high socio-economic status individuals.
中文摘要:旨在探讨社会经济地位、冠状动脉CT血管造影(CCTA)上的斑块负荷、治疗及预后之间的关系。在对多中心随机对照试验的事后分析中,我们评估了社会经济地位与定性(狭窄和不利斑块特征)及定量(总斑块、钙化斑块、非钙化和低衰减)CCTA斑块特征之间的关联,并考察了社会经济地位对心血管结局的交互作用。3948名参与者的社会经济地位数据可用,其中1989名被随机分配至CCTA组,1629次扫描适合且可用于定量斑块分析。在这1629名参与者中,15%来自社会经济地位最低的五分位组,25%来自最高五分位组。社会经济地位最差的参与者更年轻,心血管风险较低,且不太可能出现严重狭窄或多支血管病变。在调整心血管危险因素后,不同社会经济组别之间定量斑块负荷无差异。中位随访4.75年后,CCTA指导下的管理在低和高社会经济组别中均与相似的药物治疗改变、冠心病死亡或非致死性心肌梗死风险的相似降低相关,基础模型与交互模型之间无差异(P = 0.35)。社会经济地位并非冠状动脉疾病严重程度的独立预测因子;相反,该关联主要由可改变的危险因素决定。CCTA指导的预防性治疗在低和高社会经济地位个体中均获得相似的益处。
Progress in cardiovascular diseases IF 10.6 2026-11-07 PMID: 43003708
Polygenic risk scores (PRS) promise improved cardiovascular risk stratification, but most validation derives from UK or Nordic biobanks. The transferability of these scores to Central European populations and their incremental value over classical risk factors in routine care remain unestablished. To determine whether a coronary PRS derived from external European data transfers to a Polish primary-care population and adds discrimination for prevalent cardiovascular disease beyond classical risk factors. In the nationwide Polish LIPIDOGEN2015 primary-care cohort, we derived PRS for coronary heart disease, myocardial infarction (MI) and stroke from FinnGen data with continuous shrinkage priors and applied them to imputed genotypes. We compared allele frequencies of 1397 unrelated participants with a non-Finnish European (NFE) reference and, in 1328 participants with clinical data, related the PRS to coronary artery disease (CAD), MI and stroke recorded at baseline and to a composite including death during follow-up, with and without classical risk factors or SCORE2. Allele frequencies correlated with the NFE reference (r = 0.97). Per standard deviation (SD), the coronary PRS was associated with prevalent CAD (odds ratio 1.36, 95% CI 1.11 to 1.67) and the composite endpoint (1.26, 95% CI 1.04 to 1.51), as were two validated genome-wide scores. Adding it to classical risk factors changed the area under the curve (AUC) for the composite endpoint by 0.0017 (95% CI -0.0005 to 0.0076), from 0.860 to 0.861; results with SCORE2 were similar. The study had 80% power for odds ratios per SD of 1.31 (CAD) and 1.27 (composite). A coronary PRS derived from external European data retains its association with prevalent CAD without re-derivation in this Polish primary-care cohort but, in this cross-sectional, event-limited sample, adds little discrimination to classical risk factors. Its value for predicting future events in this setting remains to be tested against incident outcomes.
中文摘要:多基因风险评分(PRS)有望改善心血管风险分层,但大多数验证数据来自英国或北欧生物银行。这些评分向中欧人群的转移性及其在常规护理中超越经典风险因素的增量价值尚未确立。本研究旨在确定源自外部欧洲数据的冠心病PRS是否适用于波兰初级保健人群,并在经典风险因素之外增加对现患心血管疾病的判别能力。在全国性的波兰LIPIDOGEN2015初级保健队列中,我们利用连续收缩先验从FinnGen数据推导出冠心病、心肌梗死(MI)和中风的PRS,并将其应用于插补基因型。我们将1397名无亲缘关系参与者的等位基因频率与非芬兰欧洲(NFE)参考数据进行比较,并在1397名具有临床数据的参与者中,将PRS与基线记录的冠状动脉疾病(CAD)、MI和中风以及包含随访期间死亡的复合终点相关联,分析时分别考虑了经典风险因素或SCORE2评分。等位基因频率与NFE参考数据高度相关(r=0.97)。每增加一个标准差(SD),冠心病PRS与现患CAD(比值比1.36,95%置信区间1.11至1.67)和复合终点(1.26,95%置信区间1.04至1.51)均相关,两个经过验证的全基因组评分也呈现类似结果。将其添加到经典风险因素中使复合终点的曲线下面积(AUC)变化了0.0017(95%置信区间-0.0005至0.0076),从0.860变为0.861;SCORE2的结果相似。该研究对每标准差的比值比具有80%的统计功效,分别为CAD的1.31和复合终点的1.27。源自外部欧洲数据的冠心病PRS在此波兰初级保健队列中保留了与现患CAD的相关性,无需重新推导,但在这种横断面、事件有限的样本中,对经典风险因素的判别能力增加有限。其在预测该环境下未来事件方面的价值仍有待通过发病结局进行验证。
Circulation IF 41.3 2026-11-07 PMID: 42998238
In the ISCHEMIA-CKD trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease), at a median follow-up of 2.2 years, the primary composite outcome of death or nonfatal myocardial infarction was similar between an initial invasive strategy (INV) compared with an initial conservative strategy (CON) in patients with moderate or severe myocardial ischemia and advanced chronic kidney disease. However, the long-term outcomes comparing the 2 strategies are unknown. Participants in the ISCHEMIA-CKD trial were randomly assigned to either INV, involving coronary angiography and revascularization when feasible, added to guideline-directed medical therapy or to CON with guideline-directed medical therapy alone and invasive procedures reserved for failure of guideline-directed medical therapy. After the active intervention trial phase, long-term vital status follow-up was conducted through participant contact by participating sites and by health record and centralized death database searches. The primary outcome for the extended follow-up phase was all-cause mortality. Secondary outcomes were cause-specific mortality, including cardiovascular and noncardiovascular mortality. Among the 777 participants randomized (388 to INV and 389 to CON), over a median of 8 years of follow-up, vital status retention among survivors was 95%. There was a total of 429 deaths (55%). Cumulative all-cause mortality (57.4% versus 56.8%; adjusted hazard ratio, 1.05 [95% CI, 0.87-1.28]) or cardiovascular mortality (40.3% versus 38.4%; adjusted hazard ratio, 1.06 [95% CI, 0.84-1.34]) at 8 years did not differ between INV and CON. The restricted mean survival time was 1941 days (1834-2047 days) for INV versus 1990 days (1885-2094 days) for CON, with an adjusted estimated difference of -99 days (-245 to 46). The posterior probability of at least a 1 percentage point lower or higher death with INV at the 8-year median follow-up was 28% and 52%, respectively. Similarly, the posterior probability of at least a 1 percentage point lower or higher cardiovascular mortality with INV was 23% and 56%, respectively. In patients with at least moderate ischemia and advanced chronic kidney disease, there was no significant long-term benefit of an initial INV at reducing the risk of all-cause or cardiovascular mortality compared with an initial conservative strategy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01985360.
中文摘要:在ISCHEMIA-CKD试验中,中位随访2.2年时,中度或重度心肌缺血且患有晚期慢性肾脏病的患者中,初始侵入性策略与初始保守策略在死亡或非致死性心肌梗死的主要复合终点上相似。然而,这两种策略的长期结果尚不清楚。ISCHEMIA-CKD试验的参与者被随机分配至侵入性组,该组接受冠状动脉造影及可行的血运重建并联合指南指导的药物治疗,或保守组,仅接受指南指导的药物治疗并将侵入性操作保留给指南指导药物治疗失败的患者。在主动干预试验阶段结束后,通过参与站点联系患者以及健康记录和集中死亡数据库搜索进行长期生存状态随访。延长随访阶段的主要结局是全因死亡率。次要结局包括特定原因的死亡率,如心血管和非心血管死亡率。在777名随机分配的参与者中(388名至侵入性组,389名至保守组),中位随访8年期间,幸存者的生存状态保留率为95%。共有429人死亡(55%)。8年时全因死亡率(57.4%对56.8%;调整后的风险比1.05 [95%置信区间0.87-1.28])或心血管死亡率(40.3%对38.4%;调整后的风险比1.06 [95%置信区间0.84-1.34])在侵入性组和保守组之间无差异。侵入性组的受限平均生存时间为1941天(1834-2047天),保守组为1990天(1885-2094天),调整后的估计差异为-99天(-245至46)。在中位随访8年时,侵入性策略导致死亡率至少低1个百分点或高1个百分点的后验概率分别为28%和52%。同样,侵入性策略导致心血管死亡率至少低1个百分点或高1个百分点的后验概率分别为23%和56%。在中度及以上缺血和晚期慢性肾脏病的患者中,与初始保守策略相比,初始侵入性策略在降低全因或心血管死亡率风险方面没有显著的长期益处。
Cardiovascular research IF 12.5 2026-11-07 PMID: 42995452
The mechanisms underlying colchicine's cardiovascular benefits in patients with coronary artery disease remain unclear and warrant further translational investigation. In a randomized, double-blind, placebo-controlled trial, 111 patients with chronic coronary artery disease and aortic or carotid target-to-background ratio ≥1.6 were assigned to colchicine 0.6 mg daily (n=55) or placebo (n=56) for 24 weeks. Arterial inflammation was assessed using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) of the ascending aorta. The primary endpoint was the change in mean maximum target-to-background ratio over 24 weeks. Secondary and exploratory objectives included evaluation of systemic inflammatory markers and blood pressure. To support interpretation of the clinical findings, a complementary hypertensive rodent model, the spontaneously hypertensive rat (SHR), was treated with colchicine for 4 weeks to explore vascular and inflammatory pathways potentially influenced by colchicine using immunohistochemistry, myography and proteomics.Colchicine did not reduce aortic FDG uptake compared with placebo (adjusted mean change 0.05 [95% CI -0.02 to 0.12] vs 0.01 [95% CI -0.06 to 0.08]; p=0.38). In secondary and exploratory analyses, colchicine was associated with a reduction in neutrophil-to-lymphocyte ratio (adjusted mean change -0.36 vs -0.08; p=0.033), a trend toward lower high-sensitivity C-reactive protein (adjusted geometric mean percentage change -28.2% vs -5.8%; p=0.060) and attenuation of increases in systolic (adjusted mean change 0.88 mmHg vs. 4.94 mmHg; p=0.046) and diastolic (1.41 mmHg vs. 4.35 mmHg; p=0.048) blood pressure. In SHRs, colchicine had no effect on the aorta but attenuated the progression of hypertension and reduced inflammation and extracellular matrix remodelling in mesenteric resistance arteries, while enhancing vasodilator responses. Reductions in CXCL10, CXCL2, NLRP3 and IL-18 expression were observed in mesenteric arteries from the SHR following colchicine treatment. These findings support the hypothesis that vascular effects of colchicine likely extend beyond large conduit arteries, while the specific pathways and relevance to coronary atherosclerosis require further investigation.
中文摘要:秋水仙碱在冠心病患者中的心血管获益机制尚不明确,需进一步开展转化研究。在一项随机、双盲、安慰剂对照试验中,111名患有慢性冠心病且主动脉或颈动脉靶区背景比值≥1.6的患者被随机分配至每日服用0.6 mg秋水仙碱组(n=55)或安慰剂组(n=56),持续24周。采用18F-氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)评估升主动脉的动脉炎症,主要终点为24周内平均最大靶区背景比值的变化。次要及探索性目标包括评估系统性炎症标志物和血压。为支持对临床结果的解释,研究还采用自发性高血压大鼠(SHR)这一补充性高血压动物模型,给予秋水仙碱治疗4周,利用免疫组化、肌动描记术和蛋白质组学技术探索可能受秋水仙碱影响的血管及炎症通路。结果显示,与安慰剂相比,秋水仙碱未降低主动脉FDG摄取(调整后的均值变化0.05 [95% CI -0.02至0.12] vs 0.01 [95% CI -0.06至0.08];p=0.38)。在次要及探索性分析中,秋水仙碱与中性粒细胞淋巴细胞比值降低相关(调整后的均值变化-0.36 vs -0.08;p=0.033),超敏C反应蛋白呈现下降趋势(调整后几何均值百分比变化-28.2% vs -5.8%;p=0.060),并减弱了收缩压(调整后的均值变化0.88 mmHg vs 4.94 mmHg;p=0.046)和舒张压(1.41 mmHg vs 4.35 mmHg;p=0.048)的升高。在SHR中,秋水仙碱对主动脉无影响,但减弱了高血压的进展,减少了肠系膜阻力动脉中的炎症和细胞外基质重塑,并增强了血管舒张反应。秋水仙碱治疗后,SHR肠系膜动脉中CXCL10、CXCL2、NLRP3和IL-18的表达降低。这些发现支持秋水仙碱的血管作用可能不仅限于大传导动脉,但其具体通路及对冠状动脉粥样硬化的相关性仍需进一步研究。
Cardiovascular research IF 12.5 2026-11-06 PMID: 42762227
Inadequate pharmacologic stress may limit the diagnostic and prognostic accuracy of myocardial perfusion imaging (MPI). The splenic ratio (SR), a measure of stress adequacy, has emerged as a potential imaging biomarker. We developed an artificial intelligence (AI) method to derive SR and evaluated the prognostic value in a large multicentre 82Rb-PET cohort undergoing regadenoson stress testing. We retrospectively analysed 16 650 patients from six sites in the REFINE PET registry with clinically indicated MPI and linked clinical outcomes. SR was calculated using fully automated algorithms as the ratio of splenic uptake at stress vs. rest. Patients were stratified by SR into decile groups. The primary outcome was major adverse cardiovascular events (MACE). Survival analysis was conducted using Kaplan-Meier and Cox proportional hazards models adjusted for clinical and imaging covariates, including myocardial flow reserve (MFR ≥2 vs. <2) and presence of ischaemia. The cohort had a median age of 69 years, with 59% male patients. Common risk factors included hypertension (81%), dyslipidaemia (77%), diabetes (35%), and prior coronary artery disease (31%). Median follow-up was 3.4 years. Patients with high SR in the testing cohort (n = 950) had an increased risk of MACE [hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.06-1.34, P = 0.005]. Among testing patients with preserved MFR (≥2; n = 8067), high SR remained independently associated with MACE (HR 1.43, 95% CI 1.20-1.70, P < 0.001). Even among patients with preserved MFR and no ischaemia in the testing cohort(MFR≥2, SDS<2; n = 6508), high SR remained independently associated with MACE (HR 1.54 95% CI 1.26-1.88, P < 0.001). Elevated AI-derived SR was independently associated with adverse cardiovascular outcomes, including among patients with preserved MFR. These findings support SR as a novel, automated imaging biomarker for risk stratification in 82Rb PET MPI.
中文摘要:药物负荷不足可能限制心肌灌注成像的诊断和预后准确性。脾脏比值作为评估负荷充分性的指标,已成为一种潜在的影像学生物标志物。我们开发了一种人工智能方法来推导脾脏比值,并在接受瑞加德松负荷测试的大型多中心82Rb-PET队列中评估了其预后价值。我们回顾性分析了REFINE PET登记数据库中六个中心的16650例具有临床指征的MPI患者及其关联的临床结局数据。使用全自动算法计算脾脏比值,即负荷与静息状态下脾脏摄取量的比值。根据脾脏比值将患者分为十分位组。主要终点为重大不良心血管事件。采用Kaplan-Meier生存分析和Cox比例风险模型进行生存分析,调整了临床和影像协变量,包括心肌血流储备及缺血情况。队列中位年龄为69岁,男性占59%。常见危险因素包括高血压、血脂异常、糖尿病和既往冠心病。中位随访时间为3.4年。测试队列中高脾脏比值患者发生重大不良心血管事件的风险增加。在保留心肌血流储备的患者中,高脾脏比值仍独立与重大不良心血管事件相关。即使在保留心肌血流储备且无缺血的患者中,高脾脏比值仍独立与重大不良心血管事件相关。升高的人工智能推导脾脏比值独立于其他因素与不良心血管结局相关,包括在保留心肌血流储备的患者中。这些发现支持将脾脏比值作为一种新的自动化影像学生物标志物,用于82Rb PET心肌灌注成像的风险分层。
Cardiovascular research IF 12.5 2026-11-06 PMID: 42687758
The aetiology of coronary artery disease (CAD) appears different for men and women, yet insights into underlying sex-specific biological mechanisms are limited. We integrated genomic and proteomic analyses to investigate sex-specific associations of the plasma proteome with CAD. In 40 829 UK Biobank participants (free-of-CAD, baseline 365 days thereafter; 55% women; mean age 56.9 ± 8.1 years), we examined associations between 2922 plasma proteins and incident CAD over a median follow-up of 13.7 years (IQR 13.1-14.4) using multivariable-adjusted Cox proportional hazards models. Sex-specific analyses identified 440 female exclusive and 32 male exclusive proteins associated with incident CAD (FDR-corrected P < 0.05), revealing distinct pathway enrichments, including innate immune response in women and angiogenesis in men. Causality was assessed through combined and sex-stratified two-sample Mendelian randomization (MR) using inverse-variance-weighted analyses with genome-wide association summary statistics from 422 108 men (61 969 cases) and 521 695 women (27 128 cases) (UK Biobank, FinnGen freeze 9). Integration of direct sex-protein interaction analyses with sex-combined MR identified 59 proteins with evidence for sex-specific causal effects. Four proteins demonstrated concordant directionality in sex-stratified MR analyses (n = 943 803) and multivariable regression models, namely CDKN2D, MYH9, and SKAP2 (women) and CTSH (men). To assess translational relevance, prioritized targets were further evaluated in secondary major adverse cardiovascular events among carotid endarterectomy patients (MACE; Athero-Express) and acute myocardial infarction (AMI; MISSION!) using plasma proteomics and ELISA. After further top-target identification in the context of MACE and AMI, clinical drug candidates were identified through a machine learning framework, including CTSH (men) and TNFRSF4 (both sexes). We identified sex-specific associations of proteins and biological pathways with incident CAD. Whereas the majority of proteins had consistent associations in both men and women, our findings suggest a degree of sex-specific pathogenesis with evidence for potential causality, opening new alleys for tailored prevention strategies and clinical cardiovascular risk management.
中文摘要:冠状动脉疾病(CAD)的病因在男性和女性中似乎存在差异,但对其潜在性别特异性生物学机制的了解仍然有限。我们整合基因组和蛋白质组学分析,以探讨血浆蛋白质组与CAD发病之间的性别特异性关联。在英国生物银行40829名参与者(无CAD病史,基线后随访365天;女性占55%;平均年龄56.9±8.1岁)中,我们使用多变量调整的Cox比例风险模型,在中位随访13.7年(四分位距13.1-14.4年)期间,考察了2922种血浆蛋白与CAD发病的关联。性别特异性分析确定了440种女性专属和32种男性专属蛋白质与CAD发病相关(FDR校正P<0.05),揭示了不同的通路富集,包括女性的先天免疫反应和男性的血管生成。通过结合全基因组关联汇总统计数据的逆方差加权分析,利用来自422108名男性(61969例病例)和521695名女性(27128例病例)的数据(英国生物银行、FinnGen第9次冻结数据),采用联合和性别分层的双样本孟德尔随机化(MR)评估了因果关系。将直接性别-蛋白质相互作用分析与性别合并的MR相结合,确定了59种具有性别特异性因果效应证据的蛋白质。四种蛋白质在性别分层MR分析(n=943803)和多变量回归模型中表现出一致的方向性,即CDKN2D、MYH9和SKAP2(女性)以及CTSH(男性)。为了评估转化相关性,优先靶点在颈动脉内膜切除术患者的次要主要不良心血管事件(MACE;Athero-Express队列)和急性心肌梗死(AMI;MISSION!队列)中通过血浆蛋白质组学和ELISA进行了进一步评估。在MACE和AMI背景下进一步确定顶级靶点后,通过机器学习框架确定了临床药物候选物,包括CTSH(男性)和TNFRSF4(两性)。我们发现了蛋白质和生物学通路与CAD发病之间的性别特异性关联。虽然大多数蛋白质在男性和女性中具有一致的关联,但我们的发现表明存在一定程度的性别特异性发病机制,并具有潜在因果关系的证据,为个性化预防策略和临床心血管风险管理开辟了新的途径。

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-11-06 PMID: 42640551
Junctional cadherin 5-associated protein (JCAD/KIAA1462) is an endothelial junctional protein encoded by a locus robustly associated with coronary artery disease and myocardial infarction in genome-wide association studies. Initially identified as a structural component of endothelial cell-cell junctions, JCAD has since emerged as a mechanosensor and regulator of key intracellular pathways (i.e. Hippo/YAP, PI3K/Akt, and mitogen-activated protein kinase/extracellular signal-regulated kinase) with functional consequences for endothelial homeostasis, inflammation, and vascular tone. In this review, we summarize the current understanding of JCAD biology, from its molecular features and pathway interactions to its experimental roles in atherosclerosis, arterial thrombosis, and ischaemic stroke. We further discuss emerging translational evidence suggesting circulating JCAD as an independent predictor of adverse cardiovascular events in patients with acute coronary syndromes, and its prognostic potential in ischaemic stroke. The review also addresses the expanding biology of JCAD within the cardiovascular system, hypothesizing links to conditions, such as hypertension, heart failure with preserved ejection fraction, and calcific aortic valve disease, as well as key limitations and therapeutic challenges. Overall, the available evidence highlights JCAD as a biologically plausible and potentially clinically relevant endothelial mediator, though independent validation and substantial mechanistic work remain necessary before its translational potential can be fully realized.
中文摘要:连接区钙黏蛋白5相关蛋白(JCAD/KIAA1462)是一种内皮连接蛋白,由全基因组关联研究中与冠心病和心肌梗死强相关的基因座编码。JCAD最初被确定为内皮细胞间连接的结构性成分,随后被发现是机械感受器并调节关键细胞内通路(即Hippo/YAP、PI3K/Akt以及丝裂原活化蛋白激酶/细胞外信号调节激酶),对内皮稳态、炎症和血管张力具有功能影响。本综述总结了当前对JCAD生物学的理解,涵盖其分子特征、通路相互作用及其在动脉粥样硬化、动脉血栓形成和缺血性卒中中的实验作用。我们进一步讨论了新兴的转化证据,表明循环JCAD是急性冠脉综合征患者不良心血管事件的独立预测因子,并在缺血性卒中中具有预后潜力。该综述还探讨了JCAD在心血管系统中不断扩展的生物学特性,假设其与射血分数保留的心力衰竭、高血压和钙化主动脉瓣疾病等条件存在联系,并指出了关键的限制因素和治疗挑战。总体而言,现有证据表明JCAD是一种生物学上合理且可能具有临床相关性的内皮介质,但在其转化潜力得到充分实现之前,仍需独立的验证和大量的机制研究。

6心肌病/心肌炎 (5篇)

临床研究 (3篇)

Circulation IF 41.3 2026-11-09 PMID: 43002382
Transthyretin-lowering therapies target the underlying cause of transthyretin amyloid cardiomyopathy (ATTR-CM), but their effects on myocardial amyloid burden and cardiac remodelling remain incompletely characterized. We evaluated the myocardial effects of sustained transthyretin suppression with eplontersen using serial multiparametric cardiovascular magnetic resonance (CMR). This CMR study was a pre-specified, international, prospective study embedded within the randomized, placebo-controlled phase 3 CARDIO-TTRansform trial. Participants underwent CMR at baseline and planned assessments at weeks 25, 49, 97, and 140. The primary imaging analysis evaluated longitudinal changes in CMR parameters using mixed models for repeated measures. Myocardial amyloid regression and progression were defined as ≥5 percentage-point decreases and increases in extracellular volume (ECV), respectively. All other patients were considered stable. We enrolled 120 participants with baseline and ≥1 follow-up CMR assessment (eplontersen, n=58; placebo, n=62; mean age, 76.7±6.5 years; 95% male; baseline stabilizer, 12.5%). At week 140 eplontersen resulted in lower ECV, compared with placebo (least-squares mean difference [95% CI], -6.7 percentage points [ -8.7 to -4.7]; P<0.001) and lower native T1 ( -25.9ms [-41.7 to -10.2 ]; P=0.002) and left ventricular mass (-19.1g [-28.0 to -10.2]; P<0.001). Eplontersen also increased left ventricular ejection fraction (+5.1% [1.8-8.3]; P=0.002), right ventricular ejection fraction (+4.6% [0.6-8.7]; P=0.03), and left ventricular global longitudinal, circumferential, and radial strain and right ventricular longitudinal strain (all P<0.05), compared to placebo. At week-140, myocardial amyloid regression occurred in 12.5% receiving eplontersen versus 0% receiving placebo, whereas progression occurred in 12.5% versus 76%, respectively. Sustained transthyretin suppression with eplontersen resulted in substantially lower myocardial ECV and favorable changes in cardiac structure, biventricular systolic function, and myocardial deformation compared with placebo in a cohort of patients mostly not on background stabilizer at baseline. These findings provide randomized evidence that lowering circulating transthyretin modifies myocardial disease progression in ATTR-CM and support serial multiparametric CMR for characterizing myocardial treatment response.
中文摘要:降低转甲状腺素蛋白的疗法针对转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)的根本病因,但其对心肌淀粉样负荷和心脏重构的影响尚未完全明确。本研究利用连续多参数心血管磁共振成像(CMR)评估了持续抑制转甲状腺素蛋白对心肌的作用。该CMR研究是嵌入随机、安慰剂对照的3期CARDIO-TTRansform试验中的预先指定的国际前瞻性研究。参与者在基线及第25、49、97和140周接受计划评估。主要影像分析采用重复测量混合模型评估CMR参数的纵向变化。心肌淀粉样变性消退定义为细胞外体积(ECV)下降≥5个百分点,进展定义为增加≥5个百分点,其余患者视为稳定。共纳入120名有基线及至少一次随访CMR评估的参与者(依普隆特森组n=58;安慰剂组n=62;平均年龄76.7±6.5岁;男性占95%;基线使用稳定剂者占12.5%)。在第140周,与安慰剂相比,依普隆特森组的ECV更低(最小二乘均值差[95%CI]为-6.7个百分点[-8.7至-4.7];P<0.001),原生T1值更低(-25.9ms[-41.7至-10.2];P=0.002)且左心室质量更低(-19.1g[-28.0至-10.2];P<0.001)。与安慰剂相比,依普隆特森组还提高了左心室射血分数(+5.1%[1.8-8.3];P=0.002)、右心室射血分数(+4.6%[0.6-8.7];P=0.03)以及左心室整体纵向、周向和径向应变及右心室纵向应变(均P<0.05)。在第140周,接受依普隆特森治疗的患者中发生心肌淀粉样变性消退的比例为12.5%,而安慰剂组为0%;进展比例分别为12.5%和76%。在基线时主要未使用背景稳定剂的队列中,持续抑制转甲状腺素蛋白的依普隆特森治疗相比安慰剂显著降低了心肌ECV并改善了心脏结构、双心室收缩功能及心肌变形。这些发现提供了随机证据,表明降低循环转甲状腺素蛋白可改变ATTR-CM的心肌疾病进展,并支持使用连续多参数CMR来表征心肌治疗反应。
Circulation IF 41.3 2026-11-09 PMID: 43002247
In CARDIO-TTRansform, the TTR (transthyretin) silencer eplontersen did not significantly reduce the primary end point of cardiovascular death and recurrent cardiovascular events in patients with TTR amyloidosis with cardiomyopathy, although treatment effects varied by baseline TTR stabilizer use. Whether eplontersen favorably affects cardiac structure and function is unknown. CARDIO-TTRansform randomized 1432 patients with TTR amyloidosis with cardiomyopathy to eplontersen (45 mg) subcutaneously every 4 weeks or placebo. Echocardiograms were performed at baseline and weeks 61, 97, and 140. Associations of baseline echocardiographic measures with all-cause mortality and the primary end point were evaluated using Cox and semiparametric proportional rates models. Between-group differences at week 140 were analyzed with mixed models for repeated measures. Among 1426 participants with baseline echocardiograms (mean age, 76±7 years, 91% men, 85% wild type, 57% receiving stabilizers), baseline measures of left ventricular systolic function (LV ejection fraction, global longitudinal strain, stroke volume, myocardial contraction fraction), diastolic function (E wave deceleration time, septal e', average E/e'), and right ventricular function and hemodynamics were independently associated with all-cause mortality or the primary end point. At week 140 (echocardiograms available in 554 patients in the eplontersen group and 506 in the placebo group), eplontersen attenuated increases in mean LV wall thickness (least-squares mean [LSM] difference, -0.24 mm [95% CI, -0.48 to -0.01]) and declines in LV stroke volume (LSM difference, 1.88 mL [95% CI, 0.07-3.69]), myocardial contraction fraction (LSM difference, 0.88% [95% CI, 0.25-1.57]), average E/e' (LSM difference, -0.71 [95% CI, -1.36 to -0.07]), and right ventricular outflow tract velocity-time integral (LSM difference, 0.42 [95% CI, 0.00-0.85]) versus placebo in the overall cohort. Beneficial effects were driven almost exclusively by patients not receiving stabilizers at baseline. No significant treatment effects were observed in patients receiving stabilizers. Among patients with TTR amyloidosis with cardiomyopathy, eplontersen modestly attenuated deterioration in prognostically important measures of LV systolic, diastolic and right ventricular function, primarily among patients not receiving stabilizers at baseline. These findings complement the clinical findings of CARDIO-TTRansform and suggest that TTR silencing may attenuate progression of cardiac dysfunction in TTR amyloidosis with cardiomyopathy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04136171; URL: xxx; Unique identifier: 2019-002835-27.
中文摘要:在CARDIO-TTRansform试验中,TTR(转甲状腺素蛋白)沉默剂依普隆森未能显著降低TTR淀粉样变性伴心肌病患者的主要终点心血管死亡和复发性心血管事件发生率,尽管治疗效果因基线使用TTR稳定剂而异。依普隆森是否对心脏结构和功能产生有利影响尚不清楚。CARDIO-TTRansform试验将1432名TTR淀粉样变性伴心肌病患者随机分配至每4周皮下注射一次依普隆森(45 mg)组或安慰剂组。在基线及第61、97和140周进行超声心动图检查。采用Cox模型和半参数比例速率模型评估基线超声心动图指标与全因死亡率及主要终点的关联。采用重复测量混合模型分析第140周时的组间差异。在1426名有基线超声心动图数据的参与者中(平均年龄76±7岁,男性占91%,野生型占85%,57%接受稳定剂治疗),左心室收缩功能指标(左室射血分数、整体纵向应变、每搏输出量、心肌收缩分数)、舒张功能指标(E波减速时间、间隔部e'、平均E/e')以及右心室功能和血流动力学指标均独立关联于全因死亡率或主要终点。在第140周时(依普隆森组554名患者和安慰剂组506名患者有超声心动图数据),与安慰剂相比,依普隆森减弱了平均左室壁厚度增加(最小二乘均值[LSM]差异为-0.24 mm [95% CI, -0.48至-0.01])以及左室每搏输出量(LSM差异为1.88 mL [95% CI, 0.07至3.69])、心肌收缩分数(LSM差异为0.88% [95% CI, 0.25至1.57])、平均E/e'(LSM差异为-0.71 [95% CI, -1.36至-0.07])和右心室流出道速度时间积分(LSM差异为0.42 [95% CI, 0.00至0.85])的下降。这种有益效果几乎完全由基线未接受稳定剂治疗的患者驱动。在接受稳定剂治疗的患者中未观察到显著的治疗效果。在TTR淀粉样变性伴心肌病患者中,依普隆森适度减弱了预后重要指标中左室收缩、舒张及右心室功能的恶化,主要见于基线未接受稳定剂治疗的患者。这些发现补充了CARDIO-TTRansform试验的临床结果,并提示TTR沉默可能减缓TTR淀粉样变性伴心肌病中心脏功能障碍的进展。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT04136171; URL: xxx; 唯一标识符: 2019-002835-27.
European heart journal IF 45.3 2026-11-06 PMID: 42670759
Takotsubo syndrome (TTS) closely mimics acute coronary syndrome (ACS). Early differentiation remains challenging because diagnosis currently relies on medical, psychiatric, and neurological history, repeated cardiac imaging, and exclusion of a culprit epicardial coronary artery lesion, generally with invasive coronary angiography (ICA). The aim of this study was to develop and externally validate a biomarker-based diagnostic score supporting the early differentiation of TTS from ACS before ICA. In this study, 3615 patients with ACS or TTS from overlapping registries were investigated. Circulating levels of established and emerging cardiovascular biomarkers were measured before ICA. A biomarker-based diagnostic score for TTS (BioTAK) was developed in a cohort of 1823 patients (ACS n = 1754; TTS n = 69) using machine learning-guided feature selection and logistic regression and externally validated in an independent cohort of 1792 patients (ACS n = 1715; TTS n = 77). The final five-item score incorporated biomarkers reflecting myocardial stress (N-terminal pro-B-type natriuretic peptide), vasoconstriction and anxiety regulation (peptidylglycine α-amidating monooxygenase), atherosclerotic plaque instability (soluble lectin-like oxidized low-density lipoprotein receptor-1), and lipid metabolism (low-density lipoprotein cholesterol), along with sex. BioTAK demonstrated excellent discrimination between TTS and ACS in the development cohort [area under the receiver operating characteristic curve (AUC) .97, 95% confidence interval (CI) .95-.98] and maintained high performance on external validation (AUC .93, 95% CI .90-.96), with good calibration. Using predefined rule-in and rule-out thresholds, the score stratified almost 90% of patients to a likely diagnosis prior to ICA. TTS is characterized by a distinct biomarker profile reflecting pathophysiological differences from ACS. The non-subjective biomarker-based BioTAK score can support the early identification of TTS, help streamline diagnostic pathways, and might reduce potentially avoidable invasive procedures in patients presenting with suspected ACS. NCT01000701, NCT01947621.
中文摘要:应激性心肌病(TTS)与急性冠脉综合征(ACS)临床表现极为相似。由于目前诊断主要依赖病史、重复心脏影像学检查以及通过有创冠状动脉造影(ICA)排除责任血管病变,早期鉴别仍具挑战性。本研究旨在开发并外部验证一种基于生物标志物的诊断评分系统,以支持在ICA前早期鉴别TTS与ACS。研究纳入了来自重叠登记数据库的3615名ACS或TTS患者,并在ICA前测定了已知及新兴心血管生物标志物的循环水平。利用机器学习引导的特征选择和逻辑回归,在包含1823名患者(ACS 1754例;TTS 69例)的队列中开发了基于生物标志物的TTS诊断评分BioTAK,并在包含1792名独立患者(ACS 1715例;TTS 77例)的外部队列中进行了验证。最终的五项评分纳入了反映心肌应激(N末端脑钠肽前体)、血管收缩与焦虑调节(肽基甘氨酸α酰胺化单加氧酶)、动脉粥样硬化斑块不稳定性(可溶性凝集素样氧化低密度脂蛋白受体-1)和脂质代谢(低密度脂蛋白胆固醇)的生物标志物,以及性别。BioTAK在开发队列中展现了TTS与ACS之间优异的区分能力[受试者工作特征曲线下面积(AUC)为0.97,95%置信区间(CI)0.95-0.98],并在外部验证中保持了高性能(AUC 0.93,95% CI 0.90-0.96),校准度良好。利用预设的纳入和排除阈值,该评分在ICA前将近90%的患者分层为可能的诊断。TTS具有区别于ACS的独特生物标志物特征。这种非主观性的基于生物标志物的BioTAK评分可支持TTS的早期识别,有助于简化诊断流程,并可能减少疑似ACS患者中潜在的可避免有创操作。NCT01000701, NCT01947621.

基础研究 (2篇)

Science advances IF 13.9 2026-11-13 PMID: 43013638
Inherited cardiomyopathies are the leading cause of heart failure in young adults, with limited therapeutic options. Desmin-related cardiomyopathy (DRM), caused by mutations to cytoskeletal proteins and their chaperones, exemplifies this challenge: Here, protein quality control is compromised, leading to toxic protein aggregates that destroy cardiomyocyte contractile machinery. One of the deadliest DRM mutations in the chaperone protein αB crystallin (CRYAB-R120G) lacks a genetically matched preclinical model: Mouse models require massive overexpression of mutant CRYAB, raising questions about physiological relevance. Here, we establish a human model of CRYAB-linked DRM, using induced pluripotent stem cells expressing CRYAB-R120G at near-endogenous levels. We show that three-dimensional mechanical loading, but not fatty acid-based metabolic maturation media, is essential for expressing Desmin, whose aggregation defines DRM. Using microengineered heart tissues, we found that contractile deficits are associated with impaired calcium handling, pointing to electromechanical uncoupling in DRM. Treatment with the Janus kinase 1 inhibitor itacitinib partially rescued contractility, providing a functional validation of this emerging therapeutic strategy.
中文摘要:遗传性心肌病是年轻人心力衰竭的主要原因,且治疗选择有限。由细胞骨架蛋白及其伴侣蛋白突变引起的Desmin相关心肌病(DRM)即为此类挑战的典型代表:在此类疾病中,蛋白质质量控制受损,导致毒性蛋白聚集体破坏心肌细胞的收缩机制。在伴侣蛋白αB-晶体蛋白(CRYAB-R120G)中最致命的DRM突变缺乏基因匹配的临床前模型:小鼠模型需要大量过表达突变型CRYAB,这引发了关于其生理相关性的疑问。在此,我们利用在接近内源性水平表达CRYAB-R120G的诱导多能干细胞建立了CRYAB相关的DRM人类模型。我们发现三维机械负荷而非基于脂肪酸的代谢成熟培养基对于Desmin的表达至关重要,而Desmin的聚集定义了DRM。使用微工程心肌组织,我们发现收缩缺陷与钙处理受损有关,指向DRM中的电机械解耦。使用Janus激酶1抑制剂Itacitinib治疗部分恢复了收缩力,为该新兴治疗策略提供了功能验证。
Circulation IF 41.3 2026-11-10 PMID: 42741825
Pathogenic variants in RBM20 cause severe dilated cardiomyopathy. Loss-of-function variants disrupt splicing; neomorphic gain-of-function (GoF) variants also mislocalize RBM20 to cytoplasmic ribonucleoprotein granules and are associated with more aggressive disease. The mechanism by which RBM20 mislocalization drives cardiac dysfunction remains unknown. We investigated the effects of Rbm20 GoF and loss-of-function (LoF) variants using proteomic profiling, protein solubility assays, mitochondrial respiration and calcium flux analyses, and ultrastructural imaging in mouse models. Human induced pluripotent stem cell-derived cardioids were used to validate variant-specific phenotypes. Rbm20 GoF, but not LoF, variants caused posttranscriptional downregulation of soluble mitochondrial proteins, including the calcium efflux regulator TMEM65 (transmembrane protein 65), and reduced solubility of mitochondrial membrane proteins. Electron microscopy revealed enlarged mitochondria with cristae disorganization. Functional assays confirmed impaired oxidative phosphorylation, reduced mitochondrial membrane potential, and abnormal calcium handling in Rbm20 GoF models. Human cardioids reproduced these findings, demonstrating that cytoplasmic mislocalization, rather than splicing deficiency, drives mitochondrial dysfunction. Cytoplasmic mislocalization of RBM20 disrupts mitochondrial function by reducing mitochondrial protein abundance, leading to oxidative phosphorylation failure and abnormal mitochondrial calcium handling. This mechanism distinguishes RBM20 GoF from LoF variants and may explain the more severe heart failure phenotype observed in patients with RBM20 GoF variants. These insights advance the mechanistic understanding of RBM20-related cardiomyopathy and identify mitochondrial mRNA/protein regulation as a key node in cardiac energetics.
中文摘要:RBM20致病变异可导致严重扩张型心肌病。功能丧失型变异会破坏剪接过程;而获得性功能(GoF)型变异还会导致RBM20错误定位至细胞质核糖核蛋白颗粒,并与更严重的疾病相关。目前尚不清楚RBM20的错误定位如何驱动心脏功能障碍。本研究利用小鼠模型,通过蛋白质组学分析、蛋白质溶解度检测、线粒体呼吸及钙离子流分析和超微结构成像,探究了Rbm20 GoF和功能丧失(LoF)变异的影响。同时使用人诱导多能干细胞衍生的心肌类器官验证了变异特异性表型。与LoF不同,Rbm20 GoF变异导致可溶性线粒体蛋白质(包括钙外流调节因子TMEM65)发生转录后下调,并降低了线粒体膜蛋白的溶解度。电子显微镜显示线粒体增大且嵴结构紊乱。功能实验证实,在Rbm20 GoF模型中存在氧化磷酸化受损、线粒体膜电位降低及钙离子处理异常。人源心肌类器官重现了上述发现,证明细胞质错误定位而非剪接缺陷是驱动线粒体功能障碍的原因。RBM20的细胞质错误定位通过减少线粒体蛋白质丰度来破坏线粒体功能,导致氧化磷酸化衰竭和线粒体钙离子处理异常。该机制区分了RBM20 GoF与LoF变异,并可能解释携带RBM20 GoF变异患者中观察到的更严重心力衰竭表型。这些见解深化了对RBM20相关心肌病的机制理解,并确定了线粒体mRNA/蛋白质调节是心脏能量代谢的关键节点。

7冠心病/PCI (5篇)

临床研究 (4篇)

JAMA cardiology IF 15.2 2026-11-11 PMID: 43013292
In the Semaglutide Cardiovascular Outcomes Trial (SOUL), oral semaglutide reduced the risk of a first 3-point major adverse cardiovascular event (3-P MACE; including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular [CV] death). Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease; however, the effects of oral semaglutide on subsequent events are unknown. To evaluate the effect of oral semaglutide vs placebo on total 3-P MACE. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries. Participants had type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease. Data were analyzed from December 2024 to August 2025. Once-daily oral semaglutide (maximal dose 14 mg) or placebo, in addition standard of care. Occurrence of total (first and subsequent) 3-P MACE. Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 6860 [71.1%] male) were randomized 1:1. In the oral semaglutide group, fewer first and subsequent 3-P MACE occurred (683 total; 579 first and 104 subsequent events) compared with placebo (791 total; 668 first and 123 subsequent events) (mean ratio, 0.86; 95% CI, 0.76-0.97; P = .01). For the end point of 3-P MACE plus non-CV death, there were 138 fewer total events with oral semaglutide (910 events) compared with placebo (1048 events) (mean ratio, 0.87; 95% CI, 0.79-0.95; P = .004). As previously reported, adverse events led to treatment discontinuation in 749 (15.5%) and 559 (11.6%) participants receiving oral semaglutide and placebo, respectively. Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population. ClinicalTrials.gov Identifier: NCT03914326.
中文摘要:在Semaglutide心血管结局试验(SOUL)中,口服司美格鲁肽降低了首次3点主要不良心血管事件(3-P MACE;包括非致死性心肌梗死、非致死性卒中和心血管死亡)的风险。评估首次和后续事件的总事件分析有助于更好地理解干预措施对疾病总体负担的影响;然而,口服司美格鲁肽对后续事件的影响尚不清楚。本研究旨在评估口服司美格鲁肽与安慰剂对总3-P MACE的影响。这是一项预先指定的二次分析,基于2019年6月至2024年9月开展的为期44个中心、覆盖33个国家的中位(四分位距)随访时间为49.5(44.0-54.9)个月的随机对照、事件驱动的IIIb期SOUL临床试验。参与者患有2型糖尿病及动脉粥样硬化性心血管疾病和/或慢性肾脏病。数据分析时间为2024年12月至2025年8月。干预措施为每日一次口服司美格鲁肽(最大剂量14 mg)或安慰剂,联合标准治疗。主要结局指标为总(首次和后续)3-P MACE的发生情况。总体而言,9650名参与者(中位年龄66.0岁;男性6860名占71.1%)按1:1比例随机分组。与安慰剂组相比,口服司美格鲁肽组的总3-P MACE事件更少(共683例;其中首次579例,后续104例),而安慰剂组为791例(首次668例,后续123例)(均值比0.86;95% CI 0.76-0.97;P=.01)。对于3-P MACE加非心血管死亡的终点,口服司美格鲁肽组的总事件比安慰剂组少138例(910例对1048例)(均值比0.87;95% CI 0.79-0.95;P=.004)。如前所述,不良事件导致接受口服司美格鲁肽和安慰剂的参与者分别有749名(15.5%)和559名(11.6%)停药。与安慰剂相比,口服司美格鲁肽降低了首次加后续3-P MACE的风险,突显了其在降低该高风险人群临床发病率和死亡率总体负担方面的益处。ClinicalTrials.gov标识符:NCT03914326。
European heart journal IF 45.3 2026-11-10 PMID: 43004579
Understanding how inflammation contributes to subclinical atherosclerosis (SA) plaque burden, beyond the impact of established cardiovascular risk factors, holds significant implications for the success of preventive strategies focused on the reduction of atherosclerotic cardiovascular disease. The aim of this study was to investigate the relative contribution of inflammation, low-density lipoprotein cholesterol (LDLc), and systolic blood pressure (SBP), as determinants of SA plaque burden in a cohort of middle-aged, asymptomatic individuals, using non-invasive imaging techniques. Participants from the Progression of Early Subclinical Atherosclerosis (PESA) study (median age 45 years) underwent longitudinal screening every 3 years (baseline, 3- and 6-year visits) involving serial blood testing [including white blood cell (WBC) count, fibrinogen, oxidized LDLc, and high-sensitivity C-reactive protein], physical examinations and imaging assessments with three-dimensional vascular ultrasound of peripheral arteries, and coronary artery calcium quantification. Global plaque volume (GPV, mm3; bilateral carotid plus femoral plaque burden) at 6-year follow-up was the primary outcome. Multivariable linear regression and proportional odds models determined the link of GPV to both inflammatory markers and established cardiovascular risk factors. Of the 3471 participants, 58% had SA (GPV >0 mm3) at 6-year follow-up. WBC count had the strongest statistical associations with 6-year SA burden after adjusting for age, sex, baseline LDLc, and mean SBP, with an estimated 32.6% increase in GPV per one standard deviation (SD) increase in WBC (Z = 7.33, P < 1 × 10-10). GPV at 6 years increased 40.9% per one SD increase in baseline LDLc and 42.7% per one SD increase in mean SBP (Z = 8.80 and Z = 7.97, respectively, both P < 1 × 10-10; their SDs were 29.4 mg/dL and 11.5 mmHg, respectively), followed by fibrinogen (16.8% increase in GPV per one SD increase, Z = 3.91, P < .0001). High-sensitivity C-reactive protein was not predictive of greater GPV at 6 years (Z = 1.36, P = .174). For WBC, the marked trend in risk occurred only at levels above its median. Similar patterns were observed for separate analyses of carotid and femoral plaque volumes, and coronary artery calcium. Increasing levels of WBC and fibrinogen were also associated with a greater anatomical spread of disease. Inflammation contributes to SA burden, as assessed by direct plaque quantification, beyond the effects of LDLc and SBP. These findings indicate that inflammation, captured through the use of systemic inflammatory markers, is a risk factor relevant across the entire continuum of atherosclerosis, exerting a deleterious impact comparable to that of LDLc and SBP.
中文摘要:了解炎症如何影响亚临床动脉粥样硬化斑块负荷,超越已确立的心血管危险因素的作用,对于以减少动脉粥样硬化性心血管疾病为目标的预防策略的成功具有重要意义。本研究旨在利用无创成像技术,调查炎症、低密度脂蛋白胆固醇和收缩压作为中年无症状个体亚临床动脉粥样硬化斑块负荷决定因素的相对贡献。来自早期亚临床动脉粥样硬化进展研究的参与者(中位年龄45岁)接受了每3年一次的纵向筛查(基线、3年和6年访视),包括连续血液检测(包括白细胞计数、纤维蛋白原、氧化低密度脂蛋白胆固醇和高敏C反应蛋白)、体格检查以及通过外周动脉三维血管超声和冠状动脉钙化定量进行的影像评估。6年随访时的全球斑块体积是主要结局。多变量线性回归和比例优势模型确定了全球斑块体积与炎症标志物及已确立的心血管危险因素之间的联系。在3471名参与者中,58%在6年随访时存在亚临床动脉粥样硬化。在调整年龄、性别、基线低密度脂蛋白胆固醇和平均收缩压后,白细胞计数与6年动脉粥样硬化斑块负荷具有最强的统计学关联,估计每增加一个标准差的白细胞计数,全球斑块体积增加32.6%。6年的全球斑块体积随基线低密度脂蛋白胆固醇每增加一个标准差而增加40.9%,随平均收缩压每增加一个标准差而增加42.7%,其次是纤维蛋白原(每增加一个标准差,全球斑块体积增加16.8%)。高敏C反应蛋白不能预测6年时更高的全球斑块体积。对于白细胞计数,风险显著增加的趋势仅出现在其中位数以上的水平。颈动脉和股动脉斑块体积的单独分析以及冠状动脉钙化也观察到类似的模式。白细胞计数和纤维蛋白原水平的升高也与疾病解剖学范围的扩大相关。炎症通过直接斑块定量评估对亚临床动脉粥样硬化斑块负荷有贡献,其作用超越低密度脂蛋白胆固醇和收缩压的影响。这些发现表明,通过系统性炎症标志物捕捉到的炎症是贯穿整个动脉粥样硬化连续体的危险因素,其有害影响与低密度脂蛋白胆固醇和收缩压相当。
JAMA internal medicine IF 26.3 2026-11-09 PMID: 43002436
Low-value care costs more than $100 billion annually and remains pervasive despite decades of evidence documenting its clinical and financial harms. While several US states have begun discouraging its use, the feasibility of such statewide interventions in partnership with large health systems remains unknown. To investigate the effectiveness of a clinician-led, multistakeholder, statewide initiative to reduce low-value care in the Commonwealth of Virginia. This quality improvement study used a difference-in-differences analyses comparing low-value service changes among patients attributed to 6 health systems vs 12 control systems in the Commonwealth of Virginia preintervention (January 1 to December 31, 2019) vs postintervention (January 1 to December 31, 2022). Any patient eligible to receive 1 or more of the 9 measured low-value services in the 18 health systems evaluated were included. Data were analyzed between December 1, 2023, and September 1, 2026. The intervention, Smarter Care Virginia, included health system financial support, clinician education, and quarterly peer-comparison performance scorecards. The primary outcome was the percentage of patients receiving any of 9 selected low-value services: (1-3) preoperative laboratory, imaging, and cardiac testing; (4-5) electrocardiogram/cardiac screening and cardiac stress testing; (6-7) diagnostic imaging and opioids for acute back pain; (8) advanced diagnostic eye imaging; and (9) peripherally inserted central catheter lines for patients with chronic kidney disease. Secondary outcomes included adverse events (eg, myocardial infarction-related hospitalization) and per-capita spending on the 9 low-value services. A total of 17 223 clinicians (7222 in the intervention group and 10 001 in the control group) and 4.5 million patients (approximately 68% of Virginia's adult population) were identified. In 2019, 10.5% of patients in the intervention group and 10.7% of patients in the control group received 1 or more low-value services; in 2021 to 2022, rates declined to 8.5% and 9.1%, respectively. The intervention was associated with 10.4% fewer patients receiving 1 or more low-value services (absolute reduction, -1.1 percentage points; 95% CI, -2.1 to -0.1 percentage points; P = .04). There was no statistically significant change in adverse events (0.03%; 95% CI, -0.02% to 0.03%; P = .84) or spending on the 9 low-value services ($0.33; 95% CI, -$3.43 to $4.11). In this quality improvement study, a statewide, clinician-led initiative was associated with a small but statistically significant reduction in low-value care delivery without evidence of harm. Achieving larger reductions may require combining such health system-driven efforts with additional strategies, such as payment reform and physician and hospital accountability, that discourage the use of low-value care.
中文摘要:低价值医疗每年花费超过1000亿美元,尽管数十年的证据记录了其临床和财务危害,但其依然普遍存在。虽然美国一些州已开始鼓励减少此类服务的使用,但在与大型卫生系统合作的情况下,此类全州性干预措施的可行性尚不清楚。本研究旨在调查由临床医生主导、多利益相关方参与的弗吉尼亚州全州性倡议在减少低价值医疗方面的有效性。这项质量改进研究采用双重差分分析,比较了干预前(2019年1月1日至12月31日)与干预后(2022年1月1日至12月31日)弗吉尼亚州6个卫生系统归属患者与12个对照系统患者在低价值服务使用上的变化。评估的18个卫生系统中,任何有资格接受9项测量低价值服务中至少一项的患者均被纳入。数据于2023年12月1日至2026年9月1日期间进行分析。干预措施Smarter Care Virginia包括卫生系统财务支持、临床医生教育以及季度同行比较绩效评分卡。主要结局是接受9项选定低价值服务中任意一项的患者百分比:(1-3)术前实验室检查、影像学和心脏测试;(4-5)心电图/心脏筛查和心脏压力测试;(6-7)急性背痛患者的诊断性影像学和阿片类药物;(8)高级诊断性眼部影像学;以及(9)慢性肾脏病患者的经外周静脉置入中心静脉导管。次要结局包括不良事件(例如心肌梗死相关住院)和9项低价值服务的人均支出。共识别出17223名临床医生(干预组7222名,对照组10001名)和450万名患者(约占弗吉尼亚州成年人口的68%)。2019年,干预组和对照组分别有10.5%和10.7%的患者接受了一项或多项低价值服务;在2021至2022年间,这一比例分别下降至8.5%和9.1%。该干预措施与接受一项或多项低价值服务的患者减少10.4%相关(绝对减少-1.1个百分点;95%置信区间为-2.1至-0.1个百分点;P=.04)。不良事件(0.03%;95%置信区间为-0.02%至0.03%;P=.84)和9项低价值服务的支出(0.33美元;95%置信区间为-3.43至4.11美元)均无统计学显著变化。在这项质量改进研究中,全州性、由临床医生主导的倡议与低价值医疗交付的小幅但具有统计学意义的减少相关,且未显示出危害证据。实现更大的减少可能需要将此类卫生系统驱动的努力与额外的策略相结合,例如支付改革以及医师和医院的问责制,以 discouraging 低价值医疗的使用。
European heart journal IF 45.3 2026-11-06 PMID: 40878832
The best management approach for renin-angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery. Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73-0.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66-2.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76-1.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60-2.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56-1.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69-2.38; low certainty). These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.
中文摘要:关于术前使用肾素-血管紧张素系统(RAS)抑制剂的最佳管理方法存在争议。部分研究提示继续用药可能增加临床显著性围术期低血压及器官损伤的风险,而另一些观点认为停药会显著增加严重高血压和心力衰竭的风险。为确定最有效的策略,本研究对比较非心脏和非血管手术患者中停用与继续服用RAS抑制剂的随机对照试验进行了系统评价和荟萃分析。检索了PubMed、Embase和Cochrane对照试验中央注册库(CENTRAL)中的相关随机对照试验。共纳入5项随机对照试验(10773名患者,其中5388名被随机分配至停药组)。停用RAS抑制剂可能降低围术期低血压发生率(27.66% vs 34.06%;风险比[RR] 0.81,95%置信区间[CI] 0.73-0.89;中等确定性证据)。关于对围术期高血压的影响,证据非常不确定(9.46% vs 8.05%;RR 1.38,95% CI 0.66-2.89;极低确定性证据)。在主要临床结局方面,停药提示急性肾损伤(10.45% vs 10.69%;RR 0.98,95% CI 0.66-1.45;低确定性证据)、急性心力衰竭(5.38% vs 5.32%;RR 1.00,95% CI 0.76-1.31;低确定性证据)、心肌梗死(1.22% vs 1.00%;RR 1.19,95% CI 0.60-2.39;低确定性证据)、卒中(0.42% vs 0.40%;RR 1.04,95% CI 0.56-1.93;低确定性证据)和心律失常(1.80% vs 1.40%;RR 1.28,95% CI 0.69-2.38;低确定性证据)差异很小或无差异。这些发现表明,对于接受非心脏、非血管手术的患者,停用RAS抑制剂可能降低围术期低血压风险,但关于其对围术期高血压及主要临床结局影响的证据非常不确定。

基础研究 (1篇)

Clinical reviews in allergy & immunology IF 11.5 2026-11-11 PMID: 43013208
Kawasaki disease (KD) is an acute onset, childhood systemic vasculitis with the most important complication being coronary artery injury with aneurysm formation. In the pathogenesis of KD, innate immune overactivation is well recognized, but the role of adaptive immunity in the progression of vascular lesions is not completely understood. A local lesion in the coronary artery is thought to connect to the systemic inflammatory reaction through CD8+ T cells. In this review, we discuss evidence from peripheral blood immunophenotyping, single cell transcriptomics, TCR clonal repertoire profiling, human coronary artery pathology and KD like animal models to delineate CD8⁺ T-cell signatures and their proposed pathogenic mechanisms. The circulating CD8+ T cells from acute-phase patients have decreased numbers, increased activation markers, skewed subset distribution, and co-existent proliferative and CTL and exhaustion phenotype transcription profiles in conjunction with TCR clonal expansion. CD8+ T cells appear to infiltrate the coronary arterial lesions in human autopsy samples and CD8+ T cells induce coronary arteritis in murine models. Interestingly, classical perforin-granzyme-mediated cytotoxicity of lesional CD8+ T cells is not confirmed in human KD, underscoring a crucial gap between peripheral omics signatures, data in animal models and evidence in human tissues. The in situ effector mechanisms of disease driving CD8+ T cells subsets, and their feasibility as clinical biomarkers, warrant further investigation and may lead to precision risk stratification and targeted immunotherapies in KD related vascular complications, using multicenter prospective cohorts and paired blood and tissue functional assays.
中文摘要:川崎病是一种急性起病的儿童系统性血管炎,其最重要的并发症是冠状动脉损伤伴动脉瘤形成。在川崎病的发病机制中,固有免疫过度激活已得到广泛认可,但适应性免疫在血管病变进展中的作用尚未完全阐明。冠状动脉的局部病灶被认为通过CD8+ T细胞与全身炎症反应相联系。本综述讨论了来自外周血免疫表型分析、单细胞转录组学、TCR克隆库谱系分析、人类冠状动脉病理及川崎病动物模型方面的证据,以描绘CD8+ T细胞的特征及其提出的致病机制。急性期患者循环中的CD8+ T细胞数量减少,活化标志物增加,亚群分布发生偏倚,并伴有增殖性、细胞毒性淋巴细胞(CTL)和耗竭表型的转录谱共存,同时伴随TCR克隆扩增。人类尸检样本显示CD8+ T细胞浸润冠状动脉病变,且在鼠类模型中CD8+ T细胞可诱导冠状动脉炎。有趣的是,病灶处CD8+ T细胞的经典穿孔素-颗粒酶介导的细胞毒性在人类川崎病中未获证实,这凸显了外周组学特征、动物模型数据与人类组织证据之间的关键差距。驱动疾病的CD8+ T细胞亚群的体内效应机制及其作为临床生物标志物的可行性值得进一步研究,并可能通过多中心前瞻性队列及配对血液和组织功能检测,实现川崎病相关血管并发症的精准风险分层和靶向免疫治疗。

8心肌病 (3篇)

临床研究 (2篇)

European heart journal IF 45.3 2026-11-10 PMID: 43004584
Modern genetic testing in hypertrophic cardiomyopathy (HCM) includes newly described HCM-associated genes and full intronic regions of certain classic sarcomeric genes. This study evaluated genetic retesting in HCM patients with a prior negative test and identified predictors of a positive result to guide retesting. This multicentre study included patients with HCM who previously had negative next-generation sequencing (NGS)-based genetic testing at four centres. Subjects were retested using an updated NGS-based HCM panel. Of 508 retested HCM patients (median age 70 years; 66.9% male; median maximal left ventricular wall thickness 18 mm; median interval from initial genetic test 6.6 years), 46 (9%) had 48 HCM-related variants: 14 in new HCM-associated genes, 3 in deep intronic MYBPC3 regions, 18 intermediate-effect variants, and 13 (8 reclassified) in classic HCM-associated genes. In multivariable analysis, the presence of late gadolinium enhancement (LGE) [odds ratio (OR) 3.52; 95% confidence interval (CI) 1.38-10.25], the Mayo HCM score (OR 1.46 per 1 point increase; 95% CI 1.08-2.01), and the Toronto HCM score (OR 1.18 per 1 point increase; 95% CI 1.08-1.30) were independent predictors of detecting HCM-related variants at retesting. The diagnostic yields in patients with LGE and a high Toronto score (≥13 points), and with LGE and a high Mayo score (≥4 points), were 80% and 50%, respectively. In patients with HCM and prior negative genetic testing, retesting identified HCM-related variants in 9% of individuals, allowing counselling and risk stratification. Late gadolinium enhancement, combined with the Mayo and Toronto scores, may be used to guide which patients should be prioritized for genetic retesting.
中文摘要:现代肥厚型心肌病(HCM)的基因检测包括新描述的与HCM相关的基因以及某些经典肌节基因的完整内含子区域。本研究评估了既往基因检测结果为阴性的HCM患者进行基因复检的价值,并识别阳性结果的预测因素以指导复检策略。这项多中心研究纳入了在四个中心此前接受基于下一代测序(NGS)的基因检测结果为阴性的HCM患者。受试者使用更新版的基于NGS的HCM面板进行了复检。在508名接受复检的HCM患者中(中位年龄70岁;男性占66.9%;左心室最大壁厚度中位数18毫米;初次基因检测至复检的中位间隔时间为6.6年),46人(9%)检出48个与HCM相关的变异:其中14个位于新的HCM相关基因,3个位于MYBPC3基因的深内含子区域,18个为中等效应变异,13个位于经典HCM相关基因中(其中8个被重新分类)。在多变量分析中,晚期钆增强(LGE)的存在(比值比OR 3.52;95%置信区间CI 1.38-10.25)、Mayo HCM评分(每增加1分,OR 1.46;95% CI 1.08-2.01)和Toronto HCM评分(每增加1分,OR 1.18;95% CI 1.08-1.30)是复检时检出HCM相关变异的独立预测因子。在具有LGE且Toronto评分较高(≥13分)的患者中,诊断率为80%;在具有LGE且Mayo评分较高(≥4分)的患者中,诊断率为50%。对于既往基因检测阴性的HCM患者,复检在9%的个体中检出了与HCM相关的变异,从而有助于遗传咨询和风险分层。晚期钆增强结合Mayo和Toronto评分可用于指导优先对哪些患者进行基因复检。
Cardiovascular research IF 12.5 2026-11-06 PMID: 42670609
Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5-107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter-defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03-1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.
中文摘要:在当代肥厚型心肌病风险评估中广泛存在的晚期钆增强已被认可,但较低定量阈值的预后价值仍存在争议。本研究旨在评估定量晚期钆增强是否提供独立于既定临床和表型风险标志物的额外预后信息。该大型当代队列包含3035名患者(中位年龄58岁,男性占57%);其中56%存在晚期钆增强,包括242例(8%)晚期钆增强超过10%的患者。大多数患者患有梗阻性肥厚型心肌病(71%),其中1498例(69%)在心脏磁共振检查后中位43天(四分位距5-107天)接受了室间隔减容治疗(包括1485例肌切除术和13例酒精室间隔消融术)。在中位随访8.8年期间,发生331例(11%)主要终点事件[295例心血管死亡(9.7%)和36例植入式心脏复律除颤器适当放电(1.3%)]。在多变量Cox比例风险模型分析中(调整了标准临床和心脏磁共振变量),较高的晚期钆增强百分比(每增加1%,风险比1.05,95%置信区间1.03-1.06;P < 0.001)与主要事件相关。与无晚期钆增强相比,晚期钆增强≥10%与复合终点的较高风险相关。在该大型当代肥厚型心肌病队列中,定量晚期钆增强独立关联于长期不良结局。晚期钆增强≥10%识别出显著高风险患者,且纳入晚期钆增强提高了欧洲心脏病学会和美国心脏协会/美国心血管病学院风险评估的判别能力。

基础研究 (1篇)

Circulation IF 41.3 2026-11-10 PMID: 43006183
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC cardiomyocytes) as a model for cardiac disease have become increasingly important, bolstered by the Food and Drug Administration's initiative to promote novel alternative methods for biomedical research. A key limitation of metabolically immature iPSC cardiomyocytes is their limited ability to accurately recapitulate mitochondria-dependent pathologies, such as Friedreich ataxia-associated cardiomyopathy. Adult cardiomyocytes are characterized by a high density of interfibrillar mitochondria, abundant respiratory complexes (I-V) that form supercomplexes, and efficient utilization of fatty acids to drive mitochondrial respiration. These unique metabolic structures and functions are largely missing in iPSC cardiomyocytes. Further, whether iPSC cardiomyocytes can efficiently utilize fatty acids for respiration in the presence of glucose, a unique adult feature, remains unclear. We developed a chemically defined, 11-component maturation medium (MM11) designed using a bioinformatics-guided strategy that identified high-fidelity transcriptional markers of adult cardiac metabolic maturity. Human iPSC cardiomyocytes were treated with MM11 for 2 weeks and evaluated at the molecular, structural, and functional levels, with an emphasis on mitochondrial maturity. We benchmarked our results with isolated primary adult human cardiomyocytes. Last, we tested whether this method could enable us to more accurately model Friedreich ataxia cardiomyopathy. MM11 treatment increased expression of metabolic pathways, including mitochondrial respiration and fatty acid metabolism, at the transcript and protein levels. Ultrastructural analyses revealed the formation of interfibrillar mitochondria and mitochondrial respiratory supercomplexes, a feature never shown in previous reports. Functionally, MM11-treated iPSC cardiomyocytes exhibited substantially increased oxidative phosphorylation and a metabolic preference for fatty acid utilization in the presence of physiologic substrates, as determined by oxygen consumption assays and 13C isotope tracing. MM11 promotes robust metabolic maturation of human iPSC cardiomyocytes, enabling sophisticated mitochondrial architecture and substrate utilization. These metabolically matured cardiomyocytes more faithfully model mitochondria-dependent cardiac pathologies, including ischemia-reperfusion injury and Friedreich ataxia cardiomyopathy, improving the use of iPSC cardiomyocytes for mechanistic studies of human heart disease.
中文摘要:人类诱导多能干细胞(iPSC)衍生的心肌细胞作为心脏疾病模型日益重要,这得益于美国食品药品监督管理局推动生物医学研究替代新方法的倡议。代谢不成熟的iPSC心肌细胞的关键局限性在于其难以准确重现线粒体依赖性病理改变,如弗里德赖希共济失调相关心肌病。成人心肌细胞的特征是拥有高密度的肌原纤维间线粒体、形成超复合物的丰富呼吸复合物(I-V)以及高效利用脂肪酸驱动线粒体呼吸。这些独特的代谢结构和功能在iPSC心肌细胞中大多缺失。此外,iPSC心肌细胞在有葡萄糖存在时是否能有效利用脂肪酸进行呼吸这一成人特有特征仍不清楚。我们开发了一种由生物信息学指导策略确定的11组分化学定义成熟培养基(MM11),该策略识别了成人心脏代谢成熟的高保真转录标志物。人类iPSC心肌细胞经MM11处理2周后,在分子、结构和功能水平进行评估,重点在于线粒体成熟度。我们将结果与分离的原代人成年心肌细胞进行了基准比较。最后,我们测试了该方法是否能更准确地模拟弗里德赖希共济失调心肌病。MM11处理在转录和蛋白水平上增加了包括线粒体呼吸和脂肪酸代谢在内的代谢通路表达。超微结构分析揭示了肌原纤维间线粒体和线粒体呼吸超复合物的形成,这是先前报告中从未展示过的特征。功能上,经MM11处理的iPSC心肌细胞表现出显著增加的氧化磷酸化以及在生理底物存在时对脂肪酸利用的代谢偏好,这通过耗氧测定和13C同位素示踪确定。MM11促进了人类iPSC心肌细胞的强大代谢成熟,使其具备复杂的线粒体结构和底物利用能力。这些代谢成熟的心肌细胞更忠实地模拟了线粒体依赖性心脏病理改变,包括缺血再灌注损伤和弗里德赖希共济失调心肌病,从而改善了iPSC心肌细胞在人类心脏病机制研究中的应用。

9心肌炎 (2篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-11-06 PMID: 40928499
Fulminant myocarditis (FM) is a complex clinical syndrome characterized by acute myocardial inflammation and cardiogenic shock. Evidence on long-term outcomes, mortality risk factors, and targeted treatment options remains limited. This retrospective analysis included consecutive adult patients admitted for FM between January 2012 and November 2022 at 26 European tertiary centres. According to endomyocardial biopsy (EMB) findings, patients were categorized as lymphocytic (LM), eosinophilic (EM), necrotizing eosinophilic (NEM), and giant-cell myocarditis (GCM) for the main analyses. Patients with inconclusive histopathology and those who did not undergo EMB were analysed separately. Primary outcomes were in-hospital and 1-year mortality. Multivariable logistic regression models were employed as generalized linear models to analyse the association of prespecified risk factors with mortality. Estimated associations are reported as odds ratios, generalized marginal effects, and adjusted prediction plots. A total of 271 patients [median age 43 years (interquartile range: 33-55 years), 58% male] were included in the analysis, of whom 146 fulfilled histopathologic criteria of LM (n = 99), EM (n = 18), NEM (n = 3), or GCM (n = 26). In the remaining 125 cases, EMB was inconclusive (n = 48) or not performed (n = 77). While there were no significant differences in cardiac arrest rate, admission Simplified Acute Physiology Score (SAPS) II, ventricular function, initial pH, and liver and kidney function parameters between histopathologic subgroups, the use of immunosuppressive medications and need for organ replacement varied. In the overall population, in-hospital and 1-year mortality were 31% and 34%, respectively. The highest 1-year mortality rate was observed among patients with GCM (LM: 25%, EM: 28%, NEM: 33%, GCM: 54%, P = .04). Patients who survived to discharge had an excellent functional outcome and long-term recovery of ventricular function. In total, 17 patients (6%) received a heart transplant during follow-up. Older age, lower pH, and histopathologic diagnosis of GCM were independently associated with in-hospital and 1-year mortality. In-hospital mortality among patients with FM remains high. Age, pH, and histopathological findings may serve as prognostic markers to identify high-risk patients and to guide treatment strategies. Long-term outcomes are excellent among those who survive to discharge.
中文摘要:暴发性心肌炎是一种以急性心肌炎症和心源性休克为特征的复杂临床综合征。关于长期预后、死亡危险因素及靶向治疗方案的证据仍然有限。这项回顾性分析纳入了2012年1月至2022年11月期间在26个欧洲三级医疗中心收治的连续成年暴发性心肌炎患者。根据心内膜心肌活检结果,主要分析将患者分为淋巴细胞性心肌炎、嗜酸性粒细胞性心肌炎、坏死性嗜酸性粒细胞性心肌炎和巨细胞性心肌炎组。组织病理学结果不明确或未进行心内膜心肌活检的患者被单独分析。主要结局指标为院内死亡率和1年死亡率。采用多变量逻辑回归模型作为广义线性模型,分析预设危险因素与死亡率之间的关联。估计的关联以比值比、广义边际效应和调整预测图的形式报告。共纳入271名患者(中位年龄43岁,四分位距33-55岁,男性占58%),其中146人符合淋巴细胞性心肌炎、嗜酸性粒细胞性心肌炎、坏死性嗜酸性粒细胞性心肌炎或巨细胞性心肌炎的组织病理学标准。在其余125例中,心内膜心肌活检结果不明确或未进行。尽管各组间心脏骤停发生率、入院简化急性生理学评分II、心室功能、初始pH值以及肝肾功能的参数无显著差异,但免疫抑制药物的使用及器官替代治疗的需求存在差异。在总体人群中,院内死亡率和1年死亡率分别为31%和34%。巨细胞性心肌炎患者的1年死亡率最高(淋巴细胞性25%,嗜酸性粒细胞性28%,坏死性嗜酸性粒细胞性33%,巨细胞性54%,P=.04)。存活至出院的患者具有极佳的功能结局和心室功能的长期恢复。随访期间共有17名患者接受了心脏移植。高龄、低pH值和巨细胞性心肌炎的组织病理学诊断与院内死亡率和1年死亡率独立相关。暴发性心肌炎患者的院内死亡率仍然较高。年龄、pH值和组织病理学发现可作为预后标志物,用于识别高危患者并指导治疗策略。存活至出院的患者长期预后良好。

基础研究 (1篇)

Circulation research IF 18.0 2026-11-12 PMID: 43017775
Myocarditis is an inflammatory cardiac disease in which T helper 17 (Th17) cell-driven immune responses contribute to progression toward dilated cardiomyopathy and heart failure. Current therapies mainly rely on corticosteroids but lack specificity, while the role of miR-721, synthesized by Th17 cells, remains largely unexplored in disease pathogenesis. We characterized the presence of mmu-miR-721 and its human homolog hsa-RNA-Chr8:96 in extracellular vesicles secreted by Th17 cells from IL-17 (interleukin-17) eGFP mice with experimental autoimmune myocarditis and from patients with myocarditis. MxCre±Ppargfl/fl mice and luciferase reporter assays were used to validate the target genes of miR-721 and hsa-RNA-Chr8:96, respectively. The functional role of miR-721 in experimental autoimmune myocarditis was investigated using lentiviral vectors overexpression and miRNA sponge molecules for inhibition. Th17 responses and heart inflammation were assessed, and echocardiography was performed after in vivo blockade of mmu-miR-721 in experimental autoimmune myocarditis mice. Both mmu-miR-721 and hsa-RNA-Chr8:96 were encapsulated in extracellular vesicles and secreted by Th17 cells of mice and patients with myocarditis. Overexpression of mmu-miR-721 in draining lymph node cells from experimental autoimmune myocarditis mice promoted Th17 differentiation via Pparg inhibition and increased RORγt and IL-17 expression. In contrast, no differences in RORγt expression were observed in the absence of Pparg, a target of miR-721, indicating that miR-721 promotes Th17 responses through Pparg repression. In addition, human PPARG was validated as a target gene of hsa-RNA-Chr8:96, as its overexpression in peripheral blood leukocytes downregulated PPARG mRNA levels, suggesting that similar pathways are involved in human pathology. Finally, in vivo blockade of mmu-miR-721 increased Pparg expression, reducing RORγt and IL-17 activation in T cells, leading to decreased leukocyte infiltration in the heart and improved cardiac function thereby ameliorating disease progression. miR-721 is released by Th17 cells in extracellular vesicles and promotes Th17 responses during myocarditis through repression of PPARγ, identifying this miRNA as both a mechanistic driver of disease and a potential therapeutic target.
中文摘要:心肌炎是一种炎症性心脏疾病,其中T辅助17(Th17)细胞驱动的免疫反应有助于向扩张型心肌病和心力衰竭进展。目前的治疗主要依赖皮质类固醇但缺乏特异性,而由Th17细胞合成的miR-721在疾病发病机制中的作用仍未被充分探索。我们表征了实验性自身免疫性心肌炎IL-17(白细胞介素-17)eGFP小鼠以及心肌炎患者的Th17细胞分泌的细胞外囊泡中mmu-miR-721及其人类同源物hsa-RNA-Chr8:96的存在。使用MxCre±Ppargfl/fl小鼠和荧光素酶报告基因测定分别验证了miR-721和hsa-RNA-Chr8:96的靶基因。利用慢病毒载体过表达和miRNA海绵分子抑制,研究了miR-721在实验性自身免疫性心肌炎中的功能作用。评估了Th17反应和心脏炎症,并在实验性自身免疫性心肌炎小鼠体内阻断mmu-miR-721后进行了超声心动图检查。mmu-miR-721和hsa-RNA-Chr8:96均被包裹在细胞外囊泡中,并由小鼠和心肌炎患者的Th17细胞分泌。过表达实验性自身免疫性心肌炎小鼠引流淋巴结细胞中的mmu-miR-721通过抑制Pparg促进Th17分化并增加RORγt和IL-17的表达。相比之下,在缺乏miR-721的靶基因Pparg的情况下,未观察到RORγt表达的差异,表明miR-721通过抑制Pparg促进Th17反应。此外,人类PPARG被验证为hsa-RNA-Chr8:96的靶基因,因为其在外周血白细胞中的过表达降低了PPARG mRNA水平,表明类似的通路参与了人类病理过程。最后,体内阻断mmu-miR-721增加了Pparg的表达,减少了T细胞中RORγt和IL-17的激活,导致心脏中白细胞浸润减少并改善心脏功能,从而减轻疾病进展。miR-721由Th17细胞通过细胞外囊泡释放,并通过抑制PPARγ促进心肌炎期间的Th17反应,将该miRNA确定为疾病的机制驱动因素和潜在的治疗靶点。

10冠心病 (2篇)

临床研究 (2篇)

JAMA cardiology IF 15.2 2026-11-11 PMID: 43013289
Individuals with low or minimal coronary artery calcification (CAC) are considered at low cardiovascular risk, but a substantial absolute number of cardiovascular events occur in this population; assessment of coronary inflammation using the fat attenuation index (FAI) score may identify residual inflammatory risk beyond CAC score. To assess whether coronary inflammation measured on coronary computed tomography angiography (CCTA) or noncontrast cardiac CT (NCCT) identifies individuals at high cardiovascular risk independent of CAC burden. In this cohort study, a novel artificial intelligence algorithm for measuring FAI score on NCCT was trained and tested in an independent, multicenter, longitudinal cohort of consecutive individuals undergoing clinically indicated CCTA and NCCT for CAC score between 2010 and 2021, with median (IQR) follow-up of 6.7 (4.6-10.0) years. Data were analyzed from January 2010 to March 2024. Agatston CAC score and coronary inflammation from both CCTA (CCTA FAI score, established biomarker) and NCCT (NC FAI score, novel biomarker). The primary outcome was cardiovascular (CV) mortality; the secondary outcome was major adverse cardiovascular events (MACE), comprising myocardial infarction, new-onset heart failure, or CV death. The derivation cohort included 6818 individuals (median [IQR] age, 61 [51-71] years; 3543 female participants [52.0%]), and the external validation clinical outcomes cohort included 19 110 individuals (median [IQR] age, 56.0 [48.0-64.0] years; 9289 female participants [48.6%]). During follow-up, 536 CV deaths and 1727 MACE occurred. FAI scores independently stratified CV mortality risk across CAC score categories, with the strongest associations among individuals with CAC score of 0. Adding CCTA FAI score or NC FAI score to CAC score significantly improved risk discrimination (area under the curve increased from 0.76 to 0.81 and 0.80, respectively; P < .001), reclassification (net reclassification index), and net benefit across all risk thresholds. Among 89 CV deaths in individuals with CAC score of 0 and 138 CV deaths with CAC score of 1 through 99, 44.9% and 44.2% had NC FAI score above the 75th percentile, respectively. Among individuals with CAC score of 0, CV mortality rates increased from 1.4 to 4.0 per 1000 person-years for those with NC FAI score above the 75th percentile, and MACE rates increased from 5.9 to 13.3 per 1000 person-years. Per the results of this cohort study, NC FAI score provides prognostic performance comparable to CCTA FAI score and improves cardiovascular risk prediction and reclassification beyond CAC score. Elevated FAI score, derived from either CCTA or NCCT, should be interpreted as a risk-enhancing factor that may prompt intensification of established, evidence-based preventive measures and may serve as a potential future gatekeeper for the use of targeted anti-inflammatory treatments.
中文摘要:冠状动脉钙化(CAC)评分低或极低的个体通常被认为心血管风险较低,但该人群中心血管事件的绝对数量仍然很大;使用脂肪衰减指数(FAI)评分评估冠状动脉炎症可能识别出超出 CAC 评分的残余炎症风险。本研究旨在评估通过冠状动脉计算机断层扫描血管造影(CCTA)或非增强心脏 CT(NCCT)测量的冠状动脉炎症是否能独立于 CAC 负荷识别高危心血管个体。在这项队列研究中,一种用于在 NCCT 上测量 FAI 评分的新型人工智能算法在独立的、多中心的纵向队列中进行了训练和测试,该队列包含 2010 年至 2021 年间因临床指征接受 CCTA 和 NCCT 检查以进行 CAC 评分的连续个体,中位(四分位距)随访时间为 6.7(4.6-10.0)年。数据分析时间为 2010 年 1 月至 2024 年 3 月。评估指标包括 Agatston CAC 评分以及来自 CCTA(CCTA FAI 评分,既定生物标志物)和 NCCT(NC FAI 评分,新型生物标志物)的冠状动脉炎症。主要结局为心血管(CV)死亡率;次要结局为主要不良心血管事件(MACE),包括心肌梗死、新发心力衰竭或 CV 死亡。推导队列包括 6818 名个体(中位 [IQR] 年龄 61 [51-71] 岁;女性参与者 3543 名 [52.0%]),外部验证临床结局队列包括 19110 名个体(中位 [IQR] 年龄 56.0 [48.0-64.0] 岁;女性参与者 9289 名 [48.6%])。随访期间发生 536 例 CV 死亡和 1727 例 MACE。FAI 评分独立地分层了不同 CAC 评分类别的 CV 死亡风险,其中在 CAC 评分为 0 的个体中关联最强。将 CCTA FAI 评分或 NC FAI 评分添加到 CAC 评分中显著提高了风险区分度(曲线下面积从 0.76 分别增加到 0.81 和 0.80;P < .001)、重分类(净重分类指数)以及所有风险阈值下的净获益。在 CAC 评分为 0 的个体中,有 89 例 CV 死亡,其中 44.9% 的 NC FAI 评分高于第 75 百分位;在 CAC 评分为 1 至 99 的个体中,有 138 例 CV 死亡,其中 44.2% 的 NC FAI 评分高于第 75 百分位。在 CAC 评分为 0 的个体中,NC FAI 评分高于第 75 百分位者的 CV 死亡率从每 1000 人年 1.4 例增加到 4.0 例,MACE 发生率从每 1000 人年 5.9 例增加到 13.3 例。根据这项队列研究的结果,NC FAI 评分提供了与 CCTA FAI 评分相当的预后性能,并改善了 CAC 评分之外的心血管风险预测和重分类。源自 CCTA 或 NCCT 的升高 FAI 评分应被视为风险增强因素,可能促使加强既定的循证预防措施,并可能作为未来使用靶向抗炎治疗的潜在守门人。
NEJM evidence IF 11.6 2026-11-07 PMID: 42998055
Pelacarsen is an antisense oligonucleotide that reduces serum levels of lipoprotein(a). In a randomized placebo-controlled trial in patients with established cardiovascular disease, pelacarsen did not reduce the risk of major adverse cardiovascular events compared to placebo. We further investigated the association of pelacarsen treatment with cardiovascular outcomes. We report the association of pelacarsen treatment with a primary composite end point of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization. Analyses included on-treatment, uninterrupted treatment, total primary end point events (first and recurrent events), landmark analyses classified by changes in and achieved lipoprotein(a) at 3 months, and key subgroups including baseline lipoprotein(a), low-density lipoprotein (LDL) cholesterol, high-sensitivity C-reactive protein (CRP), and time from qualifying event to enrollment. For participants on treatment, a primary end point occurred in 434 participants (10.4%) randomly assigned to placebo and 380 participants (9.1%) assigned to pelacarsen (hazard ratio, 0.98; 95% confidence interval [CI], 0.85 to 1.12). When evaluating participants with uninterrupted treatment, a primary end point event occurred in 167 participants (11.0%) in the pelacarsen group and 204 participants (10.1%) in the placebo group (hazard ratio, 1.09; 95% CI, 0.89 to 1.34). When evaluating total primary end point events, there were 644 events in the pelacarsen group and 646 events in the placebo group (rate ratio, 1.00; 95% CI, 0.87 to 1.14). In landmark analyses evaluating participants alive and free of the composite end point at 3 months, when compared to placebo there was no association between pelacarsen treatment and the primary end point either in participants with reduction in lipoprotein(a) greater than or equal to the median (170 nmol/l) (hazard ratio, 1.09; 95% CI, 0.92 to 1.29) or in participants who achieved lipoprotein(a) lower than or equal to the median (69.5 nmol/l) (hazard ratio, 1.10; 95% CI, 0.93 to 1.29). There was also no association between pelacarsen treatment and the primary end point in any of the evaluated key subgroups including classification by median baseline lipoprotein(a), LDL cholesterol, high-sensitivity CRP, or time from qualifying cardiovascular disease to enrollment. Pelacarsen was not associated with a reduction in major adverse cardiovascular events when evaluated by treatment exposure, changes in or achieved lipoprotein(a) levels at 3 months, considering total events, or within subgroups of baseline lipoprotein(a), LDL cholesterol, or high-sensitivity CRP levels.
中文摘要:Pelacarsen是一种反义寡核苷酸,可降低血清脂蛋白(a)水平。在一项针对已确诊心血管疾病患者的随机安慰剂对照试验中,与安慰剂相比,Pelacarsen未能降低主要不良心血管事件的风险。我们进一步调查了Pelacarsen治疗与心血管结局之间的关联。报告了Pelacarsen治疗对主要复合终点(心血管原因死亡、非致死性心肌梗死、非致死性卒中或紧急冠状动脉血运重建)的关联。分析包括治疗期间、持续治疗、主要复合终点的总事件数(首次和复发事件)、按3个月时脂蛋白(a)的变化和达到的水平分类的地标分析,以及关键亚组分析,包括基线脂蛋白(a)、低密度脂蛋白(LDL)胆固醇、高敏C反应蛋白(CRP)和从合格事件到入组的时间。对于治疗中的参与者,安慰剂组有434名参与者(10.4%)发生主要终点事件,Pelacarsen组有380名参与者(9.1%)发生(风险比0.98;95%置信区间[CI] 0.85至1.12)。在评估持续治疗参与者时,Pelacarsen组有167名参与者(11.0%)发生主要终点事件,安慰剂组有204名参与者(10.1%)发生(风险比1.09;95% CI 0.89至1.34)。在评估主要复合终点的总事件时,Pelacarsen组有644个事件,安慰剂组有646个事件(率比1.00;95% CI 0.87至1.14)。在地标分析中,评估3个月时存活且无复合终点的参与者,与安慰剂相比,Pelacarsen治疗与主要终点之间没有关联,无论是在脂蛋白(a)降低大于或等于中位数(170 nmol/l)的参与者中(风险比1.09;95% CI 0.92至1.29),还是在达到脂蛋白(a)低于或等于中位数(69.5 nmol/l)的参与者中(风险比1.10;95% CI 0.93至1.29)。在按基线脂蛋白(a)、LDL胆固醇、高敏CRP或从合格心血管疾病到入组的时间分类的任何关键亚组中,Pelacarsen治疗与主要终点之间也没有关联。通过治疗暴露、3个月时脂蛋白(a)水平的变化或达到水平、考虑总事件或在基线脂蛋白(a)、LDL胆固醇或高敏CRP水平的亚组中进行评估,Pelacarsen与主要不良心血管事件的减少无关。

11基础/转化 (2篇)

基础研究 (2篇)

Ageing research reviews IF 15.5 2026-11-11 PMID: 43000086
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, and cellular senescence serves as a core driving factor in the pathogenesis and progression of cardiovascular degeneration and related diseases. Sirtuins act as a crucial molecular hub linking cellular senescence to CVDs, and their upregulated activity is closely associated with delayed cellular senescence and preserved normal cardiovascular function; therefore, the research and development of small-molecule Sirtuin-activating compounds (STACs) hold important research value and promising translational potential for CVD intervention. This review systematically elucidates the molecular mechanisms by which various Sirtuin subtypes influence senescence-related processes in CVDs through the regulation of biological events such as DNA damage repair, mitochondrial homeostasis, oxidative stress, and inflammatory responses. Furthermore, it comprehensively outlines their roles in major cardiovascular conditions, including hypertension, angiogenesis, atherosclerosis, aortic aneurysm and dissection, and heart failure. Finally, this paper summarizes recent advances in the development of Sirtuin activators and, in light of current challenges such as insufficient specificity and hurdles in clinical translation, provides perspectives on the future development of Sirtuin-targeted therapies for the prevention and treatment of CVDs.
中文摘要:心血管疾病是全球首要死因,细胞衰老是心血管退行性变及相关疾病发病机制与进展的核心驱动因素。Sirtuins作为连接细胞衰老与心血管疾病的关键分子枢纽,其活性上调与延缓细胞衰老及维持正常心血管功能密切相关;因此,小分子Sirtuin激活剂的开发对心血管疾病的干预具有重要的研究价值和广阔的转化潜力。本综述系统阐述了各类Sirtuin亚型通过调控DNA损伤修复、线粒体稳态、氧化应激和炎症反应等生物事件影响心血管疾病中衰老相关过程的分子机制。此外,全面概述了其在高血压、血管生成、动脉粥样硬化、主动脉瘤与夹层及心力衰竭等主要心血管疾病中的作用。最后,总结了Sirtuin激活剂开发的最新进展,并针对当前特异性不足及临床转化障碍等挑战,展望了Sirtuin靶向疗法在预防和治疗心血管疾病方面的未来发展。
Acta pharmacologica Sinica IF 10.4 2026-11-10 PMID: 43003868
Mitochondrial antiviral signalling protein (MAVS), also known as interferon-β (IFN-β) promoter stimulator 1 (IPS-1), virus-induced signalling adaptor (VISA), and CARD adaptor inducing IFN-β (CARDIF), has emerged as a regulatory node linking mitochondrial stress, innate immune signalling, and cardiovascular disease (CVD) pathogenesis. In the cardiovascular system, MAVS is activated not only by viral RNA sensors such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5), but also by endogenous danger signals. This activation promotes transcription of NLR family pyrin domain-containing 3 (NLRP3) and pro-inflammatory cytokines, and facilitates NLRP3 inflammasome assembly and cytokine maturation, processes implicated in myocardial inflammation, remodelling, and dysfunction in conditions such as myocardial hypertrophy, atherosclerosis, and cardiomyopathy. Beyond inflammasome activation, MAVS intersects with multiple cell death and homeostatic pathways relevant to CVD, including apoptosis, autophagy, and, potentially, ferroptosis. Preclinical studies show that genetic ablation of MAVS, or pharmacological interventions that limit mitochondrial reactive oxygen species (mtROS), mitochondrial double-stranded RNA (mtdsRNA) release, or downstream innate immune signalling, can attenuate MAVS-associated inflammation, oxidative stress, and metabolic remodelling, thereby slowing disease progression in experimental cardiovascular models. MAVS, however, also performs essential protective functions, particularly in antiviral defence and maintenance of cardiac homeostasis, underscoring the need for context-specific, cell-type-restricted, or pathway-selective modulation rather than indiscriminate inhibition. Collectively, these findings position MAVS as a promising therapeutic target in CVD, warranting further investigation into MAVS-associated signalling pathways and their modulation in cardiovascular contexts.
中文摘要:线粒体抗病毒信号蛋白(MAVS),又称干扰素β启动子刺激因子1、病毒诱导信号衔接蛋白或CARD接头诱导干扰素β,已成为连接线粒体应激、先天免疫信号与心血管疾病发病机制的关键调控节点。在心血管系统中,MAVS不仅由视黄酸诱导基因I和黑色素瘤分化相关基因5等病毒RNA传感器激活,还受内源性危险信号激活。这种激活促进NLR家族含吡啶结构域蛋白3及促炎细胞因子的转录,并推动NLRP3炎症小体组装与细胞因子成熟,这些过程与心肌肥大、动脉粥样硬化和心肌病等疾病中的心肌炎症、重构和功能障碍有关。除炎症小体激活外,MAVS还与凋亡、自噬及潜在的铁死亡等多种与心血管疾病相关的细胞死亡和稳态通路相互作用。临床前研究表明,在实验性心血管模型中,通过基因敲除MAVS或采用限制线粒体活性氧释放、线粒体双链RNA释放或下游先天免疫信号的药物干预,可减轻MAVS相关的炎症、氧化应激和代谢重构,从而延缓疾病进展。然而,MAVS也发挥重要的保护功能,特别是在抗病毒防御和维持心脏稳态方面,这强调了需要采用情境特异性、细胞类型限制性或通路选择性的调节策略,而非无差别抑制。综上所述,这些发现将MAVS定位为心血管疾病中极具前景的治疗靶点,需进一步研究心血管背景下MAVS相关信号通路及其调控机制。

12心房颤动 (2篇)

临床研究 (2篇)

European journal of preventive cardiology IF 10.0 2026-11-11 PMID: 40314396
To study the association between socioeconomic position (SEP), indicated by educational level, and incident atrial fibrillation (AF), and the role of lifestyle and cardiovascular risk factors as potential mediators in the causal pathway. Using education as indicator for SEP, we examined the association with AF and the mediation by body mass index, hypertension, smoking, alcohol, and physical activity. Our sample included 25 796 adult women and men from a population-based cohort study with median follow-up of 22 years (1994-2016). Total effect, natural direct effect (not through mediators), and natural indirect effect (through mediators) hazard ratios (HRs) were estimated using a counterfactual-based natural-effects model. Total effect of education on AF was small, and only significant for women with upper secondary as compared with primary education (19% lower hazard, 95% confidence interval 4%, 32%). All natural direct effect HRs were non-significant but suggesting increased risk by higher educational level. Compared with women with primary education, natural indirect effect hazard was 11% (4%, 17%) lower in women with upper secondary education, 18% (7%, 28%) lower in women with university/college education <4 years and 25% (12%, 34%) lower in women with university/college ≥4 years. In men, however, natural indirect effect did not differ between the levels of education. We found protective indirect effect of education on AF through lifestyle and cardiovascular risk factors in women, but not in men. The direct effect in both women and men indicated increased risk by higher education, although non-significant.
中文摘要:本研究旨在探讨社会经济地位(以教育水平为指标)与心房颤动(AF)发病率之间的关联,以及生活方式和心血管危险因素在因果路径中作为潜在中介变量的作用。利用教育水平作为社会经济地位的指标,我们分析了其与AF的关联,并考察了体重指数、高血压、吸烟、饮酒和体力活动对这些关联的中介效应。样本包括来自一项基于人群的队列研究的25796名成年男女,中位随访时间为22年(1994-2016)。采用基于反事实的自然效应模型估计总效应、自然直接效应(不通过中介变量)和自然间接效应(通过中介变量)的风险比(HR)。教育对AF的总效应较小,仅在女性中显著,即与初等教育相比,完成中等教育的风险降低19%(95%置信区间4%-32%)。所有自然直接效应的HR均不显著,但提示较高教育水平可能增加风险。与初等教育女性相比,完成中等教育女性的自然间接效应风险低11%(4%-17%),完成大学/学院教育不足4年的女性风险低18%(7%-28%),完成大学/学院教育4年及以上的女性风险低25%(12%-34%)。然而,在男性中,不同教育水平之间的自然间接效应无差异。我们发现教育通过生活方式和心血管危险因素对AF具有保护性的间接效应,但在男性中未观察到这一效应。无论男女,直接效应均提示较高教育水平增加风险,尽管该结果不显著。
Circulation IF 41.3 2026-11-07 PMID: 42998297
Electrocardiographic analysis aided by artificial intelligence (AI) may identify atrial electrical vulnerability during sinus rhythm. The objective of this study was to determine whether AI-enabled ECG (AI-ECG) is effective for detecting atrial fibrillation (AF), atrial flutter (AFl), or prespecified pre-AF atrial findings in a randomized trial. In this single-center, open-label trial, 14 665 adults 40 to 85 years of age without previous AF/AFl were randomized to an AI-ECG-guided strategy or usual care. Participants randomized to AI-ECG who were then identified by AI as having a high-risk sinus-rhythm ECG in the preceding year were offered Holter monitoring for ≤7 days. Each monitored high-risk intervention participant was paired with an age- and sex-matched control selected before control ECGs underwent AI analysis. Matched controls received identical monitoring to reduce ascertainment bias. Reporting cardiologists were blinded to AI results and randomized assignment. The primary outcome was a composite of newly detected AF, AFl, or pre-AF atrial findings within 90 days. Pre-AF atrial findings comprised frequent premature atrial complexes, short runs of premature atrial complexes, or nonsustained AF/AFl. Among 7337 intervention and 7328 control participants, 84 (1.1%) and 78 (1.1%), respectively, were classified as high risk. Of the 84 high-risk intervention participants, 48 (57.1%) underwent monitoring, as did 48 matched controls. The primary outcome occurred in 54 intervention participants (0.74%) versus 35 control participants (0.48%; odds ratio, 1.54 [95% CI, 1.01-2.37]; P=0.046). Hypothetical reclassification of 1 intervention event to a nonevent changed the primary analysis P value to 0.057. The intervention effect on detection of the primary composite outcome differed by baseline AI-ECG risk (Pinteraction<0.001): 32.1% versus 2.6% among high-risk participants and 0.4% versus 0.5% among low-risk participants. AF/AFl detection (0.3% versus 0.2%) and antiarrhythmic therapy initiation at 180 days (2.3% versus 2.4%) did not differ significantly between the intervention and control groups. Participant-reported monitoring-related adverse events, including skin reactions and discomfort, occurred in 22.9% of monitored intervention participants versus 18.8% of matched controls. AI-ECG-guided monitoring resulted in a modest increase in the detection of new AF, AFl, or pre-AF atrial findings. However, these findings were fragile statistically and sensitive to reclassification of 1 event. LATENT (Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development) demonstrates the clinical application of AI-ECG risk stratification to guide targeted rhythm surveillance, providing a foundation for larger trials evaluating its impact on patient outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06847932.
中文摘要:人工智能辅助的心电图分析可能在窦性心律期间识别心房电脆弱性。本研究旨在确定在随机试验中,基于人工智能的心电图(AI-ECG)是否有效检测心房颤动(AF)、心房扑动(AFl)或预定义的房颤前期心房表现。在这项单中心开放标签试验中,14665名年龄40至85岁且既往无AF/AFl病史的成年人被随机分配至AI-ECG指导策略组或常规护理组。被随机分配至AI-ECG组且在 preceding year 被AI识别为高危窦性心电图的患者,被提供为期不超过7天的动态心电图监测。每位接受监测的高危干预参与者均与一名在对照心电图进行AI分析前选出的年龄和性别匹配的对照组参与者配对。匹配对照组接受相同的监测以减少检出偏倚。报告结果的心电医师对AI结果和随机分组设盲。主要结局为90天内新检测到的AF、AFl或房颤前期心房表现的复合指标。房颤前期心房表现包括频发房性早搏、短阵房性早搏或非持续性AF/AFl。在7337名干预组参与者和7328名对照组参与者中,分别有84人(1.1%)和78人(1.1%)被归类为高危。在84名高危干预组参与者中,48人(57.1%)接受了监测,48名匹配对照组也接受了监测。主要结局在54名干预组参与者(0.74%)与35名对照组参与者(0.48%;比值比1.54 [95% CI 1.01-2.37];P=0.046)中发生。将干预组的1例事件假性重分类为非事件使主要分析P值变为0.057。干预对主要复合结局检测效果存在基线AI-ECG风险差异(交互作用P<0.001):高危参与者中为32.1%对比2.6%,低危参与者中为0.4%对比0.5%。AF/AFl检出率(0.3%对比0.2%)和180天时抗心律失常治疗启动率(2.3%对比2.4%)在干预组和对照组间差异无统计学意义。参与报告监测相关不良事件,包括皮肤反应和不适,在接受监测的干预组参与者中占22.9%,匹配对照组占18.8%。AI-ECG指导的监测导致新发AF、AFl或房颤前期心房表现的检出率略有增加。然而,这些发现在统计上脆弱且对1例事件的重分类敏感。LATENT试验展示了AI-ECG风险分层在指导目标性节律监测中的临床应用,为评估其对患者结局影响的大规模试验奠定了基础。

13肺动脉高压 (2篇)

基础研究 (2篇)

Hypertension (Dallas, Tex. : 1979) IF 9.8 2026-11-10 PMID: 43007062
The transcriptional mechanisms governing macrophage glutamine metabolism in pulmonary arterial hypertension remain incompletely understood. We investigated the role of ZEB1 (zinc finger E-box-binding homeobox 1)-mediated transcriptional regulation in macrophage metabolic reprogramming and the development of pulmonary arterial hypertension. Clinical samples and multiomics data sets were analyzed to characterize ZEB1 expression in pulmonary arterial hypertension. Myeloid-specific ZEB1 conditional knockout mice were subjected to hypoxia-induced pulmonary hypertension. Transcriptomic sequencing, metabolomic profiling, chromatin immunoprecipitation-quantitative polymerase chain reaction, dual-luciferase reporter assays, and coimmunoprecipitation were integrated to define ZEB1-dependent molecular, metabolic, and inflammatory programs in pulmonary and bone marrow-derived macrophages. Therapeutic potential was further evaluated using pharmacological interventions and adenoviral ZEB1 silencing in monocrotaline-induced pulmonary hypertension in rats. ZEB1 was upregulated in pulmonary arterial hypertension and enriched in recruited disease-associated macrophages. Myeloid-specific ZEB1 deletion attenuated macrophage inflammation, pulmonary vascular remodeling, and right ventricular dysfunction. Mechanistically, ZEB1 bound the GLS (glutaminase) promoter and recruited BRD4 (bromodomain-containing protein 4), enhancing histone H3 lysine 27 acetylation at the GLS promoter and promoting GLS transcription and glutamine metabolic reprogramming. Restoration of GLS partially reversed the metabolic and inflammatory effects of ZEB1 deficiency. Pharmacological targeting of ZEB1, combined BRD4 and GLS inhibition, and adenoviral ZEB1 silencing ameliorated experimental pulmonary hypertension. ZEB1 promotes macrophage glutamine metabolic reprogramming by recruiting BRD4 and enhancing histone H3 lysine 27 acetylation-dependent GLS transcription. This ZEB1-driven metabolic program promotes macrophage inflammation and pulmonary vascular remodeling, identifying the ZEB1-BRD4-GLS regulatory axis as a potential therapeutic target in pulmonary arterial hypertension.
中文摘要:肺动脉高压中巨噬细胞谷氨酰胺代谢的转录调控机制尚不完全清楚。本研究探讨了ZEB1介导的转录调控在巨噬细胞代谢重编程及肺动脉高压发生发展中的作用。通过临床样本和多组学数据集分析,表征了肺动脉高压中ZEB1的表达情况。对骨髓特异性ZEB1条件性敲除小鼠进行缺氧诱导的肺高血压模型研究。整合转录组测序、代谢组学谱分析、染色质免疫沉淀定量聚合酶链反应、双荧光素酶报告基因实验和共免疫沉淀技术,定义了肺动脉高压及骨髓来源巨噬细胞中ZEB1依赖的分子、代谢和炎症程序。进一步利用药物干预和腺病毒ZEB1沉默在吡咯环己酮诱导的大鼠肺高血压模型中评估了治疗潜力。研究发现ZEB1在肺动脉高压中上调并富集于招募的疾病相关巨噬细胞中。骨髓特异性ZEB1缺失减轻了巨噬细胞炎症、肺血管重塑及右心室功能障碍。机制上,ZEB1结合GLS启动子并招募BRD4,增强GLS启动子处组蛋白H3赖氨酸27乙酰化,促进GLS转录和谷氨酰胺代谢重编程。GLS的恢复部分逆转了ZEB1缺失的代谢和炎症效应。靶向ZEB1的药物干预、联合BRD4和GLS抑制以及腺病毒ZEB1沉默均改善了实验性肺高血压。ZEB1通过招募BRD4并增强组蛋白H3赖氨酸27乙酰化依赖的GLS转录,促进巨噬细胞谷氨酰胺代谢重编程。这一由ZEB1驱动的代谢程序促进了巨噬细胞炎症和肺血管重塑,将ZEB1-BRD4-GLS调控轴确定为肺动脉高压的潜在治疗靶点。
Cardiovascular research IF 12.5 2026-11-06 PMID: 42702807
Pulmonary arterial hypertension (PAH) is driven by sustained vasoconstriction and structural remodelling of distal pulmonary arteries. We have previously demonstrated that osteoprotegerin (OPG, tnfrsf11b) is upregulated in PAH animal models and patient tissues, with circulating levels being prognostic. OPG knock-out (KO) mice exhibit an attenuated PAH phenotype, and therapeutic inhibition using a human monoclonal anti-OPG antibody reduces disease severity in multiple rodent models. However, the key cellular source of pathogenic OPG and the mechanism underlying therapeutic blockade remain unknown. To define the main cellular source of OPG, conditional Tnfrsf11b deletion was generated by crossing OPGfl/fl mice with PGKcretg/+ (global), LysMcretg/+ (myeloid), Myl2cretg/+ (cardiac myocytes), Cdh5cretg/+ (endothelial cells), smMHCcretg/+ [vascular smooth muscle cell (VSMCs)], Col1a2cretg/+ (fibroblasts). KOs were induced by tamoxifen injection, and PAH established using Sugen5416/hypoxia (SuHx) model. Cardiopulmonary phenotyping included echocardiography, cardiac catheterization, and histological analysis. Mechanistic studies were performed in VSMCs using peptide-based kinase activity profiling (PamStation).PGKcretg/+/OPGfl/fl mice phenocopied the previous results obtained with global OPG KO (OPG-/-). Only VSMC-specific deletion (smMHCcretg/0/OPGfl/fl) resulted in significantly improved haemodynamic parameters, evidenced by reduced right ventricular systolic pressure and pulmonary vascular resistance, and reduced pulmonary vascular remodelling demonstrating that VSMC-derived OPG is the primary driver of PAH pathogenesis.Kinome profiling of control and idiopathic PAH (IPAH)-pulmonary artery smooth muscle cells (PASMCs) treated with OPG+/- anti-OPG antibody revealed IPAH-specific regulation of PI3K-Akt and enrichment of pathways involving autophagy, and longevity regulation linked to cellular stress resistance and growth. Anti-OPG antibody treatment reduced AKT phosphorylation in IPAH-PASMCs. Knock-down of AKT1 by siRNA reduced OPG-induced proliferation and migration of human PASMCs. These results align with emerging data implicating OPG in cellular senescence and vascular ageing. Together, these findings highlight VSMC-derived OPG as a critical mediator of pulmonary vascular remodelling in PAH pathogenesis and suggest that targeting OPG via a therapeutic antibody is mediated through PI3K-Akt signalling.
中文摘要:肺动脉高压由远端肺动脉的持续血管收缩和结构重塑驱动。我们先前已证明骨保护素在肺动脉高压动物模型及患者组织中上调,且循环水平具有预后价值。骨保护素敲除小鼠表现出减轻的肺动脉高压表型,而使用人源单克隆抗骨保护素抗体进行治疗可减轻多种啮齿类动物模型的疾病严重程度。然而,致病性骨保护素的关键细胞来源及其治疗阻断机制尚不明确。为明确骨保护素的主要细胞来源,通过将骨保护素floxed/floxed小鼠与PGKcretg/+(全身)、LysMcretg/+(髓系)、Myl2cretg/+(心肌细胞)、Cdh5cretg/+(内皮细胞)、smMHCcretg/+ [血管平滑肌细胞]、Col1a2cretg/+(成纤维细胞)小鼠杂交,生成了条件性Tnfrsf11b缺失模型。通过注射他莫昔芬诱导敲除,并利用Sugen5416/低氧模型建立肺动脉高压。心肺表型分析包括超声心动图、心导管检查和组织学分析。机制研究在血管平滑肌细胞中采用基于肽段的激酶活性谱分析进行。PGKcretg+/骨保护素floxed/floxed小鼠的表型与先前获得的全身骨保护素敲除结果一致。仅血管平滑肌细胞特异性缺失显著改善了血流动力学参数,表现为右心室收缩压和肺血管阻力降低,以及肺血管重塑减轻,证明血管平滑肌细胞来源的骨保护素是肺动脉高压发病机制的主要驱动因素。对对照组及特发性肺动脉高压患者肺动脉平滑肌细胞经抗骨保护素抗体处理后的激酶谱分析显示,特发性肺动脉高压特异性调节PI3K-Akt通路,并富集涉及自噬以及与细胞应激抵抗和生长相关的长寿调控通路。抗骨保护素抗体治疗降低了特发性肺动脉高压肺动脉平滑肌细胞中AKT的磷酸化水平。通过siRNA敲低AKT1减少了骨保护素诱导的人肺动脉平滑肌细胞增殖和迁移。这些结果与表明骨保护素参与细胞衰老和血管老化的新兴数据一致。综上所述,这些发现强调血管平滑肌细胞来源的骨保护素是肺动脉高压发病机制中肺血管重塑的关键介质,并提示通过治疗性抗体靶向骨保护素是通过PI3K-Akt信号通路介导的。

14动脉粥样硬化 (2篇)

临床研究 (1篇)

Circulation IF 41.3 2026-11-07 PMID: 42998308
In a target-directed low-density lipoprotein cholesterol (LDL-C)-lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease. We compared the efficacy and safety of initial statin-ezetimibe combination therapy versus statin monotherapy within intensive or conventional LDL-C-targeting strategies. In this prespecified second randomization of the randomized Ez-PAVE trial (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease: Randomized Comparison of LDL Cholesterol Targeting <70 versus <55 mg/dL) conducted at 17 centers in South Korea, a total of 3048 patients with atherosclerotic cardiovascular disease were enrolled between January 2021 and July 2022. Following the first randomization to either an intensive (<55 mg/dL) or conventional (<70 mg/dL) LDL-C-targeting strategy, patients underwent subsequent randomization (initial statin-ezetimibe combination therapy [n=1525] versus statin monotherapy [n=1523]) and were followed up for 3 years. Lipid-lowering therapy was adjusted according to a predefined protocol to achieve LDL-C targets. The primary end point was a 3-year composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina. The mean±SD age was 64.4±9.0 years, and 638 patients (20.9%) were female. The incidence of the primary end point did not differ between statin-ezetimibe combination therapy (128 patients [8.5%]) and statin monotherapy (119 patients [7.9%]; hazard ratio, 1.07 [95% CI, 0.83-1.37]; P=0.596). Patients who received statin-ezetimibe combination therapy achieved lower median LDL-C levels during follow-up than those who received statin monotherapy in both the intensive-targeting (53 mg/dL [interquartile range, 45-62 mg/dL] versus 62 mg/dL [interquartile range, 53-74 mg/dL]) and conventional-targeting (63 mg/dL [interquartile range, 55-73 mg/dL] versus 70 mg/dL [interquartile range, 62-81 mg/dL]) strategies. During follow-up, ezetimibe was added to the treatment regimen of 241 patients (34.3%) and 177 patients (24.8%) who initially received statin monotherapy in the intensive- and conventional-targeting strategies, respectively. The treatment effect of intensive-targeting versus conventional-targeting strategies was consistent regardless of therapy regimens without significant heterogeneity (Pinteraction=0.583). The safety end points were similar between the groups. Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04626973.
中文摘要:在靶向低密度脂蛋白胆固醇(LDL-C)降低策略中,初始治疗方案对动脉粥样硬化性心血管疾病患者的影响尚未得到充分研究。本研究比较了强化或常规 LDL-C 靶向策略下,初始他汀-依折麦布联合治疗与他汀单药的疗效和安全性。这是一项预先指定的二次随机分析,基于在韩国17个中心进行的随机 Ez-PAVE 试验(2021年1月至2022年7月入组3048名动脉粥样硬化性心血管疾病患者)。首次随机分组至强化(LDL-C <55 mg/dL)或常规(LDL-C <70 mg/dL)靶向策略后,患者接受后续随机分组(初始他汀-依折麦布联合治疗 n=1525 vs. 他汀单药 n=1523),随访3年。脂质降低治疗按预设方案调整以实现 LDL-C 目标。主要终点为3年内心血管原因死亡、非致死性心肌梗死、非致死性卒中、任何血运重建或不稳定心绞痛住院的复合事件。平均年龄为64.4±9.0岁,女性638名(20.9%)。他汀-依折麦布联合治疗组主要终点发生率为8.5%(128例),他汀单药组为7.9%(119例);风险比为1.07(95% CI 0.83-1.37;P=0.596),两组无显著差异。随访期间,强化靶向策略中联合治疗组的 LDL-C 中位数低于单药组(53 mg/dL vs. 62 mg/dL);常规靶向策略中亦如此(63 mg/dL vs. 70 mg/dL)。随访中,分别有34.3%(241例)和24.8%(177例)初始接受单药治疗的患者在强化和常规策略中加用了依折麦布。无论采用何种治疗方案,强化与常规靶向策略的治疗效果一致且无显著异质性(Pinteraction=0.583)。两组安全性终点相似。在靶向 LDL-C 降低策略中,无论是起始他汀-依折麦布联合治疗还是他汀单药,心血管疗效和安全性均无显著差异,但联合治疗有助于实现更低的 LDL-C 目标。

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-11-07 PMID: 42995463
Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes involved in antimicrobial defence and inflammatory regulation, yet their contribution to atherosclerosis remains poorly defined. This study aimed to characterize the distribution, phenotype, and functional role of MAIT cells in human atherosclerotic lesions and complementary murine models. MAIT cells were identified using MHC class I-related protein 1 (MR1) tetramers loaded with the agonist 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU). They were significantly enriched among CD3+ T cells in human carotid atherosclerotic plaques compared with matched peripheral blood. Plaque-resident MAIT cells displayed an activated, exhaustion-prone phenotype and a distinct transcriptional profile characterized by upregulation of inflammatory, stress-response, and chemotactic pathways, as revealed by bulk RNA sequencing of purified cells.In murine models, low-density lipoprotein receptor-deficient (Ldlr-/-) mice carrying the CAST locus, which confers increased MAIT cell frequency, exhibited enhanced MAIT cell accumulation in the liver and aorta under a high-cholesterol diet. We identified mature MAIT in the bone marrow which displayed activated state. Moreover, Bulk RNA sequencing of bone marrow-sorted MAIT cells from these mice revealed transcriptional signatures consistent with immune activation and enhanced myelopoiesis. In contrast, MAIT cell-deficient Ldlr-/-CAST MR1-/- mice showed reduced atherosclerotic burden, decreased liver fibrosis, and smaller myocardial infarcts following coronary artery ligation, without changes in plasma cholesterol levels. These protective effects were associated with reduced myeloid progenitors and bone marrow and circulating monocytes, as well as decreased macrophage accumulation within plaques. Importantly, disruption of monocyte mobilization via CCR2 deficiency abrogated MAIT cell-dependent effects, demonstrating a monocyte-mediated mechanism. MAIT cells accumulate in human atherosclerotic plaques and acquire a pro-inflammatory, functionally altered phenotype. Experimental evidence demonstrates that MAIT cells promote atherosclerosis and its complications by enhancing myelopoiesis and monocyte-driven vascular inflammation. These findings identify MAIT cells as previously unrecognized regulators of monocytosis and highlight their potential as therapeutic targets in atherosclerotic cardiovascular disease.
中文摘要:黏膜相关恒定T(MAIT)细胞是参与抗菌防御和炎症调节的先天样T淋巴细胞,但其对动脉粥样硬化的贡献尚不明确。本研究旨在表征MAIT细胞在人类动脉粥样硬化病变及互补小鼠模型中的分布、表型和功能作用。使用负载激动剂5-(2-氧代亚丙基氨基)-6-D-核糖基氨基尿嘧啶(5-OP-RU)的MHC I类相关蛋白1(MR1)四聚体鉴定MAIT细胞。与匹配的外周血相比,人类颈动脉粥样硬化斑块中的CD3+ T细胞中显著富集了MAIT细胞。斑块驻留的MAIT细胞表现出激活且易耗竭的表型,纯化细胞的批量RNA测序揭示其特征性转录谱,包括炎症、应激反应和趋化通路的上调。在小鼠模型中,携带CAST基因座的低密度脂蛋白受体缺陷(Ldlr-/-)小鼠在喂食高胆固醇饮食时,肝脏和主动脉中的MAIT细胞积累增加,该基因座赋予更高的MAIT细胞频率。我们鉴定了骨髓中处于激活状态的成熟MAIT细胞。此外,对这些小鼠骨髓分选的MAIT细胞进行批量RNA测序,揭示了与免疫激活和增强髓系生成一致的转录特征。相比之下,MAIT细胞缺陷的Ldlr-/-CAST MR1-/-小鼠在冠状动脉结扎后表现出减少的动脉粥样硬化负荷、减少的肝脏纤维化和更小的心肌梗死,且血浆胆固醇水平无变化。这些保护作用与髓系祖细胞以及骨髓和循环单核细胞的减少,以及斑块内巨噬细胞积累的减少有关。重要的是,通过CCR2缺陷阻断单核细胞动员消除了MAIT细胞依赖的作用,证明了单核细胞介导的机制。MAIT细胞在人动脉粥样硬化斑块中积累并获得促炎、功能改变的表型。实验证据表明,MAIT细胞通过增强髓系生成和单核细胞驱动的血管炎症来促进动脉粥样硬化及其并发症。这些发现将MAIT细胞确定为单核细胞增多症以前未被认识的调节因子,并突显其在动脉粥样硬化心血管疾病中的潜在治疗靶点价值。

15慢性肾病 (1篇)

临床研究 (1篇)

Kidney international IF 21.8 2026-11-12 PMID: 43020183
Apolipoprotein L1 (APOL1) variants are common in individuals of African descent and increase risk of chronic kidney disease (CKD). Renin-angiotensin system inhibitors (RASis) are a mainstay of therapy for hypertension and proteinuric CKD but were not historically recommended as first-line anti-hypertensive therapy in Black individuals. Here, we evaluated RASis versus other antihypertensive therapy on kidney outcomes in Black individuals by APOL1 genotype. We included Black participants with APOL1 genotyping on first-line anti-hypertensive therapy from the Chronic Renal Insufficiency Cohort (CRIC) and Systolic Blood Pressure Intervention Trial (SPRINT). We evaluated whether the impact of RASi-prescription on kidney outcomes was modified by APOL1 risk allele number or baseline albuminuria, using Cox models with inverse probability of treatment weighting and marginal structural models. A total of 3418 participants (62% from SPRINT), 40%, 44% and 16% carrying zero, one and two APOL1 risk alleles, respectively, were included. RASi-use compared to other first-line antihypertensive therapy was associated with a comparably lower risk of the kidney outcome in individuals with zero (hazard ratio (HR) 0.62 [95% confidence interval (CI) 0.44-0.87]), one (HR 0.68 [95% CI 0.49-0.94]) or two risk alleles (HR 0.59 [95% CI 0.40-0.86]). This benefit was driven by albuminuric participants, but estimates were similarly low for RASi-use compared to other antihypertensive therapy in albuminuric (HR 0.62, 95% CI [0.41-0.93]) and non-albuminuric (HR 0.37, 95% CI [0.13-1.08]) participants with two APOL1 risk alleles, although the estimate was imprecise in non-albuminuric participants. RASi-based therapy, addressed as a time-updated pooled treatment, provided similar benefit across APOL1 genotypes, driven by albuminuric participants. Among individuals with two APOL1 risk alleles, outcomes were similar regardless of baseline albuminuria. However, further studies are needed due to small sample sizes and the inability of statistical methods to capture clinical variables that may have affected prescription changes.
中文摘要:载脂蛋白L1(APOL1)变异在非洲裔个体中常见,并增加慢性肾脏病(CKD)风险。肾素-血管紧张素系统抑制剂(RASis)是高血压和蛋白尿性CKD的主要治疗手段,但历史上未推荐作为黑人患者的首选降压治疗。本研究评估了不同APOL1基因型黑人患者接受RASis与其他降压药对肾脏结局的影响。研究纳入来自慢性肾脏病队列(CRIC)和收缩压干预试验(SPRINT)中接受一线降压治疗且完成APOL1基因分型的黑人参与者。利用逆概率治疗加权Cox模型和边际结构模型,评估RASi处方对肾脏结局的影响是否受APOL1风险等位基因数量或基线白蛋白尿修饰。共纳入3418名参与者(62%来自SPRINT),其中携带零、一和两个APOL1风险等位基因的比例分别为40%、44%和16%。与使用其他一线降压药相比,使用RASis在携带零个(HR 0.62,95%CI 0.44-0.87)、一个(HR 0.68,95%CI 0.49-0.94)或两个风险等位基因(HR 0.59,95%CI 0.40-0.86)的个体中均与较低的肾脏结局风险相关。这种益处主要由白蛋白尿患者驱动,但在携带两个APOL1风险等位基因的白蛋白尿(HR 0.62,95%CI 0.41-0.93)和非白蛋白尿(HR 0.37,95%CI 0.13-1.08)患者中,与使用其他降压药相比估计值同样较低,尽管非白蛋白尿患者的估计值不够精确。作为时间更新汇总治疗处理的基于RASis的治疗在不同APOL1基因型中提供了相似的益处,主要由白蛋白尿患者驱动。在携带两个APOL1风险等位基因的个体中,无论基线白蛋白尿如何,结局相似。然而,由于样本量较小且统计方法无法捕捉可能影响处方变化的临床变量,仍需进一步研究。

16心血管病预防 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-11-11 PMID: 40103533
To identify the types of cardiovascular disease (CVD) and stroke prevention educational-behavioural programmes for people from culturally and/or linguistically diverse (CALD) backgrounds and investigate their effect on CVD risk factors and disease knowledge. Four electronic databases were searched from inception to September 2023. Mean difference (MD) and standardized MD was calculated using random effects model, and heterogeneity were assessed using the I2 statistic. Studies that were not included in the meta-analysis were narratively described. The Cochrane Risk of Bias tool and Joana Briggs Institute Critical Appraisal checklist were used to assess the quality of the included studies. Sixteen studies originating from USA and UK (4 RCTs and 12 quasi-experimental pre-post studies) with n = 2331 participants (mean age 57.2 years, 50% women) were included. The programmes were multi-component, 15 of which were culturally adapted and 1 was co-designed. Most were delivered face-to-face in groups. In contrast to the results among the pre-post studies, the pooled analysis showed that educational-behavioural programmes may have little to no effect on SBP (MD 1.18 mmHg, 95% CI -2.42 to 4.79) and HbA1c (MD -0.29%, 95% CI -0.89 to 0.32). The results for LDL cholesterol, BMI, physical activity and dietary intake were also mixed except for CVD or stroke knowledge which demonstrated statistically significant improvements after the intervention. The effect of educational-behavioural programmes on CVD risk factors is inconclusive but may improve CVD or stroke knowledge. Co-designing programmes underpinned by behaviour change theories/techniques with stakeholders and target CALD communities may enhance their potential impact. Future studies should use more rigorous study design i.e. RCTs, valid and reliable outcome measures to reduce inherent bias and strengthen the evidence base for the effectiveness of these programmes.
中文摘要:本研究旨在识别针对文化或语言多样化(CALD)背景人群的心血管疾病(CVD)和卒中预防教育行为干预项目的类型,并调查其对CVD危险因素及疾病知识的影响。检索了四个电子数据库,收录时间从建库至2023年9月。采用随机效应模型计算均数差(MD)和标准化均数差,使用I2统计量评估异质性。未纳入荟萃分析的研究进行了叙述性描述。使用Cochrane偏倚风险评估工具和Joanna Briggs Institute关键质量评价清单评估纳入研究的质量。共纳入16项来自美国和英国的研究(4项随机对照试验和12项准实验前后研究),共有2331名参与者(平均年龄57.2岁,女性占50%)。这些项目多为多成分组成,其中15项经过文化适应,1项为共同设计。大多数项目以面对面小组形式开展。与前后测研究的结果相比,汇总分析显示教育行为干预项目对收缩压(SBP)(MD 1.18 mmHg,95% CI -2.42至4.79)和糖化血红蛋白(HbA1c)(MD -0.29%,95% CI -0.89至0.32)的影响可能很小或没有影响。低密度脂蛋白胆固醇、身体活动量和饮食摄入量的结果也不一致,但CVD或卒中知识在干预后显示出统计学上的显著改善。教育行为干预项目对CVD危险因素的效果尚不明确,但可能提高CVD或卒中知识。在利益相关者和目标CALD社区支持下,基于行为改变理论/技术共同设计的项目可能会增强其潜在影响。未来的研究应采用更严格的研究设计(如随机对照试验)和有效可靠的结果测量指标,以减少固有偏倚并加强这些项目有效性的证据基础。

17心律失常(非房颤) (1篇)

基础研究 (1篇)

Archives of toxicology IF 10.9 2026-11-10 PMID: 43007399
Ciguatoxins (CTXs) cause ciguatera, a seafood-borne intoxication frequently associated with cardiovascular manifestations, but the underlying cardiac mechanisms remain poorly understood. We investigated the effects of purified CTX-1B and CTX-3 C in human induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs), porcine cardiac ryanodine receptor type 2 (RyR2) channels, and rats. In hiPSC-CMs, CTX-1B and CTX-3 C (0.3-5 nM) rapidly increased diastolic intracellular Ca²⁺ and altered spontaneous Ca²⁺ transients. At 5 nM, CTXs increased transient frequency, reduced transient amplitude, impaired contractile performance, and disrupted sarcomeric organisation. In planar lipid bilayers, CTX-1B (1 nM) prolonged RyR2 openings under resting cytosolic Ca²⁺ conditions and remodelled channel gating after activation with ATP (25 µM). Molecular docking predicted a CTX-1B interaction region within the RyR2 transmembrane domain, close to ligand-sensitive regulatory elements, supporting state-dependent modulation of channel gating. Cardiac sheets exposed to CTX showed reduced spontaneous field-potential activity and contraction. In rats, intravenous CTX-1B administration (0.13 ng/g bodyweight) caused bradycardia, premature atrial and ventricular contractions, atrioventricular conduction abnormalities, and atrial flutter. Echocardiography revealed impaired myocardial deformation and relaxation despite preserved ejection fraction. These findings identify altered RyR2 gating and intracellular Ca²⁺ dysregulation as plausible complementary contributors to CTX cardiotoxicity and extend the established mechanism based on persistent voltage-gated Na⁺-channel activation. Combined disruption of sarcolemmal excitability and intracellular Ca²⁺ release could explain the acute electrical and mechanical cardiac abnormalities associated with ciguatera.
中文摘要:雪卡毒素(CTXs)导致雪卡鱼中毒,这是一种常伴有心血管表现的食源性中毒,但其潜在的心脏机制尚不清楚。我们研究了纯化的CTX-1B和CTX-3C在人诱导多能干细胞衍生心肌细胞(hiPSC-CMs)、猪心脏兰尼碱受体2(RyR2)通道和大鼠中的影响。在hiPSC-CMs中,CTX-1B和CTX-3C(0.3-5 nM)迅速增加舒张期细胞内Ca²⁺并改变自发性Ca²⁺瞬变。在5 nM浓度下,CTXs增加瞬变频率,降低瞬变幅度,损害收缩性能并破坏肌节组织。在平面脂质双层中,CTX-1B(1 nM)在静息细胞质Ca²⁺条件下延长RyR2开放,并在用ATP(25 µM)激活后重塑通道门控。分子对接预测CTX-1B与RyR2跨膜结构域内的相互作用区域结合,靠近配体敏感调节元件,支持通道门控的状态依赖性调节。暴露于CTX的心肌片显示自发性场电位活动和收缩减少。在大鼠中,静脉注射CTX-1B(0.13 ng/g体重)导致心动过缓、房性和室性早搏、房室传导异常和心房颤动。超声心动图显示尽管射血分数保持正常,但心肌变形和舒张功能受损。这些发现将改变的RyR2门控和细胞内Ca²⁺失调确定为CTX心脏毒性的合理互补贡献者,并扩展了基于持续性电压门控Na⁺通道激活的既定机制。肌膜兴奋性和细胞内Ca²⁺释放的共同破坏可以解释与雪卡鱼中毒相关的急性电机械心脏异常。

18心脏外科/CABG (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-11-10 PMID: 43006184
Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0-73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94-2.31]; P=0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P=0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively (P=0.099). In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02338947.
中文摘要:衰弱与冠状动脉旁路移植术(CABG)后不良预后相关。然而,术前衰弱或衰弱患者在非体外循环CABG(OPCAB)与体外循环CABG(ONCAB)之间的比较疗效尚不明确。这项多中心、随机、开放标签试验于2018年1月至2024年12月期间招募了年龄≥60岁且被分类为术前衰弱或衰弱的患者,按1:1比例随机分组。主要结局为30天内死亡、心肌梗死、卒中、肾衰竭、急性呼吸窘迫综合征或因出血再次手术的复合终点。次要结局包括通气时间、重症监护室和住院时间、输血需求、血运重建的完整性、30天时手术切口感染以及术前和1年时的神经认知功能。分析遵循意向性治疗原则;估算相对风险及95%置信区间。共纳入508名患者(OPCAB组n=258;ONCAB组n=250;中位年龄68岁[四分位距65.0-73];女性占30.5%)。接受OPCAB的28名患者(10.9%)和接受ONCAB的40名患者(16.0%)出现了主要复合结局(相对风险1.47[95%CI 0.94-2.31];P=0.09)。ONCAB组的手术切口感染发生率更高(20例[8.0%]对比9例[3.5%];P=0.04)。在1年时,神经认知或生活质量结局未见显著差异。OPCAB组和ONCAB组的估计1年生存率分别为96.1%和92.8%(P=0.099)。在接受CABG的术前衰弱和衰弱患者中,OPCAB和ONCAB的主要复合结局发生率相似。在神经认知结局方面,OPCAB与ONCAB之间未发现显著差异。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT02338947.

19卒中/脑血管 (1篇)

临床研究 (1篇)

Environment international IF 10.2 2026-11-10 PMID: 43003740
Ambient air pollution is a leading global health risk and disproportionately affects populations of Low- and Middle-Income Countries (LMICs). In 2021, WHO revised its Air Quality Guidelines (AQG), lowering recommended annual limits for fine particulate matter (PM2.5) and nitrogen dioxide (NO2). We estimated the potential health and economic impacts of achieving WHO Interim Target 3 (IT3) and AQG concentrations across LMICs. We conducted a quantitative health impact assessment across 136 LMICs using gridded population data, high-resolution global PM2.5 and NO2 concentration estimates, and country-level Global Burden of Disease 2021 mortality and incidence rates. Published concentration-response functions were applied at ∼ 1 km x 1 km resolution to estimate one-year changes in mortality and disease incidence under IT3 (PM2.5; 15, NO2; 20 μg/m3) and AQG (PM2.5; 5, NO2; 10 μg/m3) counterfactual scenarios. Outcomes were all-cause and cause-specific mortality (chronic obstructive pulmonary disease [COPD], ischaemic heart disease [IHD], and stroke) and disease incidence (COPD, dementia, IHD, and stroke). Mortality changes were valued using country-adjusted value of a statistical life (VSL, Int$ PPP-adjusted 2021). Direct medical and productivity-related costs associated with incidence changes were estimated using a cost-of-illness (COI) framework. Uncertainty intervals (UI) reflect uncertainty in concentration-response functions only and likely underestimate uncertainty if all sources were propagated in the estimates. Estimated health impact of attaining WHO IT3 and AQG concentrations for PM2.5 was 16.04% reduction (6.58 million, UI: 4.7-8.3 million) and 22.97% reduction (9.43 million, UI: 6.8-11.7million) in annual mortality, respectively. Corresponding VSL-based estimates of annual mortality reductions were Int$5.5 trillion (7.0% of aggregate LMIC GDP) and Int$8.4 trillion (10.7% of GDP), respectively. For NO2, estimated reductions in mortality were approximately 1.06% (435,000, UI: 268,000-594,000) and 2.79% (1.1 million; UI: 706,000-1.6 million), yielding gains of Int$0.6 trillion (0.7% of GDP) and Int$1.5 trillion (1.9% of GDP), for IT3 and AQG scenarios, respectively. Disease-specific mortality reductions were most prominent for IHD and stroke in Asia and Africa. Under the PM2.5 AQG scenario, an estimated 2.82 million (2.2-3.4) COPD, 1.10 million (0.3-1.7) dementia, 7.3 million (3.3-10.4) IHD, and 2.3 million (1.8-2.7) stroke reductions in annual incidence was projected. Associated reductions in direct medical and productivity-related costs were greatest for IHD, COPD, and stroke. NO2-related morbidity reductions were smaller across all outcomes. All health impact estimates are potential reductions relative to current disease burden and reflect postponed all-cause mortality, or the avoidance of disease-specific mortality or incidence, within a single year. Effects for each exposure-outcome pair should be interpreted independently and not summed. Estimates should be interpreted considering data limitations, modelling assumptions, the one-year counterfactual design and the incomplete propagation of uncertainty beyond the CRFs. Achieving both WHO IT3 and AQG values in LMICs could yield substantial reductions in mortality and disease incidence, particularly for cardiovascular and respiratory conditions, alongside large, monetised welfare gains from reduced mortality risk. These findings quantify the potential societal benefit of air quality improvements and support accelerated action toward meeting WHO guideline levels in regions bearing the highest pollution burden.
中文摘要:环境空气污染是全球主要的健康风险,且对低收入和中等收入国家(LMICs)的人群影响尤为严重。世界卫生组织(WHO)于2021年修订了空气质量指南(AQG),降低了细颗粒物(PM2.5)和二氧化氮(NO2)的推荐年度限值。本研究评估了在136个LMICs中实现WHO临时目标3(IT3)和AQG浓度水平的潜在健康和经济影响。研究利用网格化人口数据、高分辨率全球PM2.5和NO2浓度估算值以及各国全球疾病负担2021年(GBD 2021)的死亡率和发病率数据,对136个LMICs进行了定量健康影响评估。应用已发表的浓度反应函数,在约1公里×1公里的分辨率下估算了在IT3(PM2.5:15,NO2:20 μg/m³)和AQG(PM2.5:5,NO2:10 μg/m³)反事实情景下的一年内死亡率和疾病发病率变化。结局指标包括全因及特定原因死亡率(慢性阻塞性肺病[COPD]、缺血性心脏病[IHD]和中风)以及疾病发病率(COPD、痴呆、IHD和中风)。死亡率变化采用各国调整后的统计生命价值(VSL,国际美元购买力平价2021年)进行估值。与发病率变化相关的直接医疗费用和生产成本采用疾病成本(COI)框架估算。不确定性区间(UI)仅反映浓度反应函数中的不确定性,若将所有来源的不确定性纳入估算,实际不确定性可能被低估。估计实现PM2.5的WHO IT3和AQG浓度水平可使年死亡率分别减少16.04%(658万,UI:470-830万)和22.97%(943万,UI:680-1170万)。基于VSL的估计显示,年死亡率减少带来的收益分别为5.5万亿美元(占LMICs GDP总量的7.0%)和8.4万亿美元(占GDP的10.7%)。对于NO2,估计死亡率分别减少约1.06%(43.5万,UI:26.8-59.4万)和2.79%(110万;UI:70.6-160万),IT3和AQG情景下分别带来0.6万亿美元(占GDP的0.7%)和1.5万亿美元(占GDP的1.9%)的收益。特定疾病的死亡率减少在亚洲和非洲的IHD和中风中最为显著。在PM2.5 AQG情景下,预计年发病率将减少COPD 282万(220-340万)、痴呆110万(30-170万)、IHD 730万(330-1040万)和中风230万(180-270万)。与直接医疗费用和生产成本相关的减少量在IHD、COPD和中风中最大。NO2相关的发病率减少在所有结局指标中较小。所有健康影响估计值均为相对于当前疾病负担的潜在减少量,反映的是推迟的全因死亡,或避免的一年内特定原因死亡或发病率。每种暴露-结局组合的影响应独立解读,不得加总。估算结果应在考虑数据局限性、建模假设、一年期反事实设计以及不确定性传播不完整的情况下进行解读。在LMICs中实现WHO IT3和AQG标准值可显著降低死亡率及疾病发病率,特别是心血管和呼吸系统疾病,同时带来巨大的货币化福利收益,这量化了空气质量改善的潜在社会效益,并支持在高污染负担地区加速行动以达成WHO指南水平。

20心脏瓣膜病/TAVR (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-11-10 PMID: 42808167
The Michigan Structural Heart Consortium showed that transcatheter aortic valve replacement (TAVR) stroke rates were associated with hospital Comprehensive Stroke Center (CSC) designation, suggesting that hospital structural factors affect stroke reporting. We sought to determine whether CSC designation is nationally associated with reported stroke rates and the potential impact on hospital performance and Transcatheter Valve Therapy National Data Registry (TVTR) public reporting. Consecutive TVTR cases from January 2016 through June 2023 were included, excluding sites reporting to the TVTR <1 year or performing <20 total TAVR procedures. The primary outcome was in-hospital stroke rate. Secondary outcomes were disabling stroke and 30-day stroke. Major bleeding, death, acute renal failure, and a composite end point were falsification end points to determine whether CSC status was uniquely associated with stroke. Multivariable hierarchical models were created starting with patient covariates and sequentially adding hospital variables to account for determinants of stroke. The impact of CSC status on hospital performance was estimated by correcting CSC hospital stroke rates in the validated TVTR 30-day composite model. A total of 525 919 TAVRs at 800 sites were included, and 10 963 strokes (2.1%) were reported within 30 days: 8284 (1.6%) in-hospital and 2679 (0.5%) after discharge. A total of 4733 (0.9%) were disabling strokes. Multivariate analysis showed that CSC status and participation in TAVR trials were independent predictors of in-hospital stroke rate (P=0.033 and 0.012) and disabling stroke (P=0.033 and 0.007), but not falsification end points (P=NS). Participation in TAVR trials and operator volume were independent predictors of 30-day stroke (P=0.039 and P=0.041). The impact of CSC status on the 30-day composite model showed performance improvement for 8 of 153 CSC hospitals. CSC hospital status and participation in TAVR trials are significant predictors unique for stroke. Correcting for the association of CSC status on stroke rate resulted in an estimated 8 of 153 hospitals improving their TVTR 30-day composite model performance. Further work is needed to account for potential ascertainment bias for stroke in public reporting.
中文摘要:密歇根结构心脏联盟显示经导管主动脉瓣置换术卒中率与医院综合卒中中心认证状态相关,提示医院结构性因素影响卒中报告。本研究旨在确定综合卒中中心认证状态在全国范围内是否与报告的卒中率相关及其对医院绩效和经导管瓣膜治疗国家数据注册库公开报告的影响。纳入2016年1月至2023年6月连续病例,排除向注册库报告不足1年或总手术量少于20例的机构。主要结局为院内卒中率。次要结局包括致残性卒中和30天卒中。大出血、死亡、急性肾衰竭和复合终点作为假阳性终点以评估综合卒中中心状态是否特异性关联卒中。采用多变量分层模型,从患者协变量开始并逐步加入医院变量以解释卒中决定因素。通过校正经导管瓣膜治疗注册库验证的30天复合模型中的综合卒中中心医院卒中率来评估其对医院绩效的影响。共纳入800个机构的525919例手术,报告30天内卒中10963例(2.1%),其中院内8284例(1.6%),出院后2679例(0.5%)。致残性卒中4733例(0.9%)。多变量分析显示综合卒中中心状态和参与经导管主动脉瓣置换术试验是院内卒中率和致残性卒中的独立预测因子,而非假阳性终点。参与试验和操作者经验是30天卒中的独立预测因子。综合卒中中心状态对30天复合模型的影响显示153家医院中有8家绩效改善。综合卒中中心状态和参与试验是卒中的特异性显著预测因子。校正综合卒中中心状态与卒中率的关系后,估计有8家医院改善了其注册库30天复合模型绩效。需进一步工作以解决公开报告中潜在的卒中检出偏倚。

21PCI/血运重建 (1篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-11-10 PMID: 42521444
The efficacy of prophylactic mechanical circulatory support with micro-axial flow pump or veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with severely reduced left ventricular ejection fraction (LVEF) undergoing high-risk percutaneous coronary intervention (PCI) remains unclear. Patients with complex three-vessel disease, unprotected left main coronary disease or last patent conduit and LVEF ≤ 35% were assigned to receive either a micro-axial flow pump (SynFlow 3.0) or VA-ECMO support during a non-emergent high-risk PCI procedure in this prospective, multicentre, randomized, open-label, non-inferiority trial. The primary endpoint was the incidence of 30-day major adverse events, defined as any of: all-cause death, myocardial infarction, stroke/transient ischaemic attack, repeat revascularization, major bleeding, acute kidney injury, cardiopulmonary resuscitation/cardioversion, cardiac surgery/limb ischaemia, or serious device-related complications. Safety endpoints included adverse events and serious adverse events. The primary endpoint, 30-day major adverse events, occurred in 8 of 109 patients (7.34%) in the SynFlow 3.0 group and 13 of 113 patients (11.5%) in the VA-ECMO group (absolute difference adjusted for centre effect, -4.6%; 95% confidence interval, -12.6% to 3.5%; P for non-inferiority < .001). Patients with SynFlow 3.0 had shorter post-procedural hospital stay (4.1 days vs 5.2 days on average, P = .047) and fewer device-related adverse events (3.7% vs 11.5%; P = .041). Anaemia occurred more often with VA-ECMO than with SynFlow 3.0 (20.4% vs 9.2%; P = .023). The prophylactic use of a micro-axial flow pump during high-risk PCI procedures was non-inferior to VA-ECMO in the incidence of 30-day major adverse events. The use of a micro-axial flow pump was associated with shorter post-procedural hospital stay and fewer device-related adverse events.
中文摘要:对于左室射血分数严重降低的高危经皮冠状动脉介入治疗患者,预防性使用微轴流泵或静脉-动脉体外膜肺氧合的疗效尚不明确。本研究是一项前瞻性、多中心、随机、开放标签的非劣效试验,纳入复杂三支病变、 unprotected 左主干病变或唯一通畅桥血管且左室射血分数小于等于35%的患者,在非急诊高危经皮冠状动脉介入治疗期间随机分配接受微轴流泵(SynFlow 3.0)或静脉-动脉体外膜肺氧合支持。主要终点为30天内主要不良事件发生率,定义为全因死亡、心肌梗死、卒中/短暂性脑缺血发作、再次血运重建、大出血、急性肾损伤、心肺复苏/电复律、心脏手术/肢体缺血或严重器械相关并发症。安全性终点包括不良事件和严重不良事件。结果显示,SynFlow 3.0组30天主要不良事件发生率为7.34%(109例中的8例),静脉-动脉体外膜肺氧合组为11.5%(113例中的13例),经中心效应调整的绝对差异为-4.6%(95%置信区间-12.6%至3.5%,非劣效性P值小于0.001)。SynFlow 3.0组术后住院时间更短(平均4.1天 vs 5.2天,P=0.047),器械相关不良事件更少(3.7% vs 11.5%,P=0.041)。静脉-动脉体外膜肺氧合组的贫血发生率高于SynFlow 3.0组(20.4% vs 9.2%,P=0.023)。结论表明,在高危经皮冠状动脉介入治疗中预防性使用微轴流泵在30天主要不良事件发生率方面非劣效于静脉-动脉体外膜肺氧合,且与更短的术后住院时间和更少的器械相关不良事件相关。

22脑卒中 (1篇)

临床研究 (1篇)

MedComm IF 14.1 2026-11 PMID: 43001080
Therapeutic options for neurological recovery remain limited in acute ischemic stroke (AIS) patients ineligible for thrombolysis, and while multitarget drugs like Danhong injection (DHI) demonstrate efficacy, their polypharmacological mechanisms remain understood. In this trial including 1505 thrombolysis-ineligible AIS patients with anterior-circulation and blood stasis syndrome (NCT01677208), 14-day treatment with DHI (n = 1002) versus placebo (n = 503) demonstrated superior 90-day outcomes (modified Rankin scale [mRS] score ≤1: 64.57 vs. 59.24%; adjusted odds ratio 1.43, 95%CI 1.10-1.86, p = 0.007), particularly in females and hypertensive patients, and no significant between-group differences in any serious adverse events (all p > 0.05). In the exploratory RNA-sequencing substudy of 39 patients (24 DHI, 15 placebo), we identified 19 differentially expressed modules, including two paired targeted modules "HBG2" and "TMEM108," whose topological features showed opposite correlations with the primary clinical outcome (δmRS at Day 90). Furthermore, a combination effect model was introduced to describe the time-dependent joint association of these modules with outcome (combination effect score: -0.729 at Day 0, 0.227 at Day 14, and 1 at Day 90). These findings demonstrate DHI may be a favorable treatment option for thrombolysis-ineligible AIS patients and provide a proposed analytical framework for future, independently validated studies of multitarget drug actions in complex diseases.
中文摘要:对于不适合溶栓的急性缺血性卒中患者,神经功能恢复的治疗选择仍然有限。虽然丹红注射液等多靶点药物显示出疗效,但其多药理学机制尚不明确。本研究纳入1505名前循环及血瘀综合征的不适合溶栓的急性缺血性卒中患者(NCT01677208),比较了14天丹红注射液治疗组与安慰剂组的90天功能结局。结果显示,丹红注射液组在改良Rankin量表评分≤1的比例上优于安慰剂组(64.57% vs 59.24%,调整后的比值比为1.43,95%置信区间为1.10-1.86,p=0.007),尤其在女性和高血压患者中效果更佳。两组在任何严重不良事件方面均无显著差异(所有p>0.05)。在包含39名患者的探索性RNA测序亚组研究中,我们鉴定出19个差异表达模块,包括两个配对的靶向模块HBG2和TMEM108,其拓扑特征与主要临床结局呈现相反的关联。此外,我们引入了一种组合效应模型来描述这些模块与结局随时间变化的联合关联(组合效应评分在第0天为-0.729,第14天为0.227,第90天为1)。这些发现表明丹红注射液可能是不适合溶栓的急性缺血性卒中患者的有利治疗选择,并为未来复杂疾病中多靶点药物作用的独立验证研究提供了分析框架。

23心血管病 (1篇)

临床研究 (1篇)

Cardiovascular research IF 12.5 2026-11-07 PMID: 42995003
The increasing number of pregnancies among women at cardiovascular risk or with established cardiovascular diseases (CVDs) has become a major global health concern because of its lasting influence on the health of their offspring. Maternal heart disease, hypertension, diabetes, obesity, and abnormal lipid levels, including also elevated lipoprotein(a), can disturb fetal growth and development, leading to changes in the heart, blood vessels, and metabolism that raise the risk of CVD problems in childhood and later life. The rising age of pregnant women, especially in the developed countries, also increases this risk. These effects result from a combination of inherited traits and alterations in the intrauterine environment, including impaired blood flow, inflammation, oxidative stress, and disrupted nutrient transfer through the placenta. Such disturbances can modify the structure and function of the developing cardiovascular system and contribute to lifelong vulnerability to CVDs. Studies from large populations show that children born to mothers with cardiovascular conditions have about twice the risk of developing CVD compared with those born to healthy mothers. Good maternal health before and during pregnancy, supported by balanced nutrition, regular physical activity, and effective control of blood pressure, lipids, body weight, and blood sugar, is strongly linked to better outcomes for both mother and child. Although current lifestyle interventions in pregnancy have shown promising effects on maternal wellbeing, their influence on the long-term cardiovascular health of the offspring remains uncertain. Strengthening preconception care, well-designed healthcare education, improving cardiovascular screening in women of reproductive age, and promoting heart-healthy habits across the life course are essential to prevent the transfer of cardiovascular risk from one generation to the next.
中文摘要:女性中处于心血管风险或患有既定心血管疾病的高龄孕妇数量增加,因其对后代健康产生持久影响而成为全球主要的公共卫生问题。母体心脏病、高血压、糖尿病、肥胖及血脂异常(包括脂蛋白a升高)可干扰胎儿生长发育,导致心脏、血管和代谢改变,从而增加儿童期及成年后患心血管疾病的风险。孕产妇年龄增长,特别是在发达国家,进一步增加了这一风险。这些效应源于遗传特征与宫内环境改变的综合作用,包括血流受损、炎症、氧化应激以及胎盘营养转移障碍。此类干扰可改变发育中心血管系统的结构和功能,并导致终生对心血管疾病的易感性增加。大型人群研究表明,患有心血管状况的母亲所生子女患心血管疾病的风险约为健康母亲所生子女的两倍。孕前及孕期良好的母体健康状况,通过均衡营养、规律运动和有效控制血压、血脂、体重及血糖来支持,与母婴更好的结局密切相关。尽管当前的孕期生活方式干预在改善母体福祉方面显示出积极效果,但其对后代长期心血管健康的影响仍不确定。加强孕前护理、设计完善的健康教育、提高育龄妇女的心血管筛查水平以及推广全生命周期的心脏健康习惯,对于防止心血管疾病风险代际传递至关重要。

24室性心律失常 (1篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-11-06 PMID: 42993097
Ventricular arrhythmia (VA) and heart failure (HF) frequently coexist in patients with ischaemic left ventricular (LV) dysfunction. Whether VA and HF events are bidirectionally associated remains unclear. We investigated their bidirectional relationship and associations with mortality. We analysed 1014 patients from the multicentre WICD-MI study. All received a wearable cardioverter-defibrillator after acute myocardial infarction (MI) and subsequently underwent implantable cardioverter-defibrillator (ICD) implantation, with persistent LV ejection fraction ≤35%. Associations between ICD-treated VA, HF-events (HF hospitalization, heart transplantation, or LV assist device implantation), and all-cause mortality were assessed using time-dependent Cox models. Over a median follow-up of 2.6 years post-ICD implantation, VA was independently associated with an increased risk of HF events [aHR = 3.50 (1.66-7.38), P = .001], while HF events similarly preceded subsequent VA [aHR = 2.96 (1.59-5.50), P = .0008]. Both were independently associated with all-cause mortality, with a numerically higher aHR for HF events [aHR = 7.96 (4.71-13.47), P < .0001] than for VA [aHR = 4.43 (2.35-8.36), P < .0001]. Sensitivity analyses suggested that the VA-HF association was strongest for shock-treated arrhythmias. In exploratory analyses, VA was strongly associated with subsequent HF events in subcutaneous ICD recipients [aHR = 15.08 (4.62-49.22), P < .0001] but not in transvenous ICD recipients (P for interaction = .0002). In ICD recipients with persistent LV dysfunction following MI, VA and HF events are bidirectionally associated and independently associated with mortality. The VA-HF association was strongest for shock-treated arrhythmias. These findings highlight the potential value of integrated HF and VA management.
中文摘要:室性心律失常(VA)与心力衰竭(HF)在缺血性左心室(LV)功能障碍患者中常共存。VA与HF事件是否呈双向关联尚不明确。本研究旨在探讨其双向关系及与死亡率的关联。我们分析了来自多中心WICD-MI研究的1014名患者。所有患者在急性心肌梗死(MI)后均接受可穿戴式心脏复律除颤器治疗,随后植入植入式心脏复律除颤器(ICD),且左室射血分数持续≤35%。采用时间依赖性Cox模型评估经ICD治疗的VA、HF事件(HF住院、心脏移植或LV辅助装置植入)与全因死亡率之间的关联。在ICD植入后中位随访2.6年期间,VA独立增加HF事件风险[aHR=3.50(1.66-7.38),P=.001],而HF事件同样预示随后的VA发生[aHR=2.96(1.59-5.50),P=.0008]。两者均独立与全因死亡率相关,HF事件的aHR数值高于VA[aHR=7.96(4.71-13.47),P<.0001 vs aHR=4.43(2.35-8.36),P<.0001]。敏感性分析表明,VA与HF的关联在电击治疗的心律失常中最强。探索性分析显示,皮下ICD受者中VA与随后的HF事件强相关[aHR=15.08(4.62-49.22),P<.0001],而在经静脉ICD受者中不显著(交互作用P=.0002)。在MI后持续存在LV功能障碍的ICD受者中,VA与HF事件呈双向关联且均独立与死亡率相关。VA与HF的关联在电击治疗的心律失常中最强。这些发现凸显了整合管理HF与VA的潜在价值。

25缺血性心肌病 (1篇)

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-11-06 PMID: 42605185
Free fatty acid receptor 4 (Ffar4) is a receptor for long-chain fatty acids that attenuates heart failure driven by increased afterload. Recent findings suggest that Ffar4 prevents ischaemic injury in brain, liver, and kidney, and therefore, we hypothesized that Ffar4 would attenuate cardiac ischaemic injury. Using a mouse model of ischaemia-reperfusion (I/R), we found in mice with systemic deletion of Ffar4 (Ffar4KO), loss of Ffar4 impaired the recovery of left ventricular systolic function post-I/R with no effect on initial infarct size. To identify potential mechanistic explanations for the cardioprotective effects of Ffar4, we performed bulk RNAseq to compare the transcriptomes from wild-type (WT) and Ffar4KO infarcted myocardium 3-days post-I/R. The transcriptome analysis identified the downregulation of several metabolic pathways suggesting impaired mitochondrial function in the infarcted Ffar4KO myocardium. Mechanistically, basal mitochondrial function and morphology were impaired in cardiac myocytes from Ffar4KO mice corroborating the results of the transcriptome analysis. Interestingly, phosphodiesterase 6c (Pde6c), which degrades cGMP, was the most upregulated gene in the Ffar4KO heart. Further, the soluble guanylyl cyclase stimulator, vericiguat, failed to increase cGMP in Ffar4KO cardiac myocytes, suggesting increased phosphodiesterase activity. Finally, cardiac myocyte-specific overexpression of Ffar4 in vivo and activation of Ffar4 in cardiac myocytes in vitro attenuated ischaemic/hypoxic injury respectively. Our results define a novel protective role for Ffar4 in cardiac myocytes to attenuate systolic dysfunction and prevent ischaemic cardiomyopathy post I/R by preserving mitochondrial function and activating cGMP signalling.
中文摘要:游离脂肪酸受体4(Ffar4)是一种长链脂肪酸受体,可减轻由后负荷增加驱动的心力衰竭。近期发现表明,Ffar4能预防脑、肝和肾的缺血性损伤,因此我们假设Ffar4也能减轻心脏缺血性损伤。利用小鼠缺血再灌注(I/R)模型,我们发现系统性删除Ffar4的小鼠(Ffar4KO)在I/R后左心室收缩功能恢复受损,但初始梗死面积无影响。为阐明Ffar4心脏保护作用的潜在机制解释,我们进行了批量RNA测序,以比较野生型(WT)和Ffar4KO心肌梗死后3天的转录组。转录组分析确定了几个代谢通路的下调,表明Ffar4KO梗死心肌线粒体功能受损。在机制上,Ffar4KO小鼠心肌细胞的基础线粒体功能和形态受损,证实了转录组分析的结果。有趣的是,降解cGMP的磷酸二酯酶6c(Pde6c)是Ffar4KO心脏中上调最多的基因。此外,可溶性鸟苷酸环化酶刺激剂维立西呱未能增加Ffar4KO心肌细胞中的cGMP,表明磷酸二酯酶活性增加。最后,体内心肌细胞特异性过表达Ffar4和体外激活心肌细胞中的Ffar4分别减轻了缺血/缺氧性损伤。我们的结果定义了Ffar4在心肌细胞中的一种新的保护作用,即通过保持线粒体功能和激活cGMP信号传导来减轻收缩功能障碍并预防I/R后的缺血性心肌病。

26心血管疾病 (1篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-11-06 PMID: 41711546
Delirium is a common yet underrecognized neuropsychiatric syndrome in cardiovascular medicine associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures-such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions-may be particularly vulnerable to its development. Delirium incidence varies widely across cardiovascular procedures, influenced by patient characteristics, procedural invasiveness, and diagnostic methodology. Risk factors include advanced age, baseline cognitive impairment, cerebrovascular disease, extended operative times, perioperative complications, and systemic inflammation. Diagnostic tools such as the Confusion Assessment Method (CAM) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score are established but underutilized in the diagnosis of delirium. While preventive strategies emphasizing non-pharmacological, multicomponent approaches-such as early mobilization, cognitive stimulation, and sleep hygiene-are supported by strong evidence, preventive use of pharmacologic agents remains controversial. Pharmacologic treatment is reserved for select cases; dexmedetomidine shows benefits in intensive care unit settings, while antipsychotics like quetiapine and risperidone may be used cautiously. Overall, delirium poses a significant clinical challenge in cardiovascular medicine and requires a proactive, interdisciplinary approach. Systematic risk assessment and multimodal preventive strategies should be the standard of care, while pharmacologic treatment should be symptom- and context-specific. Further high-quality studies are needed to inform evidence-based guidelines tailored to cardiovascular populations. The present state-of-the-art review summarizes the current literature on the epidemiology, mechanisms, clinical manifestations, diagnosis, prevention, and treatment of delirium in cardiovascular medicine. By integrating findings and interdisciplinary expert discussions from interventional cardiology, cardiac surgery, and psychiatry, it aims to define the unique vulnerability of this patient population, highlight critical knowledge gaps, and lay the foundation for developing targeted, evidence-based management strategies.
中文摘要:谵妄是心血管医学中一种常见但常被忽视的神经精神综合征,与住院时间延长、死亡率增加及长期认知功能下降相关。接受介入或外科手术的心血管患者(如经导管主动脉瓣置换术、外科主动脉瓣置换术、冠状动脉旁路移植术或经皮冠状动脉介入治疗)可能特别容易发病。谵妄的发生率在不同心血管手术间差异显著,受患者特征、手术侵入性及诊断方法影响。危险因素包括高龄、基线认知障碍、脑血管病、手术时间延长、围术期并发症及全身炎症。评估工具如意识模糊评估法(CAM)和重症监护病房意识模糊评估法(CAM-ICU)虽已确立但在谵妄诊断中应用不足。尽管强调非药物多组分策略(如早期活动、认知刺激及睡眠卫生)的预防性措施证据充分,但药物的预防性使用仍存在争议。药物治疗仅保留给特定病例;右美托咪定在重症监护室环境中显示出益处,而喹硫平和利培酮等抗精神病药需谨慎使用。总体而言,谵妄是心血管医学中重大的临床挑战,需要主动的多学科方法。系统性风险评估和多模态预防策略应成为标准护理,药物治疗应针对症状和具体情境。需要进一步的高质量研究来制定针对心血管人群的证据导向指南。本前沿综述总结了心血管医学中谵妄的流行病学、机制、临床表现、诊断、预防和治疗的当前文献,通过整合介入心脏病学、心脏外科和精神病学领域的发现及多学科专家讨论,旨在界定该患者群体的独特易感性,突出关键的知识空白,并为开发靶向证据管理策略奠定基础。

27其他 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-11-11 PMID: 42329687
Loneliness is common in ageing population, we aim to identify the association between loneliness and cardiometabolic disease (CMD) across diverse settings, particularly cardiometabolic multimorbidity, and investigate whether unhealthy lifestyles and socioeconomic status (SES) help explain or amplify their relationships. Data were obtained from six cohort studies across 33 countries, including the China Health and Retirement Longitudinal Study (CHARLS), English Longitudinal Study of Ageing (ELSA), Health and Retirement Study (HRS), Survey of Health, Ageing and Retirement in Europe (SHARE), Korean Longitudinal Study of Aging (KLoSA), and Mexican Health and Aging Study (MHAS). Eligible participants were aged 45 years or older. We applied time-varying Cox mixed-effects regression models to evaluate the association between loneliness and incident cardiometabolic diseases. The mediation role of unhealthy lifestyles and the joint effects of socioeconomic status, unhealthy lifestyles, and loneliness on incident cardiometabolic disease outcomes were also explored. Among 81 978 participants, with a median follow-up of 5 years, 15 750 participants developed CMD. Loneliness was associated with higher risk of any CMD (aHR 1.23, [95% CI: 1.20, 1.26]), with a stronger association for multimorbidity (aHR 1.48, [95% CI: 1.37, 1.60]) than for single CMD (aHR 1.18, [95% CI: 1.15, 1.22]). Unhealthy lifestyles mediated 5.19% (95% CI: 3.06, 7.64) of the association with any CMD. Individuals experiencing a combination of low SES, multiple unhealthy lifestyle factors, and loneliness demonstrated the greatest cardiometabolic disease risk (adjusted HR: 1.89, [95% CI: 1.76, 2.02]). Building on prior evidence that has largely come from single-cohort studies, our findings highlighted loneliness as a global risk factor in predicting the incident CMD, particularly cardiometabolic multimorbidity. The highest risk was observed among socioeconomically disadvantaged individuals with multiple unhealthy lifestyles. These findings underscore the needs to address the combined risk of socioeconomic disadvantage, loneliness, and unhealthy lifestyle in multicomponent health interventions.
中文摘要:孤独在老龄化人群中普遍存在,本研究旨在识别不同背景下孤独与心血管代谢疾病(CMD)之间的关联,特别是心血管代谢共病,并探讨不健康生活方式和社会经济地位(SES)是否有助于解释或放大其关系。数据来源于涵盖33个国家的六个队列研究,包括中国健康与养老追踪调查(CHARLS)、英国老龄化纵向研究(ELSA)、健康与退休研究(HRS)、欧洲健康、老龄化和退休调查(SHARE)、韩国老龄化纵向研究(KLoSA)以及墨西哥健康与老龄化研究(MHAS)。符合条件的参与者年龄为45岁及以上。我们应用时间依赖性Cox混合效应回归模型评估孤独与心血管代谢疾病发病之间的关联。同时探讨了不健康生活方式的中介作用以及社会经济地位、不健康生活方式和孤独对心血管代谢疾病发病结果的联合效应。在81978名参与者中,中位随访时间为5年,其中15750名参与者发生了CMD。孤独与任何CMD的高风险相关(aHR 1.23,[95% CI: 1.20, 1.26]),与共病(aHR 1.48,[95% CI: 1.37, 1.60])的关联强于单一CMD(aHR 1.18,[95% CI: 1.15, 1.22])。不健康生活方式介导了与任何CMD关联的5.19%(95% CI: 3.06, 7.64)。经历低SES、多种不健康生活方式因素和孤独组合的个体表现出最大的心血管代谢疾病风险(调整HR:1.89,[95% CI: 1.76, 2.02])。基于此前主要来自单队列研究的证据,我们的研究结果强调了孤独作为预测CMD发病的全球风险因素的作用,特别是心血管代谢共病。在具有多种不健康生活方式的社会经济弱势群体中观察到最高风险。这些发现强调了在多组分健康干预中解决社会经济劣势、孤独和不健康生活方式的联合风险的必要性。